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ABSTRACT 
ATP-dependent potassium (KATP) channels are present in the human pancreas, 
brain, nerve and muscle and play a crucial role in key biological pathways.  In 
the pancreas, KATP channels regulate insulin secretion from beta cells in 
response to glucose.  They comprise 4 Kir6.2 subunits, encoded by the 
KCNJ11 gene, which form the channel pore, and 4 SUR1 subunits, encoded by 
the ABCC8 gene, which regulate channel activity and form the binding site for 
sulphonylurea drugs.  
Mutations in KATP channel genes account for ~half of cases of neonatal 
diabetes, which is diabetes diagnosed in the first 6 months of life; this may be 
permanent (PNDM) requiring lifelong treatment, or transient (TNDM) where the 
diabetes remits and relapses in later childhood or adulthood.  Activating 
mutations in the KCNJ11 gene are the commonest cause of PNDM.  A genetic 
diagnosis is crucial for patients with these mutations because ~90% can be 
treated with oral sulphonylureas instead of insulin injections.  Sulphonylureas 
can bind and close mutant KATP channels allowing endogenous insulin secretion 
and resulting in improved metabolic control and quality of life at least in the 
short-term.  Severe sulphonylurea-related hypoglycaemia does not occur but 
mild-moderate episodes, typically related to food, have been reported by 
affected individuals.  The long-term response to sulphonylurea therapy and the 
regulation of insulin secretion in response to food in people with KCNJ11 
mutations remain key research questions with important clinical implications. 
Individuals with KCNJ11 PNDM can also have central nervous system (CNS) 
involvement; at its most severe this leads to Developmental delay, Epilepsy and 
Neonatal Diabetes (DEND) syndrome.  Sulphonylurea therapy can also benefit 
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the neurological features, which are thought to result from the action of 
sulphonylureas on brain KATP channels, although the response is only partial in 
contrast to the excellent glycaemic response.  In order to provide appropriate 
multidisciplinary assessment and support, it is important to establish the specific 
neurological, psychiatric, and neuropsychological deficits that are present in 
children and adults with sulphonylurea-treated KCNJ11 neonatal diabetes, and 
their impact on affected families. 
The overall aim of this thesis is to assess the response to sulphonylurea 
therapy in patients with PNDM due to mutations in the KCNJ11 gene, by 
undertaking clinical studies that investigate the glycaemic response as well as 
the CNS features in affected individuals.   
In chapter 1 we assess the long-term efficacy and safety of sulphonylurea 
therapy in KCNJ11 PNDM, by following clinical outcomes relating to both 
glycaemia and neurological features over 10 years in 81 patients who 
transferred from insulin to sulphonylureas before December 2006. We show 
that sulphonylurea therapy is effective and safe long-term, with 93% of 
individuals remaining on sulphonylureas without adjunctive therapies at most 
recent follow-up with no reports of severe hypoglycaemia or severe side-effects 
in over 800 patient years, and normal growth and BMI in children.  In addition, 
we show that neurological features are present in 38/81 individuals and despite 
initial improvement in 18 individuals on transfer to sulphonylureas, there is 
persistence of these features to some degree long-term. 
In chapter 2 we assess the physiological response to different foods in adults 
>18 years with sulphonylurea-treated KCNJ11 PNDM, by measuring glucose, 
insulin and glucagon levels after a high-protein meal and a high-carbohydrate 
meal in 5 affected individuals and comparing these with 5 non-diabetic controls. 
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We show that individuals with sulphonylurea treated KCNJ11 PNDM have 
similar insulin levels in response to both a carbohydrate and protein meal 
despite having higher glucose values in response to a carbohydrate meal than 
to a protein meal.  This contrasts with controls who have higher insulin secretion 
after carbohydrate than protein and therefore more tightly regulated glucose 
levels in response to both meals.  The findings suggest that individuals with 
sulphonylurea-treated KCNJ11 PNDM cannot modulate insulin secretion in 
response to glucose, consistent with a dependence on non-KATP pathways for 
insulin secretion. 
In chapter 3 we assess the psychiatric and neuropsychological profile of 
children <18 years with sulphonylurea-treated KCNJ11 neonatal diabetes.  In 
study A we use standardised questionnaires to measure psychiatric morbidity 
and impact in 10 children with KCNJ11 mutations and compared outcomes with 
school-age population norms.  We show that psychiatric disorders are present 
in 6/10 children, mainly consisting of autism, attention deficit hyperactivity 
disorder (ADHD) and anxiety disorders.  These disorders are related to the 
specific mutation (V59M or R201C),  have high impact on families and 
frequently go unrecognised clinically.  In study B we use a battery of 
neuropsychological tests to assess neuropsychological functioning in affected 
children and compare outcomes to non-diabetic sibling controls.  We show that 
learning difficulties and specific neuropsychological impairments are frequently 
present even in those children with mutations not consistently associated with a 
severe CNS phenotype, and that such features are absent from unaffected 
sibling controls.  
In chapter 4 we investigate the neurological, neuropsychological and 
behavioural features in adults with KCNJ11 neonatal diabetes, by assessing 8 
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individuals (7 sulphonylurea-treated) with KCNJ11 mutations using 
standardised neuropsychological tests, questionnaires, and clinical history and 
examination. Outcomes are compared to 4 adults with neonatal diabetes due to 
mutations in the INS gene, thereby controlling for the presence of 
hyperglycaemia from birth.  We show that adults with KCNJ11 mutations have 
learning difficulties, features of autism spectrum disorder (ASD), subtle motor 
dysfunction, moderately reduced IQ, and impaired attention, perceptual 
reasoning and working memory which persist despite long term sulfonylurea 
therapy and represent the major burden of disease once glycemia is well 
controlled on sulphonylureas.  The severity of the CNS features varies with the 
specific mutation and they do not occur in individuals with neonatal diabetes 
due to INS mutations, suggesting they occur as a consequence of dysfunctional 
brain KATP channels as opposed to indirect effects of lifelong diabetes.  
The conclusions section summarises the data chapters and describes how the 
work fits together as a coherent whole, as well as identifying directions for future 
research specific to each of the studies undertaken.   
The research in this thesis offers original and novel insights into both the CNS 
features of KCNJ11 neonatal diabetes and the glycaemic response to 
sulphonylurea therapy.  Patients with KCNJ11 neonatal diabetes represent a 
unique human experimental model for the study of KATP channel biological 
pathways in both the pancreas and brain.  Treatment of the condition with 
sulphonylureas remains one of the best examples of precision medicine and 
illustrates the benefits of targeted treatments in monogenic disease.  
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ORGANISATION OF THESIS 
Introduction 
The introduction is divided into 2 parts.  Part 1 gives an overview of neonatal 
diabetes with a focus on KCNJ11 mutations as a specific genetic aetiology.  It 
describes genotype phenotype relationships, relevant functional studies and the 
impact of treatment change from insulin injections to oral sulphonylureas.  Part 
2 is a review article published in Journal of Diabetes Research, entitled ‘Future 
roadmaps for precision medicine applied to diabetes: rising to the challenge of 
heterogeneity’.  This manuscript places sulphonylurea-treated KCNJ11 neonatal 
diabetes in the wider context, highlighting it as an outstanding example of 
precision medicine in diabetes and illustrating the utility of monogenic disorders 
as human disease models.  
 
Methods 
The methods section describes the questionnaires, data collection forms, 
neuropsychology test batteries and sample handling and analysis procedures 
used in the research.  It focuses on those methods not described in detail within 
each data chapter and makes reference to the relevant data chapters and 
Appendix 1 where copies of questionnaires can be found.   
 
Data Chapters 
Each data chapter is presented as the final accepted version(s) of one or more 
peer-reviewed publications.  Chapters 1 and 2 focus predominantly on the 
diabetes caused by KCNJ11 mutations and chapters 3 and 4 focus on the 
neurodevelopmental and neurological aspects.  Acknowledgements to co-
9
authors and details of my contribution have been placed at the beginning of 
each chapter. 
Chapter 1  
This is an original article published in Lancet Diabetes and Endocrinology in 
2018, entitled ‘Effectiveness and safety of long-term treatment with 
sulphonylureas in neonatal diabetes due to KCNJ11 mutations: an international 
cohort study’.  The study is the first long-term follow-up study of glycaemic and 
neurological outcomes in a large international cohort of 81 patients with 
KCNJ11 PNDM over 10 years.   
Chapter 2  
This is an original article published in BMJ Open Diabetes Research and Care 
in 2019, entitled ‘Patterns of post-meal insulin secretion in individuals with 
sulfonylurea-treated KCNJ11 neonatal diabetes show predominance of non-
KATP-channel pathways’.  The study is the first to assess the physiological 
response to different types of food in people with KCNJ11 neonatal diabetes 
and compare these with non-diabetic controls.   
Chapter 3  
This chapter is divided into 2 parts, both relating to the neurodevelopmental 
aspects of KCNJ11 neonatal diabetes in children.  Part A is a short report 
published in Diabetic Medicine in 2016, entitled ‘Psychiatric morbidity in children 
with KCNJ11 neonatal diabetes’.  Part B is a letter published in Diabetic 
Medicine in 2017, entitled ‘Neuropsychological impairments in children with 
KCNJ11 neonatal diabetes’.  These studies use standardised assessments to 
investigate the psychiatric and neuropsychological profiles of affected children, 
in comparison to population norms and unaffected sibling controls respectively. 
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Chapter 4 
This is an original article published in Diabetes Care in 2018, entitled ‘Cognitive, 
neurological and behavioral features in adults with KCNJ11 neonatal diabetes’.  
It is the first study to assess in detail the neurological, neuropsychological and 
psychiatric profile of adults with KCNJ11 neonatal diabetes and to compare 
these with people with neonatal diabetes due to INS mutations. 
 
Conclusions  
This is divided into four sections.   Each chapter is concluded and the impact of 
the studies and future directions for research are discussed. 
 
Appendix 1 
This appendix contains copies of the documents used for data collection in the 
studies and any relevant standard operating procedures.  These documents are 
presented in order of the studies in which they were used and referenced in the 











ABCC8 ATP Binding Cassette Subfamily C Member 8 (gene) 
ACE-R Addenbrooke’s Cognitive Examination-Revised  
ADHD  attention deficit hyperactivity disorder 
ASD  autism spectrum disorder 
AQ  Autism Spectrum Quotient 
BBB  blood brain barrier 
BB bio breeding (rat) 
BMI  body mass index 
CAMHS child and adolescent mental health services 
CBI-R  Cambridge Behavioral Inventory-Revised 
cffDNA cell-free fetal DNA 
CHI  congenital hyperinsulinism 
CNS  central nervous system  
COWAT Controlled Oral Word Association Test 
CPRD  Clinical Practice Research Datalink  
CSF  cerebrospinal fluid 
CTT  Colour Trails Test 
CYP450 cytochrome P450 
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DAWBA Development And Wellbeing Assessment 
DCCT  Diabetes Control and Complications Trial  
DEND  developmental delay, epilepsy and neonatal diabetes 
DKA  diabetic ketoacidosis  
DKEFS Delis-Kaplan Executive Function System 
DSM-IV Diagnostic and Statistical Manual of Mental Disorders, 4th Edition  
EHR   electronic health records  
ELISA enzyme-linked immunosorbent assay 
ExAC  Exome Aggregation Consortium  
FGM  flash glucose monitoring  
GATA6 GATA Binding Protein 6 (gene) 
GIP  gastric inhibitory polypeptide 
GK   Goto-Kakizaki (rat) 
GLP-1 glucagon‐like peptide‐1 
gnomAD  Genome Aggregation Database  
GP   general practice  
GRS  genetic risk score 
GWAS genome wide association study 
HADS  Hospital Anxiety and Depression Scale 
HGMD  Human Gene Mutation Database 
HNF-1A  Hepatocyte Nuclear Factor 1 Alpha (gene) 
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HNF-1B  Hepatocyte Nuclear Factor 1 Beta (gene) 
iAUC  incremental area under the curve 
iDEND intermediate developmental delay, epilepsy and neonatal diabetes 
IEP  individualised education program 
IGF  insulin-like growth factor  
IGT   impaired glucose tolerance 
INS  Insulin (gene) 
IQ  intelligence quotient 
IQR  interquartile range 
KATP  ATP-sensitive potassium (channel) 
KCNJ11 Potassium Channel, Inwardly Rectifying, Subfamily J, Member 11 
(gene) 
LCMV  lymphocytic choriomeningitis virus (rat) 
MRI  magnetic resonance imaging 
MODY maturity onset diabetes of the young 
NEPSY Developmental Neuropsychological Assessment 
NOD  non-obese diabetic (mouse) 
NSY   Nagoya-Shibata-Yasuda (mouse)  
OCD  obsessive compulsive disorder 
pmax  maximum serum concentration paracetamol 
PNDM permanent neonatal diabetes mellitus 
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SD  standard deviation 
SDS  standard deviation score 
SDQ  Strengths and Difficulties Questionnaire  
SEN  special educational needs 
SENCO special educational needs coordinator 
SPECT single photon emission computed tomography 
SU  sulphonylurea 
SUR1  sulfonylurea receptor 1 
tAUC  total area under the curve 
tmax  time to maximum serum concentration 
TNDM  transient neonatal diabetes mellitus 
tNGS   targeted next generation sequencing  
T1D  Type 1 Diabetes 
T2D  Type 2 Diabetes 
VMH  ventromedial hypothalamus 
VMI  visual motor integration 
WAIS-IV Wechsler Adult Intelligence Scale, fourth edition 
WASI  Wechsler Abbreviated Scale of Intelligence 
WISC-IV Wechsler Intelligence Scale for children, fourth edition 
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the KCNJ11 gene: clinical and genetic 








The KCNJ11 (potassium channel, inwardly rectifying, subfamily J, member 11) 
gene encodes the pore-forming Kir6.2 subunit of the ATP-sensitive potassium 
channel which is crucial for insulin secretion from pancreatic beta cells 
KCNJ11 is a single-exon gene located on the short arm of chromosome 11 
(11p15.1) (1) which is expressed in several tissues including brain, muscle, 
nerves, pancreas and heart (2).  Its protein product is Kir6.2, which forms the 
pore of the ATP-sensitive potassium (KATP) channel.  In the pancreas, KATP 
channels are comprised of 4 pore-forming Kir6.2 subunits and 4 regulatory 
SUR1 subunits, encoded by the ABCC8 gene (3).  This hetero-octameric 
structure plays a crucial role in glucose-mediated insulin secretion.  Under 
normal physiological conditions, glucose metabolism results in a rise in ATP, 
which binds to Kir6.2, closing the KATP channel and preventing efflux of 
potassium ions across the cell membrane. This results in beta cell membrane 
depolarisation and influx of calcium through voltage-gated calcium channels.  
Raised intracellular calcium triggers insulin secretion from the beta cell (4), 
figure 1.   
SUR1 regulates KATP channel activity by opening the channel in response to 
MgADP and the binding of drugs such as diazoxide (5).  SUR1 also forms the 
binding site for sulphonylureas, the insulin secretagogues used widely in the 
treatment of Type 2 diabetes (T2D) which act by closing pancreatic KATP 
channels to promote endogenous insulin secretion (6).  KATP channels are also 
present on alpha cells although a consensus on the specific role of KATP 
channel-mediated pathways in glucagon secretion has not yet been reached (7, 
8).  Furthermore, KATP channels can be found on hypothalamic glucose sensing 
neurons in the brain, where they are thought to help drive counter-regulatory 
responses to hypoglycaemia (9, 10). 
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Figure 1, from Gloyn et al. NEJM 2004 (32).  Role of the KATP channel in the 
pancreatic beta cell in linking blood glucose with insulin secretion. 
Dominant activating mutations in KCNJ11 are the commonest cause of 
permanent neonatal diabetes mellitus (PNDM) and can also cause transient 
neonatal and adult-onset diabetes 
Neonatal diabetes is defined as diabetes occurring in the first 6 months of life 
and occurs in ~1 in 100,000 live births (11, 12).  Nearly half of cases in non-
consanguineous populations are caused by mutations in the KCNJ11 and 
ABCC8 genes; KCNJ11 mutations alone account for ~30% making it the 
commonest genetic aetiology (13, 14).  Most KCNJ11 mutations arise de novo 
(~80%) or are dominantly inherited from an affected parent although germline 
mosaicism resulting in inheritance of disease-causing variants from a clinically 
unaffected parent has been described (15, 16).  These mutations cause 
neonatal diabetes by rendering KATP channels insensitive to ATP, affecting 
gating, increasing the intrinsic open probability or augmenting stimulation of 
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Kir6.2 by SUR1 (17-20).  As a result the channel remains in the open state and 
unable to respond to rising glucose, which leaves the beta cell permanently 
hyperpolarised and unable to secrete insulin.   
The majority (~80%) of cases of neonatal diabetes due to KCNJ11 mutations 
are permanent (PNDM) and persist from diagnosis in infancy throughout life: a 
smaller number have transient neonatal diabetes, characterised by remission of 
diabetes at around ~9 months of age with relapse of diabetes in later childhood 
or adolescence (21, 22).  Some KCNJ11 TNDM mutations exhibit variable 
penetrance and phenotypic heterogeneity with additional clinical presentations 
including adult-onset diabetes, childhood-onset diabetes and impaired glucose 
tolerance (IGT) in pregnancy (23-26).  The mechanisms underlying phenomena 
such as diabetes remission and relapse are not fully understood, and further 
research is required to address this. 
Clinical features of KCNJ11 neonatal diabetes related to the pancreas and CNS  
The biological impact of KCNJ11 mutations begins in utero.  Specifically, these 
mutations reduce birth weight in affected individuals by at least 1 standard 
deviation (SD) vs the general population (27-29) which is thought to result from 
insulin deficiency during development leading to reduced insulin-mediated 
growth (15, 30).  Median age at diagnosis of diabetes is ~1 month of age 
although recent research has shown that glucose is raised in babies with KATP 
channel mutations as early as day 5 of life even if they are not diagnosed with 
diabetes until much later (30).  Clinical presentation of KCNJ11 neonatal 
diabetes is typically severe; a recent study reported that diabetic ketoacidosis 
(DKA) was a presenting feature in ~80% of babies with KATP channel mutations 
and the odds of this increased with age at diagnosis (14).  This severe insulin 
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deficiency is reflected in the replacement doses of insulin historically required to 
treat the hyperglycaemia (median insulin dose ~0.7U/kg/day) (28, 29).   
In humans, the KCNJ11 gene is expressed in multiple brain regions but 
particularly high levels are found in the cerebellum (2).  Mutations in KCNJ11 
can therefore cause central nervous system (CNS) features in addition to 
diabetes.  Early studies showed that around one fifth of patients had a severe 
CNS phenotype comprising developmental delay (usually global and severe in 
nature), epilepsy and neonatal diabetes, the so-called DEND syndrome (27, 28, 
31).  Intermediate DEND (iDEND) was the term used if there was no epilepsy in 
the first 12 months of life; typically, these patients had developmental delay in 
the moderate-severe range (15, 27, 32).  Muscle weakness, impaired 
coordination, visuomotor performance, hand-eye tracking and features of 
autism spectrum disorder (ASD) were also reported in individuals with DEND / 
iDEND syndrome (31, 33-36).  More recently, research studies have shown that 
the CNS features in KCNJ11 PNDM extend beyond the severe overt syndromic 
phenotype.  In one cohort study of 27 patients without DEND / iDEND, the 
majority (almost 80%) were shown to have dyspraxia and / or attention 
difficulties when assessed using standardised neuropsychological tests (22).  
This was supported by research showing high rates of neuropsychological 
impairments in children with KCNJ11 mutations who did not have severe 
developmental delay when compared to sibling controls without diabetes (37).   
Impact of glycaemic factors on CNS phenotype 
Glycaemic factors can have neurological sequelae and it is important to 
consider the potential impact these may have in the context of neonatal 
diabetes, and how they are different to the CNS features that occur directly as a 
result of the genetic mutation.  The severe DEND / iDEND syndrome is typically 
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associated with muscle weakness (32).  This is thought to occur as a direct 
result of dysfunctional brain KATP channels as selective expression of the 
iDEND-associated V59M mutation in rat brain (but not muscle or peripheral 
nerves) replicates the human phenotype (38).  In contrast, cerebral oedema due 
to diabetic ketoacidosis (DKA) at diagnosis causes spastic tetraplegia (39).  
However, as the majority of children with KCNJ11 mutations present in DKA 
(see above), they are also at significant risk of severe neurological impairment 
secondary to the metabolic disturbance associated with this acute severe 
presentation.   
Furthermore, having diabetes from childhood is associated with a range of 
subtle cognitive impairments.  A meta-analysis of children with Type 1 Diabetes 
(T1D) showed mild-moderate impairments (in order of decreasing effect size) in 
intelligence, psychomotor efficiency, cognitive flexibility, visual perception, 
attention, and processing speed, when compared to children without diabetes 
(40).  Cognitive deficits were more pronounced in those diagnosed with 
diabetes early in life i.e. between the ages of 4-7 years, and in those with 
microvascular complications of diabetes (40, 41).  Interestingly recurrent severe 
hypoglycemia did not have an effect on cognitive performance (40).  Learning 
and memory appear to be relatively spared in children and younger adults with 
diabetes in contrast to older adults (>60-65 years) with Type 2 Diabetes (T2D) 
in whom impairments in these cognitive domains are the most predominant 
(42).  Neuroimaging studies in T1D have demonstrated alterations in grey and 
white matter volume in several brain regions in comparison to non-diabetic 
controls; typically, there is a negative correlation with HbA1c and disease 
duration (43).   
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Such studies should be taken into consideration in the context of the 
constellation of neuropsychological features observed in KCNJ11 neonatal 
diabetes.  Although the evidence to date suggests that the CNS profile in 
individuals with neonatal diabetes is largely a direct result of the dysfunctional 
KATP channels in the brain (44), the extent to which other diabetes-related 
factors play a role has not been fully elucidated.  There are several mechanistic 
theories as to how states of hyper- or hypoglycaemia may impact on the brain, 
particularly during periods of rapid brain development in childhood.  These 
include hyperglycaemia-induced oxidative stress and neurodegradation and 
hypoglycaemia-related energy deprivation resulting in cell death (43).  
Disentangling these effects from those occurring directly as a result of KATP 
channel mutations represents an interesting aspect of future research.      
Further exploration of the cognitive profile in children with sulphonylurea-treated 
KCNJ11 neonatal diabetes is described in Chapter 3 of this thesis.  The 
question of whether diabetes per se from a very early age affects CNS function 
long-term in affected individuals is addressed in chapter 4, which compares the 
CNS features in adults with sulphonylurea-treated KCNJ11 neonatal diabetes to 
adults with insulin-dependent diabetes from birth due to mutations in the INS 
gene.   
Genotype phenotype relationships and functional studies  
In individuals with KCNJ11 mutations certain phenotypes are more commonly 
associated with specific mutations.  For example, neurological features are 
frequently seen in patients with the V59M mutation, PNDM without overt CNS 
features in patients with the R201H mutation, and TNDM in those with the 
E227K mutation (21, 28).  It has been suggested that one reason for this relates 
to the position of the affected amino acid in the Kir6.2 protein structure and the 
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functional effect(s) of this on the KATP channel (27).  The R201 residue and 
others causing neonatal diabetes without severe neurological involvement lie 
within the ATP binding site and therefore directly affect ATP sensitivity, whereas 
V59M and others causing DEND/iDEND syndrome are located more distantly 
from the ATP binding site and may have additional functional effects such as 
affecting channel gating and open probability (19, 27).  Functional studies have 
shown that there is some association between the severity of the clinical 
phenotype and the severity of the mutation in vitro, at least for variants known to 
cause DEND/iDEND (18, 28).  Those mutations associated with significant 
neurological symptoms tend to have larger resting whole cell KATP channel 
currents than those associated with PNDM or TNDM (~28-40% vs ~7-10%) (17, 
19, 45).   
No clear functional associations have been established in relation to diabetes 
phenotype in the absence of overt CNS features, with no difference in the size 
of KATP channel currents in the presence of variants that cause PNDM, TNDM 
or both (17).  In addition, although broadly speaking some genotype-phenotype 
relationships such as those described above hold true, there are notable 
exceptions e.g. a few cases of non-syndromic KCNJ11 PNDM have been 
reported in association with V59M, and PNDM or later onset diabetes in 
association with E227K (27, 46, 47).  This emphasises the roles of other genetic 
and environmental factors in determining the phenotypic manifestations of 
specific KCNJ11 mutations. 
 
Neonatal diabetes due to KCNJ11 mutations can be treated with oral 
sulphonylureas: an outstanding example of precision medicine 
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Early functional studies showed that KCNJ11 mutations did not prevent 
inhibition of KATP channels by sulphonylureas (17), suggesting that these drugs 
may also be a potential treatment for patients with KCNJ11 neonatal diabetes.  
In-keeping with this, physiological studies in small numbers of affected 
individuals demonstrated insulin secretion in response to intravenous (IV) 
tolbutamide but not IV glucose (32).  Subsequently, oral sulphonylurea therapy 
was shown to be effective in 4 affected patients over 2-6 months allowing 
discontinuation of insulin (48, 49).  Glibenclamide treatment was associated 
with improved (48, 49) or equivalent (48) glycaemic control in comparison to 
that observed on insulin therapy, as well as a reduction in glycaemic variability 
measured using continuous glucose monitoring (CGM) (49).  The first large 
cohort study to investigate the treatment of KCNJ11 neonatal diabetes with 
sulphonylureas showed 44/49 patients successfully transferred and had 
excellent outcomes with median HbA1c falling from 8.1% on insulin to 6.4% 12 
weeks after switching to sulphonylureas (29).  This improvement was 
maintained at 1 year and not associated with any severe side-effects or 
increased hypoglycaemia despite the need for large doses (median 
0.45mg/kg/day glibenclamide) (29).  
Further research has shown that the main factors affecting ability to transfer 
successfully are the specific genetic variant and the age at transfer (50, 51).  
The former relates to the effect of the mutation on in vitro tolbutamide block; 
one study of 127 individuals showed that those who had mutations with a 
tolbutamide block of >73% were able to transfer in the majority of cases (50).  
The minority who did not transfer were older when the switch was attempted 
(50).  This is in-keeping with a study of 58 individuals which reported a need for 
additional medication to maintain glycaemic control in 10/17 patients who were 
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older than 13 years at the time of transfer, with those under 13 years 
consistently able to manage on sulphonylurea monotherapy (51).  One reason 
for this may relate to more marked changes in beta cell gene expression and 
function with prolonged exposure to hyperglycaemia on insulin therapy.  This 
hypothesis is supported by a mouse model of KCNJ11 neonatal diabetes in 
which selective expression of the V59M mutation in pancreatic beta cells leads 
to development of diabetes and changes in islet morphology, structure and 
gene expression after just 4 weeks (52).  Interestingly those mice who were 
given glibenclamide after 2 days of diabetes require lower doses of the drug 
than those who were treated after 4 weeks (52).  Taken together, these studies 
indicate that earlier sulphonylurea transfer increases the chances of success 
and support rapid early genetic diagnosis.  
In the large number of individuals with KCNJ11 mutations who are able to 
successfully transfer from insulin to sulphonylureas, there is a significant 
psychological impact for both the patients themselves and their families.  
Parents of babies and young children with KCNJ11 neonatal diabetes described 
moving from daily states of anxiety and fear of separation from their child whilst 
on insulin treatment, to greatly improved quality of life, more freedom and less 
distress following transfer of their child to sulphonylureas (49, 53).  This was 
largely due to the improved metabolic control and reduction in glycaemic 
variability and thus diminished need for vigilance for symptoms of 
hypoglycaemia (53-55).  Some adults who had been insulin-treated since 
diagnosis viewed insulin as part of their identity; they were initially apprehensive 
about the prospect of changing treatment and required a period of adjustment to 
become accustomed to this (53, 54, 56).  Despite this, the psychological impact 
of treatment change, when complete, was largely extremely positive (56).  Even 
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in the few cases unable to transfer from insulin to sulphonylureas, a genetic 
diagnosis was helpful particularly in those cases with overt CNS features in 
addition to diabetes.  This is because identification of a genetic aetiology offered 
an explanation for the presence of these features together; previously they were 
thought to be unrelated (57).    
Sulphonylureas fail in T2D but mechanism of action is likely to be different in 
NDM given different patterns of hypoglycaemia and tolerance of large doses 
In T2D additional treatment is required in between one third and one half of 
cases after 5-6 years of monotherapy with sulphonylureas to maintain adequate 
glycaemic control (58, 59).  Studies in small cohorts of patients with KCNJ11 
PNDM suggested that the improved glycaemic response following transfer to 
sulphonylureas lasted for at least 3-5 years (60, 61), but prior to the research in 
this thesis, the long-term effects remained unknown with questions around the 
safety of high doses, especially in children.  In T2D a known side-effect of 
sulphonylurea therapy is hypoglycaemia, which can be severe in nature and 
typically occurs in the fasting state (62, 63).  Patients with KCNJ11 PNDM can 
tolerate much higher doses of sulphonylureas than patients with T2D without 
experiencing severe hypoglycaemia (29).  Furthermore, any mild-moderate 
hypoglycaemia that occurs in sulphonylurea-treated KCNJ11 PNDM may be 
related to meals, a different pattern to that observed in T2D (51, 64).  Such 
observations suggest that the mechanism of action of sulphonylureas in 
patients with KCNJ11 mutations is also different to that in T2D.  Early 
physiological studies showed that individuals with KCNJ11 mutations on 
sulphonylurea therapy could secrete insulin in response to glucose given orally 
but not intravenously, implying that the presence of food was essential for this 
process either through GLP-1 or nutrient stimulation of beta cells (29).  It was 
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suggested that the action of sulphonylureas in KCNJ11 PNDM was therefore 
permissive in nature, allowing the beta cell to respond to amplifying pathways of 
insulin secretion (29).  This contrasts with the situation in T2D where 
sulphonylureas directly inhibit KATP channels to cause beta cell depolarisation 
and drive endogenous insulin secretion (65).  
Chapter 1 of this thesis addresses the crucial question of the long-term 
durability of sulphonylurea therapy in KCNJ11 PNDM including drug efficacy 
and safety over 10 years.  Chapter 2 explores the mechanistic questions 
relating to insulin secretion in more detail by measuring the physiological 
response to different foods in patients with sulphonylurea-treated KCNJ11 
neonatal diabetes.  It demonstrates the utilisation of amplifying non KATP-
channel-mediated pathways of insulin secretion, which predominate over the 
classical ATP pathway in contrast to the situation in the non-diabetic state 
where individuals remain glucose-responsive. 
CNS features improve following treatment with oral sulphonylureas 
An unexpected benefit of treating KCNJ11 neonatal diabetes with 
sulphonylureas was an improvement in the CNS features associated with the 
condition, with early case reports and clinical anecdotes describing changes in 
motor function, IQ and attention that occurred fairly soon after sulphonylurea 
transfer (35, 57, 66, 67).  It was suggested that this was due to a central action 
of sulphonylurea therapy in the brain as opposed to simply improved diabetes 
control.  In-keeping with this, single photon emission computed tomography 
(SPECT) scanning showed enhanced cerebellar perfusion in 4/5 individuals 6 
months after insulin to sulphonylurea transfer when compared with pre-transfer 
perfusion.  In one individual, this was also associated with resolution of a 
temporal lobe perfusion defect and significant clinical improvement in 
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neurological and cognitive functioning (45, 67).  Further neuroimaging studies in 
17 individuals with sulphonylurea-treated KCNJ11 neonatal diabetes showed no 
significant structural abnormalities of the brain, but white matter hyperintensities 
in 10 patients, consistent with what had been reported in a previous case (32, 
44).   
Although the clinical improvements in neurological functioning were an exciting 
finding in individuals who transferred to sulphonylureas, it became evident that 
they were often incomplete, and patients were frequently left with residual 
deficits.  The only study to examine this prospectively showed that after 12 
months of sulphonylurea therapy, in children <4 years of age there was marked 
improvement in fine and gross motor skills, tone and attention (44).  In those >4 
years of age, there was improvement in tone, laterality, visual attention and 
visuospatial integration, but the changes were not as marked as those observed 
in the younger children (44).  This supports previous research that 
demonstrated a correlation between the age of initiation of sulphonylurea 
therapy and visuomotor performance in patients with iDEND-related mutations 
(34).  A more recent study has questioned this hypothesis by finding no effect of 
earlier sulphonylurea treatment on neurodevelopmental outcomes in patients 
with the V59M mutation; however the analysis only included 5 individuals and 
may not have been sufficiently powered to detect differences (68).  Research in 
other fields suggests that there may be a ‘window’ of ~6 months following birth 
whereby interventions may have the most impact on CNS function, which is 
thought to be related to increased neuroplasticity of the young brain (69-71).  
Currently clinicians are encouraged to start sulphonylurea therapy in patients 
with KCNJ11 neonatal diabetes as early as possible, but further research in 
larger cohorts of patients is required to provide a definitive answer as to 
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whether the early initiation of treatment (in the first 6 months of life) brings 
measurable improvements in neurodevelopmental outcomes over starting 
treatment later in life.        
Another hypothesis as to why there is only partial recovery of the CNS with 
sulphonylurea treatment is that insufficient drug levels are achieved in the 
cerebrospinal fluid (CSF).  In rats, extremely high systemic doses of 
glibenclamide are required to obtain measurable levels in the CSF, and the drug 
is rapidly exported back out of the brain via an active transport mechanism as 
demonstrated by rapidly diminishing CSF concentrations following 
intraventricular administration (72).  The extent to which this also occurs in 
humans has not been established, although anecdotally patients with significant 
neurological involvement report greater improvements on doses of ~1mg/kg/day 
glibenclamide or occasionally even higher (44, 73).  Similarly, the CNS 
penetration and clinical effects on neurological function of sulphonylureas other 
than glibenclamide has not been studied and this is an area where further 
research will be crucial in the future, to inform clinical recommendations for 
patients.  
Finally, most of the studies described previously have identified 
neuropsychological impairments after transfer to sulphonylureas and it is not 
clear whether larger doses would benefit these more subtle impairments.  
Interestingly the one patient who did not show improvement in cerebellar 
perfusion on transfer to sulphonylureas in the study by Fendler et al carried the 
R201H mutation which is regarded as clinically milder given its lack of 
association with overt neurological features (45).  Further studies are required 
to investigate the impact of treatment-related factors on patients with only subtle 
CNS features.   
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Despite these caveats, the positive impact of sulphonylurea therapy on the 
neurobehavioural features in many patients with KCNJ11 mutations is very 
exciting.  Not only does it present an opportunity to improve CNS function in 
affected children, but also it highlights the possibility of precision therapy for 
developmental disorders related to monogenic disease more broadly.  This will 
be a key area for research in the future. 
The long-term neurological outcomes in patients with sulphonylurea-treated 
KCNJ11 neonatal diabetes is explored in Chapter 1 of this thesis.  In addition, 
chapters 3 and 4 give a more detailed account of the CNS features that persist 
in affected children and adults.     
ABCC8 neonatal diabetes shares many features in common with KCNJ11 
neonatal diabetes but requires further study as a separate clinical syndrome 
Mutations in the ABCC8 gene, which encodes the SUR1 subunit of the KATP 
channel, account for ~15-20% cases of neonatal diabetes in non-
consanguineous populations, making this the second commonest known cause 
after KCNJ11 mutations (13).  SUR1 regulates KATP channel activity by MgADP 
(74) and is the binding site for channel inhibitors and openers such as 
sulfonylureas and diazoxide (74, 75).  Although the molecular effects of ABCC8 
mutations are distinct from those of KCNJ11 mutations, the cellular effects are 
similar, with reduced sensitivity to ATP-mediated channel closure, beta cell 
hyperpolarisation and lack of insulin secretion (76). 
Initial descriptions indicated that the clinical features of KCNJ11 and ABCC8 
neonatal diabetes were similar; specifically, there were no significant 
differences in birth weight, presence of ketoacidosis, or age at diagnosis of 
diabetes (76).  However, there are some notable differences both clinically and 
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genetically.  Whilst KCNJ11 mutations result in PNDM in the majority (~80%) 
cases, ABCC8 mutations frequently cause TNDM, with PNDM occurring in only 
~20% cases (22).  Variants in the ABCC8 gene causing neonatal diabetes tend 
to be a mixture of dominant heterozygous mutations as well as compound 
heterozygous, homozygous or mosaic variants (77), whereas dominant 
activating mutations predominate in KCNJ11 neonatal diabetes.  In ABCC8 
neonatal diabetes genotype-phenotype relationships are not particularly distinct, 
in contrast to KCNJ11 neonatal diabetes where the correlation is stronger as 
described above (78).  Finally, there is no animal model of ABCC8 neonatal 
diabetes unlike the V59M mouse, which has had some utility in generating 
hypotheses about human neonatal diabetes due to KCNJ11 mutations (38, 52, 
79).  Some or all of these factors may explain why, broadly speaking, neonatal 
diabetes due to ABCC8 mutations has not been so extensively researched as 
KCNJ11 neonatal diabetes.   
Nevertheless, ABCC8 neonatal diabetes is amenable to treatment with 
sulphonylureas with ~85% patients able to transfer from insulin onto 
glibenclamide with improvements in glycaemic control, which is maintained in 
the short-term (80).  Previous research has suggested that lower doses of 
sulphonylurea are required to treat ABCC8 neonatal diabetes in comparison to 
KCNJ11 neonatal diabetes (80, 81), although many studies of ABCC8 neonatal 
diabetes contained a higher proportion of individuals with TNDM (76, 80) which 
may have resulted in a lower average dose.  Further studies are needed 
specifically in ABCC8 PNDM to assess this in more detail.  
ABCC8 and KCNJ11 are both expressed in the brain as well as the pancreas 
(82, 83), which explains why neurological features have also been described in 
patients with ABCC8 mutations.  Early observational studies suggested that the 
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CNS phenotype may be less frequent and / or severe in ABCC8 neonatal 
diabetes than in individuals with KCNJ11 mutations (76, 84, 85), although 
detailed neurobehavioural assessments of ABCC8 patients are lacking.  In the 
largest cohort study to date of individuals without DEND/iDEND, subtle deficits 
in attention and praxis were present in a similarly high proportion (~80-100%) of 
KCNJ11 and ABCC8 patients (22).  In addition, the more overt CNS features 
appear to respond to a degree to sulphonylurea therapy.  In 2 patients with 
ABCC8 mutations followed prospectively in the study by Beltrand et al., both 
had improved tone after 12 months of treatment with sulphonylureas, although 
other neurological features persisted (44).  Further investigation of the CNS 
features and response to treatment specifically in patients with ABCC8 neonatal 
diabetes will be crucial to allow more accurate genetic counselling and clinical 
management of this subgroup of patients in the future.   
Impact of technology on diagnosis and management in neonatal diabetes 
The replacement of Sanger sequencing with high throughput targeted next 
generation sequencing (tNGS) means that many genes can now be tested 
simultaneously, rapidly and relatively cheaply (86).  Gene panels used to test 
for neonatal diabetes yield a genetic diagnosis in over 80% of cases (13).  In 
non-consanguineous populations, almost half of the cases identified will have a 
KATP channel mutation and will be sulphonylurea responsive therefore a rapid 
genetic diagnosis is crucial for selecting the optimum treatment.  Furthermore, 
early genetic diagnosis facilitates prediction of prognosis including development 
of extra-pancreatic features (13).   
As cohorts of patients with KCNJ11 neonatal diabetes become older, the 
number of monogenic pregnancies will rise and in each case, there will be a 
50% chance of the offspring of an affected parent inheriting the causal variant.  
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The use of cell free fetal DNA (cffDNA) to identify those babies who have 
inherited mutations at an early stage of development (87) affords opportunities 
at both a clinical and research level.  Glibenclamide can cross the human 
placenta and stimulate the fetal pancreas (88). This is supported by reports of 
macrosomia due to excess insulin-mediated growth and neonatal 
hypoglycaemia in non-diabetic infants of mothers with KCNJ11 mutations who 
have been treated with sulphonylureas during pregnancy (89).  However, for the 
affected fetus of a mother with a KCNJ11 mutation the potential benefits of 
maternal glibenclamide therapy in pregnancy are two-fold.  Firstly, stimulation of 
fetal insulin secretion can normalise birth weight (90).  Secondly, there is a 
potential positive impact on neurodevelopment in the affected fetus, although 
this would have to be tested formally in a longitudinal research study.  
Therefore, cffDNA is another exciting technological advance that is making 
extremely early diagnosis, selection of specific therapies in pregnancy and 
prospective research into the in utero effects of KCNJ11 mutations a possibility 
for affected individuals. 
Conclusions and contributions of this thesis to the scientific literature 
Discovery of the KCNJ11 gene and its role in neonatal diabetes was a hugely 
exciting breakthrough that changed many lives for the better by allowing 
treatment change from insulin to sulphonylureas.  Affected individuals not only 
exemplify beautifully the utility of precision medicine in monogenic disease, but 
they represent unique human models for the study of biological pathways 
related to KATP channels which may have wider relevance for more common 
polygenic conditions.  Research in the field has grown rapidly over the past 15 
years, with increasing interest in the CNS manifestations of KCNJ11 mutations 
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as well as the diabetes and the response of both aspects to sulphonylurea 
therapy.    
The research described in this thesis addresses key gaps in knowledge relating 
to KCNJ11 neonatal diabetes, by investigating crucial questions about 
sulphonylurea treatment response and exploring both pancreatic and extra-
pancreatic features of the condition.  Part 2 of the introduction and all of the 
data chapters are peer-reviewed publications, which have made a significant 
contribution to the scientific literature, as well as forming the basis for future 
studies in the field of neonatal diabetes.  Importantly, the translational nature of 
the research has also resulted in a positive impact on patient care.   
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Abstract  
Precision medicine, the concept that specific treatments can be targeted to 
groups of individuals with specific genetic, cellular or molecular features, is a 
key aspect of modern healthcare and its use is rapidly expanding.  In diabetes 
the application of precision medicine has been demonstrated in monogenic 
disease, where sulphonylureas are used to treat patients with neonatal diabetes 
due to mutations in ATP-dependent potassium (KATP) channel genes. However, 
diabetes is highly heterogeneous, both between and within polygenic and 
monogenic subtypes.  Making the correct diagnosis and using the correct 
treatment from diagnosis can be challenging for clinicians, but it is crucial to 
prevent long-term morbidity and mortality.  To facilitate precision medicine in 
diabetes, research is needed to develop a better understanding of disease 
heterogeneity and its impact on potential treatments for specific subtypes.  
Animal models have been used in diabetes research but they are not 
translatable to humans in the majority of cases.  Advances in molecular 
genetics and functional laboratory techniques, and availability and sharing of 
large population data provide exciting opportunities for human studies.  This 
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review will map the key elements of future diabetes research in humans and its 
potential for clinical translation to promote precision medicine in all diabetes 
subtypes.   
 
Introduction 
Diabetes is a heterogeneous group of metabolic disorders that represents an 
enormous health burden globally. In 2014, an estimated 422 million adults had 
diabetes, and the prevalence continues to rise.[1,2]  Complications related to 
diabetes cause significant morbidity and mortality.[1]  At a time when healthcare 
resources to support an ageing population are limited, it is crucial to develop 
more effective treatments and make sure that patients receive the treatment 
appropriate to their condition.  
Diabetes is multifactorial and caused by both genetic and environmental factors. 
Monogenic forms of diabetes (caused by mutations in single genes), including 
Maturity Onset Diabetes of the Young (MODY) and neonatal diabetes 
(diagnosed before 6 months of age), are rare, representing ~3.6% of all cases 
diagnosed under 30 years.[3]  Indeed, for most types of diabetes, multiple 
genes are involved.  Type 1 diabetes (T1D) is characterised by insulin 
deficiency most often resulting from immune-mediated destruction of pancreatic 
beta (β) cells, whilst Type 2 diabetes (T2D) results from insulin resistance and 
hence β cell failure.[4]  Also, it is becoming clear that specific subtypes within 
T1D and T2D have different aetiologies. Correct diagnosis is crucial to allow 
selection of appropriate therapy, but this can be a challenge for clinicians; even 
the UK Prime Minister was misdiagnosed as having T2D and started on the 
wrong treatment before it became apparent that she had T1D requiring insulin 
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therapy.[5]  Indeed, up to 15% of patients with diabetes are misclassified in 
Primary Care in England.[6]  A recent cross-sectional study showed rates of 
misclassification are particularly high in those patients with T2D (defined by 
presence of significant endogenous insulin secretion more than three years 
after diagnosis) who are older (>34 years) at diagnosis and who start insulin 
immediately; they are misclassified as T1D in around half of cases.[7]  This 
experience is not unique to the UK; an 11 year follow-up of an American 
paediatric diabetes cohort revealed initial misclassification of diabetes in over 
20% of individuals.[8]  Add to this the heterogeneity within T1D and T2D, and 
diagnostics and treatment become a major challenge even for the most 
experienced clinicians.   
Precision medicine is the tailoring of treatment to specific molecular or cellular 
characteristics of groups of patients; this can also be influenced by 
environmental and lifestyle factors.  Precision medicine is rapidly becoming a 
key concept in many areas of modern clinical practice.[9]  Perhaps its most 
widely recognised application is in oncology, where the specific genetic profile 
of the tumour can determine the targeted treatment.[10,11]  However, the 
precision approach has also been applied to other areas of medicine[9], and the 
field is rapidly developing, largely due to ongoing advances in molecular genetic 
techniques such as next generation sequencing (NGS).[12]   
There is increasing interest in applying precision medicine to diabetes. In fact, it 
has already been done in rare monogenic subtypes of the disease, but there 
are challenges when it comes to applying precision medicine to T1D and 
T2D.[13-15]  One aspect that makes translational research for new targeted 
treatments particularly challenging in common polygenic subtypes of diabetes is 
the heterogeneity within these broad disease categories as described above.  
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The first step will be developing an understanding of the often subtle differences 
in pathophysiology and factors influencing treatment response between 
individuals with the same ‘type’ of diabetes.  This has not been possible using 
artificial animal models of diabetes.  Even though the recent advances in human 
research methods are more promising than using animals, still some difficulties 
exist as the lessons learned from monogenic disease are not readily 
translatable to polygenic diabetes.[13]   
To facilitate application of a precision medicine approach in diabetes, a 
comprehensive map of the pathophysiology and treatment targets for each 
known diabetes subtype is needed, in-keeping with the ‘adverse outcome 
pathway’ based approach applied to human drug discovery.[16]  In this review, 
we will outline why applying precision medicine to diabetes is unachievable 
using research findings from traditional animal models, and discuss the 
challenges faced in future translational research in the field. 
 
Animal models of diabetes are not reliably translatable to humans  
Animals have been used in diabetes research for over a century in an attempt 
to create models that are relevant to humans.[17,18]  To date, there is no single 
animal model that accurately represents all aspects of human T1D or T2D.  
Rodent models have provided some insights into isolated pathways and 
mechanisms relevant to polygenic diabetes without the time and expense 
associated with clinical trials and long term follow up studies in humans.[19]  
However, results from these experiments must be interpreted with caution. Most 
animal models have little relevance to human diabetes; this is exemplified by 
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the problems encountered when attempting to translate animal models of T1D 
and T2D to humans.   
 
Animal models in T1D 
Early spontaneous rodent models of T1D include the Non Obese Diabetic 
(NOD) mouse 20 and the bio breeding (BB) rat.[21-23]  In the NOD mouse, 
insulitis occurs at 3-4 weeks of age and is accompanied by infiltration of islets 
by CD4 and CD8 lymphocytes, resulting in cytotoxicity and β-cell destruction 
with onset of overt diabetes at around 18 weeks.  However, the patterns of 
insulitis seen in NOD mice are different to those observed in human T1D.[24]  In 
addition, there are significant gender differences in the prevalence of diabetes 
in NOD mice,[25] with females showing earlier onset and more aggressive 
disease, likely due to modification of cytokine production and STAT4 gene 
expression by sex hormones.[25]  The gender difference noted in the mice is 
not apparent in human T1D; this is one of the few circumstances where an 
autoimmune disease does not occur more frequently in females.[26]  BB rats 
develop diabetes at 8-16 weeks of age and have severe insulin deficiency, but 
despite not showing the gender differences seen in NOD mice, the rats are 
lymphopaenic [27], which is not a characteristic of T1D in humans.  Importantly, 
in both NOD mice and BB rats, therapeutic interventions for diabetes that have 
shown promise e.g. oral insulin and nicotinamide, have not been successful 
when tried in humans.[28,29]  More recently, the Akita mouse, which has a 
mutation in the insulin 2 gene, has been used as a genetically-induced model of 
T1D.[30]  These mice show severe insulin deficiency and have a short lifespan; 
however, caution should be used in extrapolating findings from a monogenic 
model in a rodent to a more complex polygenic disease in humans, as the 
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pathophysiologies are likely to be different.  The lymphocytic choriomeningitis 
virus (LCMV) rat is a virus-induced model of T1D.[31]  LCMV is a rodent-borne 
virus but if human infection occurs, there can be neurological sequelae, 
particularly in the context of congenital infection.[32]  However, LCMV has not 
been linked with diabetes in humans. Indeed, the types of viruses and their 
precise role in the pathophysiology of T1D in humans is still an active area of 
research,[33] therefore the mechanisms of disease are likely to be different to 
the LCMV-induced rat model.   
 
Animal models in T2D 
Rodent models of T2D can be categorised into obese and non-obese and are 
similarly flawed by their inability to fully capture the human phenotype.  Non-
obese models, generated by selective inbreeding, include the Nagoya-Shibata-
Yasuda (NSY) mouse and the Goto-Kakizaki (GK) rat.[34,35]  Similar to the 
T1D NOD mouse, the NSY mouse shows gender differences in the prevalence 
of diabetes[25], with a cumulative incidence of diabetes of 98% and 31% at 48 
weeks of age in males and females respectively.[34]  This pronounced male 
excess is not observed in humans with T2D.[26]  GK rats have had some utility 
in the study of diabetes complications and beta cell dysfunction but limitations 
include significant heterogeneity between different rodent populations leading to 
variation in the aetiology of hyperglycaemia, which appears to be mainly due to 
beta cell dysfunction and / or reduced mass as opposed to insulin 
resistance.[18]  
The most widely used models of T2D in animals are the obese models, 
comprising the monogenic leptin-deficient ob/ob mouse and the leptin receptor 
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deficient db/db mouse.[36,37]  Both have severe obesity as well as 
hyperinsulinemic hyperglycemia.[18]  In humans, it is known that the monogenic 
leptin deficiency from either a leptin or a leptin receptor gene mutation is 
associated with unregulated appetite and very severe obesity[38,39], but 
despite this, T2D has not been described to date in these patients.  The most 
severe hyperglycaemia in ob/ob mice occurs aged 3-5 months and the severity 
decreases thereafter; islet volume in the pancreas is increased and insulin 
secretion is maintained.[40]  This process does not reflect the β cell failure seen 
in human T2D.  In db/db mice, ketosis occurs at a few months of age and they 
do not live long (only 8-10 months).[41]  Again, this does not reflect the natural 
history of T2D in humans.  For full detailed reviews of animal models in 
diabetes, see King A, British Journal of Pharmacology 2012.[18] 
 
Animal models in monogenic diabetes 
Rodent models of monogenic diabetes have tended to follow on from the 
discoveries of single gene aetiologies in humans.  They have had some utility in 
providing support for hypotheses relating to mechanism and expression 
patterns for specific genes, particularly in MODY caused by mutations in the 
transcription factors Hepatocyte Nuclear Factor 1 Alpha (HNF-1A)[42,43], 
Hepatocyte Nuclear Factor 1 Beta (HNF-1B)[44], and in neonatal diabetes due 
to KCNJ11 mutations.[45-47].  However, the phenotype of the monogenic 
mouse, both in relation to diabetes and extra-pancreatic features, is not always 
consistent with what is observed in humans.[48,49]  In addition, the natural 
history of disease may differ, for example humans with glucokinase MODY do 
not have renal complications long-term which contrasts with the proteinuria and 
structural kidney changes observed in a liver-specific hemizygous glucokinase 
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knockout mouse model.[50,51]  These issues limit translatability of such animal 
models to monogenic diabetes in humans. 
 
Human research is needed to address the questions that cannot be answered 
using animals 
The fundamental differences in the natural history of T1D and T2D in animal 
models and humans makes it impossible to interrogate these broad disease 
categories at an individual or indeed subgroup level using rodents.  Monogenic 
diabetes rodent models bear a slightly closer resemblance to their human 
equivalents but clinical translation remains limited. As research in animals does 
not provide the insights into the heterogeneity of diabetes that are needed for 
therapeutic advances in the field, new approaches, focusing on research in 
humans, are needed (Table 1).   
 
Advances in human molecular genetics have driven treatment change and 
improved clinical care in monogenic diabetes 
We have outlined the significant limitations of using a monogenic disease in 
animals to model a disease that is polygenic in humans.  However, one key 
question is whether we can learn lessons from monogenic diabetes in humans 
that are generalisable to polygenic forms of diabetes.  
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Table 1.  Opportunities and limitations in diabetes research.  
NGS = next generation sequencing.   
+++ = excellent potential for future advances    
++ = good potential   
+ = possible potential   
- = limited potential 
 
Advances in human genetics have revolutionised monogenic diabetes research 
and clinical care for affected families by accelerating gene discovery and 
Models in diabetes 
research 
Utility Limitations Facilitators Future 
potential 
Human  Populations * GWAS for risk 
variants in polygenic 
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allowing better treatments to be developed for some subtypes. Historically, 
single candidate genes for a disease in question were screened using Sanger 
sequencing. This is an accurate method of sequencing, but the analysis is 
relatively slow and expensive as single genes need to be analysed sequentially 
in sections (by exon). Sanger sequencing of specific genes is therefore not ideal 
for disorders where there is significant overlap in phenotype both within and 
between different genetic aetiologies, or where the genetic cause is not yet 
known. Next-generation sequencing is a relatively new technique that allows 
sequencing of many genes all at once, at a similar cost to sequencing just a few 
genes by the traditional Sanger method.[12]  This is highly advantageous in 
monogenic diabetes, where an early and rapid genetic diagnosis is crucial for 
two reasons.  Firstly, there are treatments that are available for specific types of 
diabetes but not for others.  For example, Maturity Onset Diabetes of the Young 
due to HNF1A/4A mutations can be treated with low-dose sulphonylureas; 
neonatal diabetes due to potassium channel gene mutations can be treated with 
high-dose sulphonylureas, whereas mild fasting hyperglycaemia due to 
glucokinase mutations does not require pharmacological treatment.[13]  
Secondly, early identification of diabetes caused by a single gene allows early 
prediction of other (extra-pancreatic) clinical features associated with that 
specific gene, facilitating provision of necessary support and interventions soon 
after diagnosis; in the case of neonatal diabetes this would be in the first six 
months of life. This contrasts with previous approaches where clinicians would 
have to wait for the patient to develop extra-pancreatic features before 
determining which genes to sequence.[52]  In neonatal diabetes a genetic 
diagnosis can now be made in 80% of cases,[52] because all babies who 
present with diabetes in the first 6 months of life can have a panel of known 
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disease-causing genes sequenced rapidly and accurately using the NGS 
method.   
 
Humans with KCNJ11 mutations represent the best example of precision 
medicine in diabetes  
A good example of precision medicine in monogenic diabetes is the treatment 
of KCNJ11 neonatal diabetes with sulphonylureas.[53]  KCNJ11 encodes the 
Kir6.2 subunit of the pancreatic ATP-dependent potassium (KATP) channel; it is 
present in β cells and links blood glucose to insulin secretion. In 2004, the 
sequencing of KCNJ11 in human subjects established mutations in this gene as 
a cause of permanent neonatal diabetes (PNDM).[54]  PNDM affects 
≈1/100,000 live births[55] and is defined as diabetes diagnosed within the first 6 
months of life.  To date there have been 24 genetic causes of neonatal diabetes 
identified,[52,56,57] and KCNJ11 mutations are the commonest cause 
accounting for around one third of all cases.[52] 
KCNJ11 mutations result in diabetes by rendering the KATP channel 
unresponsive to metabolically-generated ATP. Affected babies are clinically 
very sick and show insulin deficiency, with almost 80% presenting in diabetic 
ketoacidosis (DKA).[58]  Until pathogenic variants in the KCNJ11 gene were 
discovered these children were thought to have T1D and were treated with 
insulin injections.[54]  Physiological experiments in affected individuals 
highlighted the possibility that sulphonylureas, used in T2D to bind and close 
the KATP channel, could be used as a targeted treatment option in KCNJ11 
PNDM. This was confirmed in 2006 when the first large cohort study showed 
that 90% of patients were able to switch from insulin injections onto oral 
58
sulphonylureas with improvements in glycaemic control and less glycaemic 
variability.[53,59]  Inability to switch, although uncommon, is associated with 
specific genotypes and long duration of diabetes before attempting to change 
treatment.[60,61]  In those who switch successfully, the excellent initial 
glycaemic response is maintained over at least 5 years and is not associated 
with any increase in hypoglycaemia rates.[62-64]    
The repurposing of an existing oral diabetes therapy that resulted in near 
normalisation of blood glucose for the great majority of affected individuals with 
KCNJ11 PNDM was life-changing for patients and their families, and human 
research was crucial for this discovery.  Indeed, without the gene discovery and 
the clinical trial of targeted therapy in humans, people with KCNJ11 PNDM 
would have remained on a treatment that was not very efficient and that allowed 
only suboptimal glycaemic control, leading to increased risk of long-term 
diabetes complications.   
 
Neurological features in KCNJ11 PNDM reflect expression of the KCNJ11 gene 
in the brain and vary according to genotype 
Initial reports of KCNJ11 PNDM showed that  ≈20% of affected individuals 
exhibited overt and severe neurological features in addition to their diabetes; 
this was named DEND syndrome (developmental delay, epilepsy and neonatal 
diabetes - or intermediate DEND (iDEND) if epilepsy was not evident in the first 
12 months of life.  The clinical phenotype was found to be related to the 
genotype, with more severe clinical features being associated with the more 
functionally severe mutations.[49,66]  For example, early studies reported 
developmental delay / intellectual disability (often severe), motor problems and / 
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or epilepsy in ≥80% of patients with the V59M mutation, in contrast to the 
R201H mutation where diabetes without neurological features was reported in 
>95% cases.[54,59,66-77]   
The presence of neurological features in this type of diabetes is due to 
expression of KCNJ11 in KATP channels in several brain regions as well as the 
pancreas, with particularly high levels of expression in the cerebellum.[78]   
Recent research has shown that in addition to the classical DEND syndrome, 
patients can have a range of other specific features.  Neurodevelopmental 
disorders such as autism and ADHD are associated with the more functionally 
severe mutations like V59M.[79,80]  Furthermore, a range of specific 
neuropsychological impairments affecting executive function, attention, praxis, 
working memory, vocabulary, and visuomotor performance have been 
identified.[79,81-83]  Interestingly, subtle abnormalities are also observed in 
patients with mutations previously thought to cause diabetes alone e.g. R201H. 
One large cohort study of patients without overt neurological features reported 
attention deficits in all patients and dyspraxia (developmental coordination 
disorder) in 80%.[81]   
Performing this detailed phenotyping in humans has provided clinical insights 
that would not have been possible using non-human research methods.  For 
example, selective expression of the V59M mutation in the rodent brain gives 
rise to a model of DEND syndrome which shares characteristics with the human 
neurological phenotype.[46]  However, there are also notable differences e.g. 
the mice show reduced anxiety behaviour whereas humans show more 
anxiety.[47,79]  In addition, the milder neurological phenotypes associated with 
other mutations in the same gene have not been explored in rodent models, 
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and subtle cognitive deficits would be very difficult to assess in animals in the 
same way as they can be assessed in humans. 
 
Impact of sulphonylureas on the neurological phenotype in KCNJ11 PNDM, and 
generating mechanistic hypotheses from the rodent model 
In addition to achieving excellent metabolic control, an exciting aspect of 
switching patients with KCNJ11 mutations from insulin to sulphonylureas, which 
was initially described in clinical case reports and neuroimaging studies, is an 
improvement in the neurological features.[76,84,85,86,87]  This was recently 
confirmed by a prospective study which showed partial improvement in some of 
the neurological features in the first year after switching to sulphonylureas.[88]  
It has been suggested that the neurological response may be better the earlier 
in life the sulphonylureas are started,[83] due to increased neuroplasticity in 
younger children, but further studies are needed to address this issue. 
Another possible reason for the incomplete CNS response to sulphonylurea 
treatment in people with KCNJ11 PNDM is that therapeutic concentrations of 
sulphonylurea are not achieved in the human CSF.  In rats, active transport of 
glibenclamide out of the brain across the blood brain barrier (BBB) has been 
demonstrated.[89]  Therefore high concentrations of glibenclamide, as seen in 
the blood, are not achieved in the brain.  This concept has led to clinical 
recommendations of higher doses of sulphonylureas in individuals with 
neurological features, with improvements reported by patients at doses of 
around 1mg/kg/day glibenclamide. These higher doses appear to be safe with 
no increase in rates of hypoglycaemia.[90]  However, given the issues around 
translation of animal models outlined above, and the structural differences 
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between the rodent and human brain,[91] it will be important to confirm in future 
human studies how glibenclamide and other sulphonylureas are handled in the 
human CNS.  This may include direct in vivo measurement of sulphonylurea 
concentrations in human cerebrospinal fluid (CSF), or the use of in vitro 
experiments with BBB models[92] which may provide a potential means of 
investigating this question without the risks of invasive procedures in patients.   
 
Lessons learned from KCNJ11 PNDM are not directly applicable to all neonatal 
diabetes or to polygenic forms of diabetes 
KCNJ11 PNDM is a good example of how human molecular genetics has driven 
the application of precision medicine in diabetes.  However, KCNJ11 mutations 
are only one cause of neonatal diabetes, and findings in one subtype are not 
generalisable to all, although the general concept of using molecular genetics to 
determine aetiology and treatment can be applied more widely (Figure 1).  
Other subtypes of neonatal diabetes are caused by mutations in a variety of 
genes; all share the clinical characteristic of diabetes in the first 6 months of life, 
but there are significant phenotypic differences between them.  For example, 
people with neonatal diabetes due to insulin (INS) gene mutations (which 
account for around 10% of cases of neonatal diabetes) do not have any specific 
neurological phenotype[93], whereas CNS features comprise a large part of the 
phenotype in KCNJ11 PNDM, as discussed above.  Individuals with other 
syndromic forms of neonatal diabetes have neurocognitive impairments in 
addition to other multi-system features e.g. GATA6 mutations cause cardiac 
defects, pancreatic exocrine insufficiency, gut abnormalities and hypothyroidism 
/ hypopituitarism.[94]   
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Figure 1; Human-specific research methods (orange boxes) can be applied to 
key areas (green boxes) relevant to diabetes pathophysiology, leading to 
development of new targeted treatments. 
 
In addition to phenotypic differences, differing genetic aetiologies also means 
that different treatment approaches are needed.  Heterozygous dominant 
negative INS mutations result in production of structurally abnormal 
preproinsulin and proinsulin within the beta cell, ER stress, cell death and 
absolute insulin deficiency.[52]  This requires lifelong treatment with 
replacement doses of insulin[95], in stark contrast to the sulphonylurea-
sensitivity of patients with KCNJ11 mutations.[53]  Even within KCNJ11 
neonatal diabetes, there is heterogeneity amongst patients with the same 
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mutation in terms of phenotype and treatment response, as described above.  
This heterogeneity is true for all subtypes of diabetes, including the common 
polygenic forms (T1D and T2D); however, it provides an opportunity to define 
discrete subgroups in a precise manner, with significant implications for new 
drug discovery and repurposing of existing treatments. 
 
A human-specific roadmap for future diabetes research  
We have established that findings obtained with animal models are not 
efficiently translated into humans, and it is impossible to generalise research 
findings from one subtype of human diabetes to another.  Therefore alternative 
approaches are needed to drive advances in diabetes research that are 
clinically translatable.  A range of rapidly evolving methods can be applied to 
human cells and human populations to enhance understanding in key areas, 
facilitating development of new targeted treatments between and within all 
subtypes of diabetes and allowing application of precision medicine (Figure 1). 
 
The impact of molecular genetics in T1D and T2D – aetiology and correct 
diagnosis 
Before we can develop effective new therapies in diabetes we must identify and 
understand aetiological pathways that can provide targets for treatment.  One of 
the ways in which human molecular genetics has enhanced our understanding 
of the pathophysiology of polygenic diabetes is through genome wide 
association (GWA) studies.[96,97]  These have been made possible by 
development of high throughput genotyping technologies such as NGS, 
increased availability of large cohorts of individuals with the disease in question 
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and control population data with which to compare them (see below), and better 
understanding of sequence pattern variation.[97]  Over 100 T2D susceptibility 
loci have been identified to date, and there is now much focus on determining 
the function of associated genes and the pathways in which they play a role.[98]  
However, interpretation of the function of associated genetic variants is 
challenging as it is frequently difficult to prove a causal link between the variant 
and the disease.[98]  In addition, effect sizes of causal variants in T2D are 
small,[97] making it extremely difficult to develop specific therapies targeted at a 
single gene or pathway, as has been described above for monogenic diabetes.  
For these reasons clinical translation of GWAS findings has been limited to 
date.  In the future, as whole genome sequencing becomes less costly it is likely 
that larger populations will be screened which may assist the discovery of new 
variants or help explain existing associations and how they relate to T2D risk.  
Further, advances in functional experimental techniques may enhance our 
ability to move from associations to causal relationships.  T2D GWAS will 
therefore be an important tool in terms of biological insights, drug targets, and 
disease prediction (Figure 1). 
Despite the complexities of functional interpretation of genetic risk variants in 
polygenic diabetes, they can be useful in assisting diagnosis, which is 
fundamental for selecting the correct treatment.  In T1D, a genetic risk score 
(T1D GRS) comprising 30 T1D-associated risk variants each weighted 
according to individual risk contribution, has been developed; this score can 
reliably differentiate T1D from T2D, and T1D from monogenic diabetes.[99,100]  
The T1D GRS is now being used in both research and clinical contexts.  This 
has significant implications in terms of making the correct clinical diagnosis 
early and starting the correct treatment, as well as ensuring phenotypic purity in 
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research cohorts in T1D.  As it is a relatively low-cost investigation, its use is 
likely to become more widespread in the future and there is potential for similar 
methodology to be applied to other polygenic diseases.  
Finally, genes involved in monogenic diabetes may also be implicated in 
polygenic disease, for example activating mutations in KCNJ11 cause neonatal 
diabetes whilst the common E23K variant in KCNJ11 has been associated with 
T2D susceptibility.[54,101]  Therefore monogenic diabetes has utility in 
identifying potential mechanisms that contribute to polygenic diabetes risk.[102]  
However, the complex inheritance patterns, multifactorial aetiologies and small 
effect sizes of genetic risk variants in polygenic diabetes give rise to very 
heterogeneous populations of patients, and multiple complementary 
approaches are required to unpick this. 
 
Availability of large population based data sets and sharing of data can provide 
new insights into polygenic diabetes  
Historically, one of the drawbacks of research in humans has been the inability 
to power studies adequately due to lack of availability of cohorts of patients with 
a specific disease or aspects of a disease of interest.  This is particularly 
problematic in genetics studies, where large populations are required to identify 
risk variants with relatively small effect sizes in polygenic diseases like T1D and 
T2D.  In recent years, the problem has been mitigated by the availability of 
increasing numbers of large-population research cohorts, such as UK 
Biobank.[103]  UK Biobank contains anonymized health data, including genetic 
and clinical information, on over 500,000 volunteers which is available for 
approved researchers to use.  Application of rapidly advancing bioinformatics 
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techniques to these population-based datasets represents an exciting 
opportunity to gain novel insights.  Indeed, one recent publication using UK 
Biobank and applying the T1D GRS outlined above[100] provided new insights 
into T1D, by demonstrating persistence of T1D risk beyond the age of 30 
thereby highlighting the need for clinicians to continue to consider this diagnosis 
in adults.[104]     
Another means of acquiring data from large populations is data sharing from 
large-scale clinical trials, which is now actively encouraged and endorsed by 
many trial sponsors and influential bodies.[105]  Full individual participant data 
for many trials can be requested and accessed by researchers via websites 
such as Clinical Study Data Request.[106]  Secondary analysis and statistical 
modelling of trial data allows evaluation of outcomes in subgroups of patients 
based on clinical characteristics, presence of specific biomarkers, or genotype. 
These population-based methods can facilitate an alternative approach to 
precision medicine in polygenic forms of diabetes, such as T2D, whereby 
clinical features and biomarkers are used to stratify patients into specific 
treatment  groups.[13]  An excellent example of this is using clinical features to 
stratify patients with Type 2 diabetes when deciding which second-line glucose 
lowering therapy to use.[107]  Therefore, future clinical research in diabetes will 
rely heavily on shared human population data. 
The concept of large scale data sharing is also applicable to genetic data.  NGS 
technologies have reduced the cost of genetic testing by a factor of between 
100 and 200 in the last 5 years.  As genetic testing continues to decrease in 
price and analysis methods improve, sequencing particularly at the level of 
exome or whole genome will become more accessible to larger numbers of 
individuals.  This will generate vast quantities of genetic data requiring accurate 
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interpretation, which can be a major challenge.  However, in recent years 
databases generated from data sharing containing genetic variants from human 
populations (e.g. the Genome Aggregation Database (gnomAD), Exome 
Aggregation Consortium (ExAC), dbSNP) and human disease (e.g. the Human 
Gene Mutation Database (HGMD), ClinVar) have revolutionised the ability of 
clinical scientists to interpret variants and their likely pathogenicity.  Further, 
initiatives such as the 100,000 genomes project seek to not only provide clinical 
diagnoses for people with rare genetic conditions, but also to generate a large 
population sample of genomic data that will be invaluable for researchers in the 
future as the patients’ health records and outcome data can be linked to their 
genetic data.[108]   
Indeed, the concept of integrating research with clinical practice has evolved 
substantially in recent years, particularly where there is availability of Electronic 
Health Records (EHR).  Primary Care is particularly well placed to apply this 
because many practices have moved to an EHR approach.  In the UK, Clinical 
Practice Research Datalink (CPRD) is a well-established source of anonymised 
clinical information from General Practice (GP) records that can be utilised for 
research; it has resulted in over 1800 publications to date.[109]  Most patients 
with diabetes are followed up clinically by their GP therefore this is a key 
opportunity for research in the field.  Indeed, it has been shown that diabetes 
and its treatment are two of the main topics of research being generated from 
primary care databases in the UK.[110]  However, there are several legal and 
ethical issues relating to data sharing and storage that have hindered the use of 
EHR in many healthcare settings; this is particularly pertinent when it comes to 
linking genomic data with personally identifiable data.[111,112]  To make the 
most of the opportunities afforded by EHR in the future, robust policies 
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addressing confidentiality and security of information should be developed by 
key regulatory authorities.[113] 
A caveat of the clinical and genomic data repositories that are currently 
available is the paucity of ethnic diversity in the populations studied leading to 
under-representation of non-European groups.[114]  The ever-increasing 
numbers of individuals contributing data to such repositories bodes well for 
improved stratification by ethnicity in the future, but in the meantime caution 
should be used when attempting to generalise findings to minority populations. 
 
Availability of human islets for research and new experimental techniques 
provide insights into pathways involved in diabetes pathophysiology  
Modern immunohistochemical and imaging techniques and availability of 
collections of specific human tissues for research can greatly enhance our 
understanding of the pathophysiology of diabetes.  A recent study of pancreas 
sections obtained at post-mortem from a UK cohort of patients with T1D 
provided exciting mechanistic insights, demonstrating a different insulitic profile 
in patients diagnosed under 7 years versus those diagnosed over 13 
years.[115]  In addition, the latter group retained ~40% of insulin containing 
islets at diagnosis, which implies β cell dysfunction as opposed to loss may be 
important. This work and ongoing research in the field will have important 
implications for patient stratification in T1D immunotherapy trials and in the 
development of targeted treatments for specific patient groups.  
Research in human islets harvested from cadaveric donors has also advanced 
knowledge relating to cellular and molecular pathways relevant to T2D. Recent 
advances in genetic techniques have facilitated identification of many T2D 
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susceptibility genes and allowed genetic data to be combined with functional 
data to map pathways and define mechanisms associated with human islet 
dysfunction, including key regulatory networks.[116,117]  These approaches 
have great potential to further enhance our understanding of polygenic forms of 
diabetes and gene-environment interactions, and in combination with findings 
from large population studies, to guide development of new therapeutic 
interventions. 
 
Precision medicine must also encompass patient preference and impact on 
quality of life 
Another area of precision medicine where human studies are essential is 
exploring the influence of psychosocial factors on patient outcomes.  Quality of 
life measures are frequently used in evaluating cost-effectiveness of medical 
interventions.[118]  Development of targeted treatments for specific subtypes of 
diabetes should therefore include research that evaluates patients’ perceptions 
of these treatments and impact on quality of life.  Even when the biological 
efficacy of new treatments has been proven, the willingness of patients to 
accept them will be variable and influenced by psychological factors.  For 
example, treatment change from insulin injections to oral sulphonylureas had a 
hugely positive impact on many families affected by KCNJ11 neonatal diabetes. 
They experienced improved quality of life, more freedom and reduced levels of 
psychological distress as a result of better glycaemic control, less glycaemic 
variability and reduced need for hypervigilance of parents towards their affected 
children.[119-121]  However, for a few adults with KCNJ11 mutations who had 
been assumed to have Type 1 diabetes all of their lives, there was initial 
uncertainty about the implications of a genetic diagnosis as it could result in a 
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loss of the insulin injections on which they had always been 
dependent.[119,120]  These individuals viewed insulin very much as part of 
their identity and loss of this identity required significant adjustment.[122]   
In addition, mental illness is a significant problem in individuals with chronic 
physical health conditions. The incidence and prevalence of depression is 
increased in people with diabetes[123], which will have implications for 
adherence, response and attitudes to new treatments.  Severe mental illness 
such as schizophrenia and bipolar disorder are associated with a 2-3 fold 
increase in diabetes prevalence and this is only partly explained by the adverse 
metabolic effects of antipsychotic treatment.[124]  Patient stratification using 
only biomarkers or genetic risk variants for diabetes does not take account of 
psychological influences and psychiatric co-morbidity.  Future models for 
precision approaches in diabetes should incorporate these ideas; this will be 
challenging but could be facilitated by integration of qualitative methods into 
biological studies and inter-disciplinary collaboration.   
 
Human-specific research can enhance understanding of heterogeneity and is 
the first step towards precision medicine across all subtypes of diabetes 
In diabetes, the correct diagnosis is essential to ensure the correct treatment is 
given.  However, both diagnostics and therapeutics continue to represent 
significant challenges to diabetologists.  Heterogeneity between and within 
subtypes of diabetes is becoming increasingly recognised and only serves to 
make the task more difficult.  To enable a precision medicine approach in 
diabetes, we need to significantly enhance our understanding of this 
heterogeneity.   
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Animals have been used historically to model diabetes in humans, but their 
utility is limited especially as the emphasis in humans is on specific treatments 
for specific diabetes subtypes.  The animal models used have fundamental 
genetic and phenotypic differences to diabetes in humans and cannot reflect the 
diversity of subtypes. This is exemplified by the lack of effective translation of 
treatments developed in animal models into humans.  Therapeutic advances in 
diabetes therefore require alternative human-specific research methods.   
Monogenic diabetes is an excellent example of the application of precision 
medicine.  In particular, the treatment of KCNJ11 neonatal diabetes with 
sulphonylureas represents the best precision approach in diabetes and 
illustrates how advances in human molecular genetic techniques have 
facilitated major discoveries, with huge implications for patient care.  However, it 
also illustrates how specific targeted treatment for one subtype within a broader 
category (in this case neonatal diabetes) cannot be generalised to all subtypes.  
In polygenic diabetes such as T1D and T2D, genetics can help by providing 
information about risk variants but effect sizes are small.  The situation is 
particularly complex given that within T1D and T2D there is significant 
heterogeneity between groups of individuals, whether they are defined by 
clinical characteristics or response to treatment. 
In summary, the road ahead in diabetes research is exciting but complex.  A 
combined approach that uses advanced molecular genetic techniques, 
pathway-focused research in human islets, computational methods in large 
population cohorts and trial data, qualitative research, and other techniques yet 
to be developed, may help to unpick the differences between diabetes 
subtypes. This will be the first step towards understanding and rising to the 
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challenge of heterogeneity in diabetes, to facilitate precision medicine and 
improved clinical care. 
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This section describes the methods used in the data chapters, focusing on 
those aspects not already covered in detail in the publications relating to each 
study.  Copies of the relevant documents are included in Appendix 1.  
CHAPTER 1 
In our long-term follow-up of patients with KCNJ11 PNDM, data collection forms 
were sent to participating clinicians to complete using the clinical records of 
their patients.  These forms contained fields relating to glycaemic control 
(including HbA1c and any episodes of hypoglycaemia or ketoacidosis), side 
effects, diabetes complications, puberty and development, other cardiovascular 
risk factors, and neurological features and whether these improved following 
transfer from insulin to sulphonylureas.   A copy of the data collection form can 
be found in Appendix 1. 
 
CHAPTER 2 
Meal plans and preparation 
In our study of the physiological response to different foods in people with 
sulphonylurea-treated KCNJ11 PNDM, meals were designed with the 
assistance of a diabetes dietician taking into consideration palatability and 
quantity required to achieve the desired proportions of given nutrients.  We 
opted for solid meals using everyday foods as opposed to a liquid meal to 
enhance generalisability to the ‘real-life’ context.  The content of the 
carbohydrate and protein meals are shown in Tables 1, 2a and 2b in Appendix 
1.  Three months into the study the original brand of ham used was 
discontinued therefore subsequent protein meals used a different brand of ham, 
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the quantity of which was adjusted to achieve near-identical proportions of 
nutrients to the original protein meal.   
Fasting guidelines 
Prior to each visit participants were asked to follow fasting guidelines as follows; 
• Eat normally on the day prior to the test.  
• Do not consume any alcohol for 48 hours before your visit.   
• Do not have anything to eat or drink (except water) from 10pm on the 
night prior the blood test.  Please drink plenty of water prior to your appointment 
but do not add anything to it.  You must not drink tea or coffee.   
• Do not consume any paracetamol or paracetamol-containing medicines 
for 24 hours before your visit.  Please take all other medications as normal apart 
from those that are to be taken with food (these are to be taken later with 
breakfast).  
• Exercise will affect your blood sugar so do not exercise excessively for 
48 hours prior to your visit.  
• Do not smoke on the morning of the test. 
Baseline data collection forms 
Baseline data comprising height, weight, medications and time of last food / 
drink were collected at each visit using the data collection form in Appendix 1. 
Hypoglycaemia questionnaires 
To screen for subjective symptoms of hypoglycaemia throughout the study 
visits, participants were given a questionnaire at each blood sampling time 
point.  This used a Likert scale (1-7, where 1 is absent and 7 is severe) to score 
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neuroglycopenic and autonomic symptoms as previously described (1, 2) 
(Appendix 1). 
Blood sampling, handling and storage 
Blood samples were obtained, processed and stored as per the sample 
handling / processing standard operating procedure (SOP) and study flowchart 
in Appendix 1.  These were developed in accordance with standard procedures 
employed by the Exeter NIHR Clinical Research Facility (CRF) and the Royal 
Devon and Exeter Hospital biochemistry laboratory.  Biochemical analysis of 
samples is described in the methods section in chapter 2.   
 
CHAPTER 3 
Medical and developmental history  
A medical and developmental history was obtained from the parent(s) of 
participating children.  This included information about diabetes presentation, 
sulphonylurea transfer and glycaemic control, any other medical problems 
(including epilepsy, previous psychiatric diagnoses and neurological features), 
current medications, family history, pregnancy and birth, ages at which major 
milestones (gross motor, fine motor, social / emotional and speech / language) 
were attained, education and learning support required.   
Psychiatric Evaluation 
The Development and Wellbeing Assessment (DAWBA) (3) and Strengths and 
Difficulties Questionnaire (SDQ) (4) are described in detail in chapter 3A.  




A selection of neuropsychological tests from different standardised batteries 
was used, with advice and guidance from the Consultant neuropsychologist in 
the study team.  The objective was to assess a broad range of cognitive 
domains whilst ensuring that the specific areas of difficulty that had been 
highlighted by affected individuals and families or described in previous studies 
were included (5).  Neuropsychological testing was undertaken at a neonatal 
diabetes family day event, by medical professionals in the research team who 
had been trained in administering the tests by the study Consultant 
neuropsychologist.  Tests were scored by the Consultant neuropsychologist and 
neuropsychology assistant.  Below is a description of the tests used and the 
standardised batteries to which they belong; 
Developmental Neuropsychological Assessment (6) explores the 6 domains of 
attention and executive functions.  For the purpose of this study we used only 
the ‘narrative memory’ subscale, which measures episodic memory, as the child 
is required to listen, store and recall a story. Children are asked to freely recall 
the story and are then cued with age-appropriate questions relating to it.   
Delis-Kaplan Executive Function System (7) tests various aspects of executive 
functioning.  We used the ‘verbal fluency’ subtest, which involves the young 
person being asked to generate as many words as possible in 1 minute using 
the letter ‘F’, and then to repeat this for words beginning with ‘A’, then ‘S’. No 
names of people or places should be used. The task is a test of abstract 
thought and cognitive flexibility whilst retaining rules.   
Wechsler Intelligence Scale for Children (8) measures full scale IQ.  We used 
three subscales of the WISC-IV. The first was the ‘symbol search’ task 
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measuring processing speed; it is a timed pen and paper test that assesses the 
ability to focus attention and quickly scan, discriminate between, and order 
visual information. The young person is asked to identify if a symbol presented 
on the left of the page is in the block of symbols on the right of the page.  The 
second subtest, ‘digit span’, assesses memory capacity and working memory, 
by measuring how many numbers can be remembered (forwards and in 
reverse) after they are read to the child by the examiner.  The ‘vocabulary’ 
subtest measures verbal comprehension. Words of increasing difficulty are read 
to the child and they are asked to define the words. The test is scored based on 
sophistication of the definition given.  Reliability coefficients for the subtests 
used are good (symbol search (.79), digit span (.87) and vocabulary (.89)) (9). 
Beery-Buktenica Test of Visual Motor Integration (10) involves written tasks 
used to assess fine motor skills, visual perception and visual-motor integration 
(‘hand eye coordination’).  The visual perception test presents the child with a 
series of geometric shapes of increasing complexity and underneath a series of 
shapes which are similar.  The child’s task is to identify the shape that is exactly 
the same. The motor coordination test requires children to copy increasingly 
complex geometric shapes within predetermined lines. The visual motor 
integration test requires the children to copy predetermined increasingly 
complex geometric shapes but with no guidance (10).  
 
CHAPTER 4 
All participants were assessed at home by the Consultant neurologist and 
Consultant neuropsychologist in the research team.  Each participant 
underwent a comprehensive neurobehavioural assessment.   
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Medical and developmental history and neurological examination 
The Consultant neurologist obtained a medical history, with an informant 
present if possible.  This included information about the participants’ early 
presentation with diabetes, episodes of hypoglycaemia, seizures, any other 
medical problems, medications, family history and social and occupational 
history.  A developmental history was also taken, which included information 
about the pregnancy and birth, ages at which major milestones (gross motor, 
fine motor, social / emotional and speech / language) were attained, education 
and any learning support required.  A full neurological examination was 
performed which involved assessment of tone, power, reflexes, coordination, 
and sensation, as well as a cranial nerve examination and some simple tests of 
motor sequencing and praxis.  
Questionnaires administered to participants / informants 
The Autism-Spectrum Quotient (AQ) (11, 12) (Appendix 1) contains 50 items 
relating to social skills, attention, communication and imagination.  The 
participant selects one response for each statement (definitely agree, slightly 
agree, slightly disagree, definitely disagree).  One point is given for each 
response that is associated with autism spectrum disorder (ASD), therefore 
higher scores indicate more autistic traits, with the clinical threshold being 32 
points or higher (11).  
The Hospital Anxiety and Depression Scale (HADS) questionnaire (13) 
(Appendix 1) is a mood assessment consisting of a series of 14 statements 
which the participant reads and rates from 0-3.  There are different statements 
relating to depression and anxiety, which are scored separately; a score of 11 
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or greater is the threshold for clinically significant depression or anxiety 
symptoms.  
The Cambridge Behavioural Inventory Revised questionnaire (14) (Appendix 1) 
is a functional and behavioural assessment which is completed by an informant 
/ carer who knows the participant well.  It is described in detail in chapter 4. 
Neuropsychological tests 
The Consultant neuropsychologist administered and scored a series of pre-
selected neuropsychological tests from standardised batteries.  As per the 
paediatric study, tests were selected to capture key areas of difficulty 
highlighted previously by patients and in the literature (5, 15, 16) whilst 
obtaining information on a broad range of cognitive domains.  The 
neuropsychological tests used are described in Chapter 4 and summarised 
briefly below;   
• The verbal paired associates and visual reproduction subtests of the 
Wechsler Memory Scale (WMS-IV) (17, 18) were used to assess verbal and 
non-verbal (visual) memory in terms of recall and recognition.  Verbal paired 
associates involves the examiner reading pairs of words to the participant and 
then presenting them with a word from each pair and asking them to recall the 
other word.  Visual reproduction involves the participant looking at designs for 
10 seconds each and then drawing the designs from memory. 
• The Wechsler Abbreviated Scale of Intelligence (WASI) was used as a 
brief measure of current IQ (19).  The vocabulary subtest involves the 
participant providing definitions for words and images provided by the examiner.  
The matrix reasoning subtest provides a series of patterns to the participant in 
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grids that are not fully complete; the participant has to choose the response that 
best fits each pattern. 
• The cancellation and digit span subtests of the WAIS-IV (18) were used 
to assess processing speed and working memory.  The cancellation subtest 
involves the participant looking at a sequence of pictures and then crossing out 
specific target pictures. The digit span subtest is administered as described 
above for the paediatric study. 
• The Colour Trails Test CTT1 and CTT2 were used to assess attention 
and hand-eye coordination (20). The CTT1 is a timed pen and paper test that 
involves the participant connecting circles numbered 1-25 in sequence.  The 
CTT2 applies the same principle but the participant alternates between different 
colours (21).   
• The Controlled Oral Word Association Test (COWAT) (22) was used as a 
test of executive function.  It is administered as described above for the ‘verbal 
fluency’ subtest in the paediatric study. 
• The Visual Object and Space Perception battery (VOSP)(23) was used 
to assess visuospatial function. The incomplete letters and object decision 
subtests measured object perception.  Incomplete letter involves a series of 
letters with parts missing being presented to the participant, who is asked to 
identify them. Object decision involves different stimuli being shown to the 
participant who has to select the real shape from the distractor stimuli.  The dot 
counting and cube analysis subtests assess spatial perception.  In the former, 
the participant counts black dots against a white background.  In cube analysis, 
the participant has to identify the number of cubes on boards showing a series 
of solid structures.  
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• The Addenbrooke’s Cognitive Examination-Revised (ACER) (24) 
(Appendix 1) was used as a broad cognitive screen, assessing 
attention/orientation, memory, fluency, language, and visuospatial function.   
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RESEARCH IN CONTEXT 
EVIDENCE BEFORE THIS STUDY 
A large cohort study established in 2006 that high dose sulphonylureas could be 
used to treat permanent neonatal diabetes (PNDM) due to KCNJ11 mutations.  
This was life-changing for patients as it allowed 90% to stop insulin injections 
and achieve better glycaemic control in the short-term (1 year) without any 
increase in hypoglycaemia. The short-term benefit of transferring to 
sulphonylureas has been replicated in many follow-up studies since then. A key 
question is whether this excellent outcome is maintained in the long-term, 
particularly as in type 2 diabetes after 5 years on therapy ~44% patients show 
sulphonylurea failure requiring additional therapies to maintain glycaemic 
control.  Furthermore, in type 2 diabetes sulphonylureas have been associated 
with hypoglycaemia, raising a safety question especially as high doses (typically 
0.2-0.8mg/kg/day glibenclamide) are used in PNDM compared to the lower 
doses used in type 2 diabetes (typically ~0·1mg/kg/day glibenclamide). 
 
We searched PubMed with the terms “KCNJ11”, “kir6.2”, “neonatal”, “diabetes", 
“sulphonylurea”, "sulfonylurea”, “glibenclamide”, “glyburide”, “therapy”, 
“treatment”, to identify follow up studies.  Only a few small (n<11) relatively 
short term (2.5-5.7 years) series have been reported with the best study to date 
reporting maintenance of good control in 11 patients from a single centre 
followed up for a median of 5.7 years.  Prior to our study it was not known when 
PNDM due to KCNJ11 mutations was treated with sulphonylurea therapy in the 
long-term (10 years) if the glycaemic control would be maintained, whether this 
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long-term therapy was safe and what would be the long-term impact on 
neurological features. 
 
ADDED VALUE OF THIS STUDY 
To our knowledge, this is the first study of the long-term efficacy and safety of 
sulphonylureas in a large multi-centre international cohort with KCNJ11 PNDM.  
We show that sulphonylurea failure, seen commonly in type 2 diabetes, is not a 
feature of KCNJ11 PNDM.  Sulphonylureas are safe long-term even in high 
doses in this unique group of patients and excellent glycaemic control is 
maintained over 10 years. Despite initial improvement in some patients, 
neurological features persisted on long term sulphonylureas. 
 
IMPLICATIONS OF ALL THE AVAILABLE EVIDENCE   
All babies diagnosed with diabetes under 6 months of age should undergo rapid 
genetic testing to facilitate early transfer of those with KCNJ11 mutations to 
sulphonylureas as first line treatment, and this should be expected to result in 
safe long lasting excellent glycaemic control for at least 10 years but 




KCNJ11 mutations cause permanent neonatal diabetes (PNDM) due to 
pancreatic KATP channel activation. 90% of patients successfully transfer from 
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insulin to oral sulphonylureas with excellent glycaemic control initially. It is not 
known if this outstanding example of precision medicine is maintained in the 
long term. Sulphonylurea failure is seen in ~44% of people with type 2 diabetes 
after 5 years of treatment. We report the first 10-year follow-up of sulphonylurea 
efficacy and safety in a large international cohort of patients with KCNJ11 
PNDM. 
METHODS  
We followed up 81 patients who transferred from insulin to sulphonylureas 
before December 2006. Primary outcomes were sulphonylurea failure and 
metabolic control. Secondary outcomes were adverse effects of sulphonylureas, 
diabetes complications, insulin secretory response, and impact of sulphonylurea 
therapy on neurological features. This study is registered with ClinicalTrials.gov, 
number NCT02624817. 
FINDINGS 
Median follow-up duration was 10.2 years. At recent follow-up, 75/81 (93%) 
remained on sulphonylureas alone. Excellent glycaemic control was maintained; 
median HbA1c pre-transfer to sulphonylureas was 8.1% (65.0mmol/mol), falling 
to 5.9% (41.0mmol/mol) at 1 year, p<0.0001 and 6.4% (46.4mmol/mol) at 10 
years, p<0.0001. Median sulphonylurea dose decreased (1-year 0.30 
mg/kg/day, 10-year 0.23 mg/kg/day, p=0.03). There were no reports of severe 
hypoglycaemia in 809 patient years on sulphonylureas. Eleven patients (14%) 
reported mild, transient side-effects but did not need to stop sulphonylureas. 
Seven patients (9%) had microvascular complications: they were on insulin 
longer compared to those without complications (median age at transfer 20.5 
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vs. 4.1years, p=0.0005). Despite initial improvement in some patients, 
neurological features persisted despite long-term therapy with sulphonylureas. 
INTERPRETATION 
Patients with KCNJ11 PNDM should be treated with high dose sulphonylurea 
therapy from diagnosis as this therapy is safe and highly effective, maintaining 
excellent glycaemic control for at least 10 years. 
 
FUNDING 
Wellcome Trust, Diabetes UK, Royal Society, ERC, Norwegian Research 
Council, Kristian Gerhard Jebsen Foundation, South-Eastern Norway Regional 




The best example of precision medicine in diabetes is the treatment of neonatal 
diabetes with sulphonylurea therapy [1]. Mutations in KCNJ11 resulting in 
activation of the pancreatic KATP channel are the commonest cause of 
permanent neonatal diabetes (PNDM) [2,3]. A genetic diagnosis is crucial as at 
least 90% of patients can transfer from insulin injections to oral sulphonylureas, 
which bind to the SUR1 component of the KATP channel resulting in channel 
closure enabling insulin secretion [4-6]. Following transfer to sulphonylureas, 
patients have improved glycaemic control at 1 year without increase in 
hypoglycaemia [6] and less glycaemic variability [4,5].  
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A key question has been whether the excellent results in neonatal diabetes will 
be maintained or whether there will be sulphonylurea failure or adverse side 
effects with long-term therapy. Sulphonylurea failure, where sulphonylurea 
therapy no longer maintains good glycaemic control, is seen in ~44% of people 
with type 2 diabetes after 5 years of treatment [7]. The only follow-up studies 
have shown that the glycaemic response to sulphonylureas is maintained in 
KCNJ11 PNDM but these have been single cases or small single centre cohorts 
(all n≤11) and of short duration (between 2.5-5.7 years) [8-10].  Furthermore, 
there are safety issues; hypoglycaemia is a known side effect of sulphonylurea 
treatment in type 2 diabetes, particularly in relation to glibenclamide [11] which 
is the sulphonylurea commonly used to treat KCNJ11 PNDM.  It is not known if 
hypoglycaemia and additional side effects will occur as a result of the long-term 
use of much higher doses of sulphonylureas in KCNJ11 PNDM compared to 
type 2 diabetes (0·45mg/kg/day vs. ~0·1mg/kg/day glibenclamide) [6].    
The long-term sustainability of therapy in KCNJ11 PNDM is an important 
question as in many other areas of precision medicine the initial excellent 
results have not been maintained.  For example, in oncology, long-term 
outcomes in clinical studies have been disappointing, primarily due to 
heterogeneity within tumours allowing selection and proliferation of subclones of 
cancer cells that are resistant to treatments targeted at specific pathways [12]. 
In addition to diabetes, patients with KCNJ11 mutations exhibit central nervous 
system (CNS) features, owing to expression of KCNJ11 in the brain as well as 
the pancreas [13].  CNS features range from the overt and severe DEND / 
iDEND syndrome comprising developmental delay, epilepsy and varying 
degrees of muscle weakness / hypotonia [14], to neurodevelopmental problems 
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such as autism and Attention Deficit Hyperactivity Disorder (ADHD) [15], to 
more subtle neuropsychological deficits, specifically inattention, dyspraxia and 
executive dysfunction [16,17].  A recent prospective study showed that 
sulphonylurea treatment results in a partial improvement in the CNS features in 
people with KCNJ11 PNDM in the first year of therapy [18].  However, the initial 
CNS response is not as marked as the glycaemic response, which may be in 
part due to active transport of glibenclamide out of the brain, resulting in sub-
therapeutic concentrations in the cerebrospinal fluid (CSF) [19].  An important 
question, which has not to our knowledge been investigated by any studies to 
date, is whether long-term therapy with sulphonylureas has an impact on CNS 
features in KCNJ11 PNDM.   
To address the key questions relating to long-term efficacy and safety of 
sulphonylureas in KCNJ11 PNDM, we performed a 10-year multi-centre follow-




Study design, setting and patient selection 
All patients diagnosed with KCNJ11 PNDM in laboratories in Exeter, Rome, 
Bergen, Paris, and Poland, who transferred from insulin to oral sulphonylureas 
prior to December 2006, were eligible for the study.  Clinicians collected clinical 
characteristics and annual data relating to glycaemic control, sulphonylurea 
dose, severe hypoglycaemia, side-effects, diabetes complications, and growth. 
Height and BMI were converted to SDS using WHO reference ranges [20]. 
Patients aged >19 years were assigned an age of 19 for calculating BMI SDS. 
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CNS features, both neurological and psychiatric, were documented prior to 
transfer and at most recent follow-up. Clinicians were specifically asked about 
clinical characteristics frequently associated with KCNJ11 mutations 
(developmental delay, learning difficulties, epilepsy, muscle weakness, autism, 
ADHD, sleep problems, anxiety) [15,17,18,21,22] and whether there was an 
improvement in CNS features at the time of transfer to sulphonylureas. In cases 
where the sulphonylurea used was not glibenclamide, the dose was expressed 
as a percentage of the maximum recommended daily dose (as per British 
National Formulary) and converted to an equivalent dose of glibenclamide [23]. 
Hypoglycaemia was defined as severe if the patient had a seizure, loss of 
consciousness or was admitted to hospital for intravenous glucose or glucagon, 
as per International Society for Paediatric and Adolescent Diabetes criteria [24]. 
The research was conducted in accordance with the Declaration of Helsinki.  
Clinical data was collected during the course of the patients’ routine care and 
was anonymised for use in the study.  Informed consent was obtained from all 
patients or parents for participation in the physiological studies. 
 
Physiological studies 
We performed oral and intravenous glucose tolerance tests in 6 patients on 




The primary outcomes were sulphonylurea failure, defined as permanent re-
introduction of daily insulin, and metabolic control, specifically HbA1c and 
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sulphonylurea dose. The secondary outcomes were severe hypoglycaemia, 
side-effects, diabetes complications, growth, and effects of sulphonylurea 
therapy on CNS features. 
 
Statistical analysis 
Data was analysed in Stata 14·0. Nonparametric statistical methods were used; 
Wilcoxon test for paired and Mann-Whitney test for unpaired data. Unless 
otherwise stated, results are presented as median (interquartile range [IQR]).  A 
primary objective of the study was assessing the number of patients needing 
reintroduction of insulin and the time to reintroduction of insulin therefore a 
Kaplan-Meier survival analysis was used (see Supplementary Appendix, 
statistical methods for details).  
For analysis of longitudinal annual follow-up data, we used values that were 
nearest to the transfer date anniversary. When values were not available within 
6 months either side of the anniversary of transfer, missing values were imputed 
(for year 1 data we included values from 3 months to 1.5 years) (see 
Supplementary Appendix, statistical methods for details) [6].  Where possible 
HbA1c and sulphonylurea dose were recorded on the same date within each 
year. When this was not possible the HbA1c and sulphonylurea dose were 
measured as close together as possible within the same year. In 2 patients, 
who were on insulin due to pregnancy at most recent follow-up, data from the 
most recent pre-pregnancy review was used. Patients who had received a short 
course of insulin treatment at any point during the follow-up but had 
subsequently transferred back to sulphonylureas, and patients who required 
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small occasional (non-replacement) doses of insulin, were assigned to the 
sulphonylurea only group.  
Data on hypoglycaemia was compared with a cohort from the Norwegian 
Childhood Diabetes Registry of 664 Norwegian patients with type 1 diabetes of 
duration mean(SD) 10.8(2.2) years, followed up for >8 years from diagnosis.  
This study is registered with ClinicalTrials.gov, number NCT02624817. 
 
Role of the funding source 
The funder of the study had no role in study design, data collection, data 
analysis, data interpretation, or writing of the report. The corresponding author 




The numbers of individuals in each stage of the study are shown in Figure 1. 
Ninety patients were eligible for inclusion and 81 (90%), were enrolled in the 
study and provided long-term (>5·5 years) outcome data.  
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Figure 1. Overview of Study Design.   
Flow diagram showing cohort selection and follow-up in accordance with 
Strengthening the Reporting of OBservational studies in Epidemiology 
(STROBE).  Long-term follow-up was achieved for 90% of the eligible patients. 
Duration of follow-up was median(IQR) 10.2(9.3-10.8) years. We used 5.5 years 
(year 6 data) as cut-off for the term ‘long-term’ follow-up. 
 
The clinical characteristics of patients are shown in Table S1 in the 
Supplementary Appendix. All patients were diagnosed with diabetes under 6 
months and transferred from insulin to sulphonylureas between 0·2 and 34·5 
years. The subjects not followed up were similar to the subjects in the study 
except they were older at transfer from insulin to sulphonylureas and younger at 
diabetes diagnosis (Table S1, Supplementary Appendix). Duration of follow-up 
for the cohort was median (IQR) 10·2 (9·3-10·8) years.   
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Sulphonylurea therapy remained highly effective, with 75 of 81 (92·6%) 
remaining on sulphonylureas without regular insulin at most recent follow-up 
(Figure 2A). No patient stopped sulphonylureas. Excellent glycaemic control 
was maintained and sulphonylurea dose fell over 10 years (Figure 2B). In 
patients remaining on sulphonylureas alone, HbA1c pre-transfer, at 1 year and 
most recent follow-up (median 10·3 years) was 8·1 (7·2-9·2)% (65.0 (55.2-
77.1)mmol/mol), 5·9 (5·4-6·5)% (41.0 (35.5-47.5)mmol/mol) and 6·4 (5·9-7·3)% 
(46.4 (41.0-56.3)mmol/mol) (n=64). In the same patients, sulphonylurea dose 
(median[IQR]) at 1 year and most recent follow-up was 0·30 (0·14-0·53) vs. 









Figure 2. Sulphonylurea Efficacy and Metabolic Control, and CNS Features.  
Panel A shows Kaplan Meier survival estimate of time to introduction of insulin 
in patients with sulphonylurea-treated KCNJ11 PNDM. Panel B shows 
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longitudinal data for glycated haemoglobin values (primary y-axis) and 
sulphonylurea dose (secondary y-axis) in 74 patients on sulphonylurea without 
daily insulin at most recent follow-up (n=70 for pre-transfer glycated 
haemoglobin). Missing values were imputed by assuming a linear trend 
between available data points, carrying the last value forward or carrying the 
next value back. Panel C shows the number of patients for whom CNS features 
were reported before and after sulphonylurea transfer, and the number of 
patients who showed improvement of CNS features on sulphonylurea therapy. 
 
Sulphonylurea therapy also remained safe.  There were no reports of 
hypoglycaemia resulting in seizures or loss of consciousness in a total of 809 
patient years of follow-up. This contrasts with the hypoglycaemia observed in 
664 Norwegian patients with type 1 diabetes followed up for >8 years, with 296 
patients (44.6%) reporting at least 1 episode of severe hypoglycaemia and 912 
episodes reported in total. 
Side-effects were reported by only 11/81 (13·6%) patients; 9 had 
gastrointestinal disturbance including 4 with transient diarrhoea, 1 with 
diarrhoea requiring further investigation, 2 with transient nausea, 1 with weight 
loss due to reduced appetite, and 1 with transient abdominal pain. One patient 
had initial hepatic steatosis and 1 had tooth discoloration. There were no 
reports of photosensitivity, hypersensitivity reactions, or abnormal renal 
function. No patients discontinued sulphonylurea treatment as a result of side-
effects. 
Daily insulin was required in addition to sulphonylureas in 6 patients at most 
recent follow-up (Table S2, Supplementary Appendix). Compared to patients 
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treated with sulphonylurea alone, patients also requiring insulin had worsened 
HbA1c at recent follow-up (HbA1c 8·5 [8·1-10·2]% (69.4 (65.0-88.0)mmol/mol) 
vs. 6·3 [5·9-7·1]% (41.0-54.1) mmol/mol), p=0.0006). A higher proportion in the 
insulin-treated group was male (40 of 75 vs. 6 of 6, p=0·03). Other 
characteristics were similar between the 2 groups (Table 1). 
 
BMI decreased during follow-up, despite improved glycaemia: BMI SDS prior to 
sulphonylurea transfer vs. BMI at 10 years was (median[IQR]) 0·21(-0·25-0·84) 
vs. -0·25(-1·07-0·42), p=0·0009, n=58. Growth of Paediatric patients who 
remained independent of insulin over the period of follow-up was within the 
normal WHO reference range. Height SDS (median[IQR]) prior to sulphonylurea 
transfer and 10 years post-transfer (median[IQR]) was  -0·46(-1·29-0·37) vs. -
0·29(-1·01-0·73), p=0·31, n=38. 
 
Diabetes complications were rare. Seven of 81 (8.6%) patients reported 
microvascular complications; retinopathy (n=5: 1 background, 2 non-
proliferative, 1 pre-proliferative, 1 proliferative), microalbuminuria (n=2), 
proteinuria (n=1), and neuropathy (n=1). In 2 patients, complications developed 
prior to transfer to sulphonylureas. There were no macrovascular complications. 
Patients with complications were older at age of transfer to sulphonylureas than 
those without complications (age at transfer median[IQR] 20·5 [10·5-24·0] vs. 
4·1 [1·3-10·2] years, p=0·0005). Other clinical characteristics were similar 













Table 1. Characteristics of Patients on Sulphonylurea Alone vs. Sulphonylurea and Insulin.   
Characteristic 
 
Patients Still on Sulphonylurea Without Daily 
Insulin (n=60-75)* 
Patients Now on Insulin (+/- 
Sulphonylurea) (n=5-6)* 
P Value (Patients on Sulphonylurea 
Alone vs. Patients on Insulin)§ 
KCNJ11 mutation 31 R201H, 18 V59M, 10 R201C, 2 G53D, 2 
H46Y, 2 K170R, E51A, F33I, F35V, G53R, 
G53S, K170N, K170T, R201L, R50P, V59A 
4 R201H, 1 R201C, 1 V59M N/A 
Age at sulphonylurea initiation (years), median(IQR)  4·3 (1·3-11·8) (n=75) 7·4 (4·7-10·5) (n=6) 0·36 
Current age (years), median(IQR) 17 (13-23) (n=75) 19 (16-22) (n=6) 0·43 
Male sex - % (number) 53 (40/75) 100 (6/6) 0·03 
Birth weight (g), median(IQR) 2715 (2470-3040) (n=72) 2730 (2551-3120) (n=6) 0·71 
Duration of follow-up (years), median(IQR) 10·2 (9·3-10·8) (n=75) 10·7 (9·7-11·2) (n=6) 0·39 
Pre-sulphonylurea HbA1c (%), median(IQR)  8·0 (7·2-9·2) (n=70) 9·0 (8·9-9·7) (n=6) 0·12 
Pre-sulphonylurea HbA1c (mmol/mol), median(IQR) 63.9 (55.2-77) 74.9 (73.8-82.5)  
Year 1 HbA1c (%), median(IQR) 5·9 (5·4-6·4) (n=66) 6·5 (6·2-6·6) (n=5) 0·06 
Year 1 HbA1c (mmol/mol), median (IQR) 41 (35.5-46.4) 47.5 (44.3-48.6)  
Most recent HbA1c (%), median(IQR) 6·3 (5·9-7·1) (n=74) 8·5 (8·1-10·2) (n=6) 6x10-4 
Most recent HbA1c (mmol/mol),median (IQR) 45.4 (41-54.1) 69.4 (65-88)  
Pre-sulphonylurea insulin dose (U/kg/day), median 
(IQR) 
0·68 (0·54-0·99) (n=66) 0·78 (0·70-0·80) (n=5) 0·58 
Year 1 sulphonylurea dose (mg/kg/day), 
median(IQR) 
0·30 (0·14-0·54) (n=68) 0·40 (0·25-0·52) (n=5) 0·58 
Most recent sulphonylurea dose (mg/kg/day), 
median(IQR) 
0·23 (0·12-0·45) (n=74) 0·27 (0·21-0·42) (n=6) 0·50 
Pre-sulphonylurea BMI SDS 0·17 (-0·27-0·84) (n=60) 0·34 (-0·69-0·85) (n=5) 0·90 
Most recent BMI SDS -0·22 (-1·03-0·44) (n=72) -0·40 (-0·72-0·06) (n=6) 0·74 
Neurological features present at recent follow-up 65 (49/75) 50 (3/6) 0·46 
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Table 1. Characteristics of Patients on Sulphonylurea Alone vs. Sulphonylurea 
and Insulin.  *n is different for each variable due to missing data. Year 1 values 
are those closest to the anniversary of the sulphonylurea transfer and had to fall 
between 3 months and 2 years for inclusion. Neurological features are defined 
as 1 or more of developmental delay, learning difficulties, sleep problems, 
ADHD, muscle weakness, epilepsy, anxiety, autism, or ‘other’ reported on by 
clinician.§Mann-Whitney test was used for numerical data, and test of 
proportions for categorical data.  Abbreviations: BMI, body mass index; IQR, 
interquartile range; N/A, not applicable; SDS, standard deviation score 
 
To evaluate beta-cell function, we performed oral and intravenous glucose-
tolerance tests on sulphonylurea therapy in 6 patients 9·83 years (6·75-11·4) 
after transfer from insulin. Oral glucose-tolerance tests revealed a good insulin 
response to the glucose challenge (Figure 3). We observed a greater maximum 
insulin secretory response to oral than intravenous glucose (maximum insulin 
increment in response to oral glucose 69·6 pmol/litre [range 42·0-135·1] and in 
response to intravenous glucose 30·5 pmol/litre [range 0·0-46·9]) despite an 
increased plasma glucose stimulus. This suggests the increased incretin effect 
seen with sulphonylurea treatment after initial transfer [6] is well preserved after 
10 years on sulphonylurea treatment. 
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Figure 3. Physiological Studies. 
Shown is median incremental increase in glucose and insulin concentration 
above baseline in an oral glucose tolerance test (6 patients) and an intravenous 
glucose tolerance test (6 patients). The test was performed after a median time 
of 9.83 years on sulphonylurea treatment. 
CNS features were documented prior to transfer in 38/81 patients (Figure 2C, 
Table S4 Supplementary Appendix). Features were usually consistent with 
those previously described in patients with KCNJ11 mutations but features 
associated with severe cerebral insult at the time of presentation with 
ketoacidosis were also present in 4 patients. All 17 patients with V59M, the 
commonest DEND-associated mutation, had CNS features prior to transfer 
(Table S4, Supplementary Appendix). There was an improvement reported in 
18/38 patients at the time of sulphonylurea transfer, specifically in muscle tone 
(n=4), concentration/ADHD (n=5), gross motor skills (n=3), epilepsy (n=3), 
muscle weakness (n=3), learning difficulties (n=2), speech (n=1) and tics (n=1).  
However, improvement was incomplete in 17/18 patients and significant CNS 
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features remained.  Full resolution occurred in only one female patient with 
unilateral hypotonia of the arm. At 10-year follow-up CNS features were seen in 
52/81 patients, including 15 patients in whom CNS features were not noted prior 
to transfer to sulphonylureas (Table S4, Supplementary Appendix). These 15 
patients transferred at median age 2.1 years and the new CNS features were 
mainly neuropsychological / psychiatric which would be more obvious as the 
child got older.  Several additional neuropsychological / psychiatric features 
were also detected after transfer in those patients who had neurological 
involvement at baseline (Table S4, Supplementary Appendix).   
 
DISCUSSION 
In a large international cohort study of patients with KCNJ11 PNDM, 
sulphonylurea therapy is effective and safe over 10 years. Over 90% of patients 
maintained excellent glycaemic control at long-term follow-up and were taking 
on average a lower dose of sulphonylurea when expressed as a dose per 
kilogram. This is consistent with previous studies, which followed single cases 
or much smaller cohorts of patients with KCNJ11 PNDM over 2.5-5·7 years [8-
10].  
Our findings contrast markedly with type 2 diabetes where ~44% have 
inadequate glycaemic control despite increasing to a maximum dose after 5 
years of treatment [7]. This difference probably reflects that: 1. in KCNJ11 
PNDM there is a fixed beta-cell defect which does not change over time while in 
type 2 diabetes there is a deterioration in beta-cell function after 1 year of ~5% 
per year [25], and 2. in KCNJ11 PNDM high dose sulphonylureas facilitate the 
response to alternative pathway stimuli and are not directly stimulating insulin 
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secretion as they do in type 2 diabetes [6]. The prolonged action seen in 
KCNJ11 PNDM also contrasts with many other examples of precision medicine 
where excellent initial results have not been maintained in the long term [12].  
Excellent glycaemic control has been achieved without the usual side effects of 
hypoglycaemia and weight gain seen when intensive insulin therapy is used to 
improve glycaemic control [26]. The absence of any episodes of hypoglycaemia 
resulting in unconsciousness or seizures in over 800 patient years of follow-up 
is remarkable and in marked contrast to type 1 diabetes where intensive insulin 
treatment to improve control resulted in a ~3-times increase (16 vs. 5 episodes 
per 100 patient years) [27]. Most of our cohort were treated with glibenclamide 
which has been the sulphonylurea most associated with hypoglycaemia in type 
2 diabetes [11].  The lack of severe hypoglycaemia is particularly reassuring as 
the doses of glibenclamide used in KCNJ11 PNDM are ~4-10-times higher than 
those used in type 2 diabetes.  In addition, our data shows a reduction in BMI of 
0·46 SDS, p=0·0009 (~7% reduction in baseline adult equivalent BMI) over the 
10-year follow-up period despite significantly improved metabolic control. In 
contrast, in the DCCT improved control was associated with ~4% increase in 
BMI over 1 year compared to conventional treatment [26]. Both lack of 
hypoglycaemia and lack of weight gain reflect that endogenous insulin secretion 
is tightly regulated in these patients.   
Our extensive study has not found any unexpected side effects of high dose 
sulphonylurea therapy, but given that it only follows 81 patients, long-term 
surveillance of this cohort and other patients who transfer should continue to 
detect any unexpected side effects. 
There are several possible reasons why 6/81 patients required daily insulin in 
addition to sulphonylurea therapy at follow-up. The median age at introduction 
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of insulin was 15 years, so many patients were peripubertal. This is important 
as puberty is associated with increased insulin resistance [28] and suboptimal 
treatment adherence in diabetes [29]. For 2 patients, poor adherence was 
specifically mentioned by their clinicians, and poor control usually continued 
even after insulin was added. Patients requiring re-introduction of insulin were 
on a relatively modest sulphonylurea dose (0·27 mg/kg/day, range 0·19-0·43), 
suggesting there was capacity to increase the dose further in all these. Taken 
together, our data suggest that other factors may have contributed to the need 
for additional daily insulin rather than sulphonylureas having stopped working at 
the level of the KATP channel.   
We report low rates of diabetes-related complications in patients with KCNJ11 
PNDM. This likely reflects the improved glycaemic control that reduces micro-
vascular complication risk as has been reported in type 1 diabetes [27].  The 
8.6% of patients with complications transferred from insulin later than those 
without complications (20·4 vs. 4·1 years). Therefore, these had the suboptimal 
glycaemic control (8·7% pre-transfer) associated with insulin therapy for many 
years before the excellent control on sulphonylureas (6·5% post transfer). We 
propose therefore that the complications noted were largely the result of 
chronically elevated HbA1c prior to sulphonylurea transfer. 
We demonstrate in physiological studies that the sulphonylurea-assisted insulin 
secretion shows a similar pattern after 10 years of follow-up as it did 
immediately post transfer [6]. Insulin secretion is excellent in response to oral 
glucose but is minimal in response to intravenous glucose reflecting that 
activating mutations in KCNJ11 prevent the KATP channel from closing in 
response to metabolically generated ATP – a defect that is bypassed by 
sulphonylureas. Whilst the presence of sulphonylureas does increase the effect 
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of glucose-stimulated insulin secretion, this effect is small in comparison to the 
potentiation of insulin secretion seen in response to the incretins produced 
following a meal.      
We report persistence of CNS features in KCNJ11 PNDM despite long-term 
treatment with sulphonylureas, in contrast to the excellent glycaemic response. 
Although some initial improvement in CNS features was seen in 18/38 following 
sulphonylureas transfer, this was usually incomplete and subsequently 
plateaued. This initial improvement is consistent with the recent detailed 
prospective study by Beltrand et al [18].  Of note, a higher proportion of patients 
(64%) had CNS features reported at most recent follow-up than prior to transfer 
(47%).  This may be explained by some patients having been too young to have 
had subtle features picked up clinically when first diagnosed, or heightened 
awareness amongst clinicians to look for subtle features at the most recent 
clinical follow-up as a result of improved characterisation of the CNS phenotype 
over the past decade. 
The reason for the poor or absent CNS response despite an excellent long term 
glycaemic response in the same patients is uncertain.  Both CNS features and 
diabetes are thought to be a direct result of the mutated channel, and 
sulphonylureas are likely to have a similar impact on the channels wherever 
their location. One possible explanation is that concentrations of glibenclamide 
in the CSF remain sub-therapeutic as a result of active transport across the 
blood brain barrier out of the brain [19]. Another possibility is that insulin 
secretion is supported by non-KATP channel mediated pathways which are not 
available for neuronal function [6] In addition, late transfer may have resulted in 
critical periods for brain development being missed; this is supported by the 
suggestion that earlier initiation of sulphonylurea treatment brings greater 
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benefit to neurological outcomes [18,30]. Further research is needed to 
investigate what treatment can improve CNS function in patients with KCNJ11 
mutations as our data shows this is a major clinical challenge for patients who 
now have excellent glycaemic control. 
Our study has several strengths. To our knowledge, this is the largest cohort of 
people with KCNJ11 PNDM to have been followed up, with 81 patients 
compared to 11 patients in the largest previous study [10]; it also represents the 
longest period of follow-up, greatly exceeding the 2.5-5.7 year follow up 
reported previously [8-10]. Ninety percent of eligible patients were included in 
the analysis, which is an excellent follow-up rate and ensures the findings 
accurately represent this unique population. 
The study has limitations. Firstly, patients were not initially randomized to either 
sulphonylurea therapy or continuing on intensive insulin treatment so we cannot 
definitively rule out that the same outstanding outcome would not have been 
achieved on insulin therapy alone. However, these patients were insulin 
dependent and no long-term study of any type of insulin regime has produced 
long-term outcomes like these in type 1 diabetes. Secondly, the research 
involved multiple centres around the world, and there will have been variation in 
clinical practice in terms of type of sulphonylurea used, dosing of sulphonylurea, 
and threshold for reintroduction of insulin. However, the research reflects real-
life clinical practice, and its multi-centre nature ensured that the largest possible 
number of patients was followed up, thereby increasing the power of the study 
and the generalisability of the findings. The main limitation of the evaluation of 
neurological features is the absence of a detailed neuropsychomotor 
assessment in one single centre before and after transfer in all patients. 
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Nevertheless, our data strongly supports the clinical experience of only a partial 
response of these features in some, but not all, affected patients.   
Further work is required to establish efficacy and safety of sulphonylureas 
beyond 10 years and to investigate other aspects of treatment response such 
as effects of puberty.  In addition, future research should further explore the 
impact of long-term sulphonylurea treatment on the neurological, 
neuropsychological and psychiatric features, through in-depth 
neuropsychomotor assessments repeated over time.   
In conclusion, in a large international cohort of patients with KCNJ11 PNDM, we 
have shown that sulphonylureas remain highly effective and safe when used for 
over 10 years. This supports the early and rapid genetic testing of infants with 
diabetes under 6 months of age, to facilitate prompt transfer of all patients with 
KCNJ11 PNDM to sulphonylureas as an excellent long-term treatment.  
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Hôpital Robert Debré, AP-HP, Faculté de Médecine Paris Diderot, Paris, France 
- Helene Cave, Anne-Laure Fauret; Hôpital Necker Enfants Malades, Paris, 
France - Marie Hoarau; Centre hospitalier et universitaire d'Angers, Angers, 
France - Régis Coutant; Centre hospitalier et universitaire de Brest, Brest, 
France - Chantale Metz; Centre hospitalier et universitaire de Besançon, 
137
Besançon, France - Anne-Marie Bertrand; Groupe Hospitalier de Havre, Havre, 
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All 81 patients were included in this analysis. For the 6 patients who had insulin 
reintroduced, time to reintroduction of insulin was calculated. For one patient in 
whom the date of reintroduction of insulin was not known, the most recent 
follow-up date was used to calculate duration and allow inclusion in the survival 
analysis. Patients who had not recommenced insulin were censored and their 
most recent follow up date was used in analysis.  Number at risk at each year 
was plotted as shown in Figure 2A. 
Data Imputation 
Imputed data were generated by taking average values between 2 data points, 
assuming linear trends between data points and using equal increments 
depending on number of missing values, carrying the last value back or carrying 
the most recent value forward. Where 2 sets of data were available within a 
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given year, the data closest to the anniversary of the transfer were used and the 
other data were excluded. 
 
Physiological Tests Repeated After 10 Years. 
Oral Glucose Tolerance Test 
Following an overnight fast and basal sampling, 1.75 g per kilo oral glucose 
(maximum 75 g) was ingested over 2 minutes at time 0 and plasma was 
collected at 0, 30, 60, 90 and 120 minutes for assay of glucose, insulin and c 
peptide. Sulphonylurea was taken as normal in the morning the day of the 
plasma collection.  
Intravenous Glucose Tolerance Test 
Following an overnight fast and basal sampling, 0.3 g per kg glucose was given 
over 1 minute and plasma was collected at -10, -4, 0, 1, 3, 5, 7, 10, 20, 60 
minutes for glucose, insulin and c peptide assay. Sulphonylurea was taken as 
normal in the morning the day of the plasma collection. Increment was 
calculated as a delta value for each time point. 
  
Laboratory Assays 
Venous blood was obtained for centralized assays. Serum glucose and insulin 
were obtained before and after the glucose load. The Laboratory Clinic at 
Haukeland University Hospital, Norway, performed assays for glycated 
haemoglobin (HbA1c) with values aligned with those in the Diabetes Control 
and Complications Trial (DCCT) according to its standard procedures.  
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Table S1. Characteristics of Whole Cohort vs. Patients Eligible but Not Followed Up. 
Characteristic All Patients (N=65-81)* Patients Eligible but Not 
Included (N=3-8)* 
P Value§ 
KCNJ11 mutation 35 R201H, 19 V59M, 11 
R201C, 2 G53D, 2 H46Y, 2 
K170R, E51A, F33I, F35V, 
G53R, G53S, K170N, 
K170T, R201L, R50P, V59A 
2 R201H, 2 unknown, E22K, 
G53D, R201C, R50Q 
N/A 
Age at initiation of sulphonylurea treatment (years), median(IQR)  4.8 (1.7-11.4) (n=81) 15.0 (7.0-18.0) (n=8) 0.04 
Age at diagnosis (weeks), median(IQR) 8.0 (4.0-12.0) (n=74) 0 (0-4.5) (n=8) 0.002 
Male sex - % (number) 57 (46/81) 50 (4/8) 0.70 
Birth weight (g) 2715 (2480 – 3050) (n=78) 2638 (2315-2875) (n=8) 0.36 
Pre-sulphonylurea BMI SDS 0.18 (-0.28 – 0.84) (n=65) 0.51 (-0.83-1.91) (n=6) 0.63 
Pre-sulphonylurea HbA1c (%), median(IQR)  8.2 (7.2-9.2) (n=76) 8.1 (7.4-8.3) (n=6) 0.70 
Pre-sulphonylurea HbA1c (mmol/mol), median (IQR) 66.1 (55.2-77) (n=76) 65 (57.4-67.2) (n=6) 0.70 
Year 1 HbA1c (%), median(IQR) 5.9 (5.5-6.5) (n=71) 6.2 (6.2-7.3) (n=5) 0.07 
Year 1 HbA1c (mmol/mol), median (IQR) 41 (36.6-47.5) (n=71) 44.3 (44.3-56.3) (n=5) 0.07 
Pre-sulphonylurea insulin dose (units/kg), median(IQR) 0.69 (0.59-0.94) (n=71) 0.68 (0.52-0.78) (n=8) 0.63 
Year 1 sulphonylurea dose (mg/kg/day) 0.30 (0.14-0.53) (n=73) 0.53 (0.10-0.59) (n=5) 0.96 
 
*N is different for each variable due to missing data. Year 1 values are those closest to the anniversary of the sulphonylurea transfer and 
had to fall between 3 months and 2 years for inclusion.   
§Mann-Whitney test was used for numerical data, and 2 sample test of proportions for categorical data.  




Table S2. Characteristics of Patients Now on Daily Insulin and Sulphonylurea.* 
Case 1 2 3 4 5 6 Median 
Current age 21 13 21 26 16 17 19 
Age at sulphonylurea transfer (years) 10 3.2 10.5 14.3 4.7 4.8 7.4 
Age at which insulin re-introduced (years) 15.3 12.6 18.3 22.5 n/a 12 15.3 
Birth weight (g) 2551 2750 2450 3160 2710 3120 2730 
Mutation R201C R201H R201H R201H V59M R201H N/A 
Duration of follow-up (years) 7.3 9.7 10.6 11.2 10.8 11.7 10.7 
Duration when insulin re-introduced (years) 5.3 9.4 7.9 8.2 n/a 7.2 7.9 
Most recent sulphonylurea dose (mg/kg/day) 0.43 0.42 0.23 0.31 0.21 0.19 0.27 
HbA1c when insulin re-introduced (%)  9.2 8.1 11.4 7.7 n/a n/a 8.7 
HbA1c when insulin re-introduced (mmol/mol) 77 65 101.1 60.7 n/a n/a 71.6 
Most recent HbA1c on insulin (%) 8.8 n/a 12.9 8.2 10.2 7.7 8.5 
Most recent HbA1c on insulin (mmol/mol)  72.7 n/a 117.5 66.1 88 60.7 69.4 
Insulin name Detemir Glargine Lispro and 
Glargine 
Detemir Detemir Glargine N/A 
Most recent insulin dose (units/day) 26 31 21 8 91 12 23.5 
Most recent insulin dose (units/kg/day) 0.45 0.75 0.32 0.13 1.89 0.22 0.38 
Adherence* issues noted by clinician No Yes Yes No No No N/A 
 
*Adherence was not formally measured as part of the study, however 2 clinicians specifically reported poor adherence at some point 
during the follow up period. 




Table S3. Characteristics of Patients With and Without Microvascular Complications. 
Clinical Characteristic Without Complications  
(N=59-74)* 
With Complications  
(N=6-7)* 
P Value§ 
Age at sulphonylurea transfer (years) 4.1 (1.3-10.2) (n=74) 20.5(10.5-24.0) (n=7) 5x10-4 
Pre-sulphonylurea insulin dose (units/kg/day) 0.68 (0.57-0.94) (n=64) 0.82 (0.60-1.16) (n=7) 0.52 
Pre-sulphonylurea HbA1c (%) 8.0(7.1-9.1) (n=69) 8.7(7.4-9.6) (n=7) 0.28 
Pre-sulphonylurea HbA1c (mmol/mol) 63.9(54.1-76) (n=69) 71.6(57.4-81.4) (n=7) 0.28 
Most recent HbA1c (%) 6.3(5.9-7.3) (n=73) 6.5(6.3-8.5) (n=7) 0.16 
Most recent HbA1c (mmol/mol) 45.4(41-56.3) (n=73) 47.5(45.4-69.4) (n=7) 0.16 
Pre-sulphonylurea BMI SDS 0.25(-0.32-0.89) (n=59) 0.17(0.02-0.24) (n=6) 0.63 
Most recent BMI SDS -0.24(-1.1-0.42) (n=71) -0.24(-0.75-1.63) (n=7) 0.45 
 
*N is different for each variable due to missing data. Complications were retinopathy (5 of 7), microalbuminuria (2 of 7), proteinuria (1 of 
7), and neuropathy (1 of 7). 
§Mann-Whitney test was used for numerical data 
Abbreviations: BMI, body mass index; SDS, standard deviation score. 
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* Other features reported pre-transfer were hypotonia (5), cerebellar signs (5), gross/fine motor problems (2), myoclonic jerks (2), ptosis 
(1), tics (Tourette’s) (1).  Other features reported post transfer were hypotonia (1), cerebellar signs (2), gross/fine motor problems (2), 
ptosis (1), tics (Tourette’s) (1). 
**Other features reported pre-transfer attention or concentration deficits/hyperkinesis (5). Other features reported post-transfer attention 
or concentration deficits/hyperkinesis (2).  
Abbreviations: ADHD, attention, deficit hyperactivity disorder; CNS, cerebral nervous system; IQR, interquartile range; N/A, not 
applicable; SU, sulphonylurea
Table S4. Neurological Features   
Characteristic Neurological features identified 
before transfer to sulphonylureas 
(n=38) 
Neurological features identified 
after transfer to sulphonylureas 
(n=15) 
No neurological features 
identified (n=28) 
Mutation in  KCNJ11 gene 19 V59M,  7 R201H,  3 R201C,   2 G53D,  2 
R50P, G53R,  G53S, E51A, H46Y, V59A 
6 R201H, 4 R201C, F33I, F35V, H46Y, 
K170N, R201L 
21 R201H, 4 R201C, 2 K170R, 
K170T 
Age at sulphonylurea initiation (years), median(IQR)  6.1 (1.3-12.1) 2.1 (0.4-8.9) 6.1 (2.8-12.5) 
Current age (years), median(IQR) 18.0 (14.0-23.0) 14.0 (12.0-20.0) 19.0 (15.0-24.5) 
Male sex - % (number) 55 (21/38) 60 (9/15) 57 (16/28) 
Most recent sulphonylurea dose (mg/kg/day), 
median(IQR) 
0.27 (0.12-0.50) 0.26 (0.14-0.36) 0.20 (0.13-0.38) 
KCNJ11 associated neurological features  
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Main messages of the article 
• Individuals with sulfonylurea-treated KCNJ11 PNDM exhibit higher 
glucose values in response to a carbohydrate meal than to a protein meal, and 
for both meals glucose levels are higher than controls without diabetes, who 
exhibit much more tightly regulated glucose levels regardless of meal type.  
• The more tightly regulated glucose levels in controls results from much 
higher insulin secretion in response to carbohydrate than to protein, whereas 
cases with sulfonylurea-treated KCNJ11 PNDM have similar insulin levels in 
response to both meal types.  
• The similar insulin secretion with the different meals in individuals with 
sulfonylurea-treated KCNJ11 PNDM suggests a relative inability to modulate 
insulin secretion in response to both higher (carbohydrate) and lower 
(protein/fat) glucose levels, consistent with a dependence on non-KATP 
pathways for insulin secretion.  
• Individuals with sulfonylurea-treated KCNJ11 PNDM should avoid meals 
lacking carbohydrate or missing meals to mitigate the risk of post-prandial 
hypoglycemia. 
 
Research questions remaining / emerging as a result of this work 
• Do individuals with sulfonylurea-treated KCNJ11 PNDM have intact 
glucagon secretion at low levels of glucose? 
• Is the counter-regulatory response to hypoglycemia preserved in patients 
with sulfonylurea-treated KCNJ11 PNDM? 
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• What is the effect of different doses and types of sulfonylurea on the 




Insulin secretion in sulfonylurea-treated KCNJ11 permanent neonatal diabetes 
(PNDM) is thought to be mediated predominantly through amplifying non-KATP-
channel pathways such as incretins.  Affected individuals report symptoms of 
post-prandial hypoglycemia after eating protein/fat-rich foods.  We aimed to 
assess the physiological response to carbohydrate and protein/fat in people 
with sulfonylurea-treated KCNJ11 PNDM. 
Research Design and Methods  
5 adults with sulfonylurea-treated KCNJ11 PNDM and 5 age, sex and BMI-
matched controls without diabetes had a high carbohydrate and high protein/fat 
meal on 2 separate mornings.  Insulin(i) and glucose(g) were measured at 
baseline then regularly over 4 hours post-meal.  Total area under the curve 
(tAUC) for insulin and glucose were calculated over 4 hours and compared 
between meals in controls and KCNJ11 cases.   
Results  
In controls, glucose values after carbohydrate and protein/fat were similar 
(median glucose tAUC0-4h 21.4 vs.19.7mmol/L, p=0.08).  In KCNJ11 cases 
glucose levels were higher after carbohydrate than after protein/fat (median 
glucose tAUC0-4h 58.1 vs.31.3mmol/L, p=0.04).  These different glycemic 
responses reflected different patterns of insulin secretion: in controls, insulin 
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secretion was greatly increased after carbohydrate vs. protein/fat (median 
insulin tAUC0-4h 727 vs.335pmol/L, p=0.04), but in KCNJ11 cases insulin 
secretion was similar after carbohydrate and protein/fat (median insulin tAUC0-4h 
327 vs.378pmol/L, p=0.50).   
Conclusions  
Individuals with sulfonylurea-treated KCNJ11 PNDM produce similar levels of 
insulin in response to both carbohydrate and protein/fat meals despite 
carbohydrate resulting in much higher glucose levels and protein/fat resulting in 
relatively low glucose levels. This suggests an inability to modulate insulin 
secretion in response to glucose levels, consistent with a dependence on non-
KATP pathways for insulin secretion.  
 
Introduction  
Activating KCNJ11 mutations are the commonest cause of permanent neonatal 
diabetes (PNDM), diagnosed in the first 6 months of life (1).  KCNJ11 encodes 
Kir6.2, the pore-forming subunit of the ATP-sensitive potassium (KATP) channel 
that, in the beta-cell, closes in response to metabolically generated ATP, 
causing beta-cell depolarisation and insulin secretion.  The SUR1 subunit, 
encoded by the ABCC8 gene, further regulates KATP channel activity by opening 
in response to Mg-ADP, preventing insulin release (2).  KCNJ11 mutations 
impair the ATP sensitivity of pancreatic KATP channels rendering them 
unresponsive to rising blood glucose and the beta cell remains hyperpolarised 
(3), resulting in absolute insulin deficiency.  Affected individuals required 
treatment with replacement doses of insulin until it was shown that 
sulfonylureas could bind and close pancreatic KATP channels resulting in beta-
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cell depolarisation and endogenous insulin secretion (4).  This allowed 90% of 
individuals with KCNJ11 PNDM to stop insulin injections completely gaining 
excellent metabolic control which is maintained long-term (4, 5).   
Severe hypoglycemia is rarely observed in sulfonylurea-treated KCNJ11 PNDM 
(5, 6).  This is remarkable given that the doses of sulfonylurea used in affected 
individuals are around 5-10 times those used to treat Type 2 diabetes (T2D) 
and indicates that sulfonylurea-stimulated KATP channel activity is regulated, at 
least in part, in the presence of KCNJ11 mutations.  However, as these 
mutations prevent regulation by ATP, it has been suggested that non-KATP-
channel-mediated amplifying pathways of insulin secretion e.g. incretin 
hormones, predominate over the classical ATP pathway (4).  This is supported 
by the very low levels of insulin secretion observed after intravenous glucose in 
comparison to oral glucose or meals, in individuals with sulfonylurea-treated 
KCNJ11 PNDM (4).  The role of sulfonylureas is assumed to be largely 
permissive in allowing the beta-cell to respond to non-KATP-channel-mediated 
amplifying pathways, as opposed to directly stimulatory (4).  
Anecdotal reports from patients with KCNJ11 PNDM have suggested mild-
moderate hypoglycemia occurs after meals rich in protein/fat and lacking 
carbohydrate (7) or meals smaller than usual in size (6).  This may reflect an 
inability to moderate food-stimulated insulin secretion in the context of falling 
glucose after a low carbohydrate meal; both GLP-1 and nutrient stimulation of 
the beta cell may play a role, as fatty acids and amino acids can drive insulin 
secretion through ATP-independent as well as ATP-dependent pathways (8-
11).  Similarly, KATP channels on pancreatic alpha cells (12) and glucose-
sensing neurons in the brain ventromedial hypothalamus (VMH) (13) are 
thought to play a role in counter-regulatory responses to hypoglycemia via ATP-
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dependent and independent mechanisms (14, 15).  Sulfonylurea inhibition and 
protein can both stimulate alpha cell depolarisation and glucagon secretion in 
vitro (16, 17).   However, counter-regulatory processes are complex and remain 
incompletely understood. 
Despite its clinical importance in relation to dietary advice and hypoglycemia 
risk, no studies have investigated the impact of protein or other food types on 
insulin or glucagon secretion in sulfonylurea-treated KCNJ11 PNDM.  We 
therefore aimed to assess the insulin, glucose and glucagon response to 
carbohydrate and protein/fat in people with KCNJ11 PNDM, and to compare 
this with the physiological response to the same food types in individuals 
without diabetes. 
 
Research Design and Methods 
Participants 
5 adults >18 years of age with sulfonylurea-treated KCNJ11 PNDM and 5 
controls without diabetes matched for age, sex and BMI participated in the 
study.  Clinical characteristics of the study participants are shown in Table 1.  
All measured characteristics were similar between the groups except fasting 
glucose which was higher in cases. 
The study was approved by South West – Cornwall and Plymouth Research 
Ethics Committee and the Health Research Authority (REC reference 
16/SW/0150).  Written informed consent was obtained from all individuals prior 




Table 1.  Clinical characteristics of study participants.  All continuous numerical 
data are presented as median (range) unless otherwise stated.  In one patient 
who was taking gliclazide and not glibenclamide, dose was converted to 




Participants attended the Exeter NIHR Clinical Research Facility and were 
given a high carbohydrate breakfast (77g carbohydrate, 9g protein, 1g fat, 371 
calories) consisting of orange juice and white toast with jam, and a high 
protein/fat breakfast (46g protein, 18g fat, 6g carbohydrate, 369 calories) 
consisting of ham and cheese, on 2 separate mornings in a random order.  
Participants with KCNJ11 PNDM took their usual prescribed dose of 
sulfonylurea (5 on glyburide, 1 on gliclazide) with each breakfast.  These 
Clinical feature KCNJ11 Cases Non-diabetic controls p-value 
Age (years) 39.1 (24.4 – 41.0) 39.6 (24.2-41.8) 0.60 
Sex male (%) 1 (20) 1 (20) 1.00 
BMI 22.9 (22.4-26.8) 24.6 (23.9-25.6) 0.60 
Fasting glucose 
(mmol/mol) 
10.1 (8.6-11.9) 5.3 (4.8-5.5) 0.009 
KCNJ11 mutation 4 R201H, 1 R201C N/A N/A 
SU dose (mg/kg/day 
glibenclamide) 
0.28 (0.07-1.21) N/A N/A 
HbA1c (%) 6.9 (6.5-7.9) N/A N/A 
HbA1c (mmol/mol) 52 (48-63) N/A N/A 
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individuals also took part in a third visit during which they did not have any 
breakfast but took their sulfonylurea tablet as usual that morning.    
Before each visit the participants fasted overnight for a minimum of 10 hours.  
Prior to breakfast an IV cannula was inserted and 2 baseline blood samples (-5, 
0 minutes) were taken for measurement of insulin, glucose, and glucagon.  
Breakfast was provided, on visits 1 and 2, and participants were given 15 
minutes to eat.  Participants were also given a glass of water and 1000mg 
paracetamol with the meal as a non-invasive measure of gastric emptying (11).  
Any food remaining after 15 minutes was removed and weighed.  One control 
participant and one case did not finish the protein meal within 15 minutes (they 
ate 90% and 75% of the breakfast respectively).  All participants ate the full 
carbohydrate meal.  Blood samples were taken at regular intervals after 
breakfast (every 15 minutes for the first hour then every half hour for the last 3 
hours); they were immediately centrifuged and frozen at -80oC for later 
measurement of glucose, insulin, glucagon, and paracetamol levels.  
Participants were also screened at each time point for autonomic and 
neuroglycopenic symptoms of hypoglycemia using standard questions scored 
from 1-7 on a Likert scale as previously described (12, 13).  For the individuals 
with KCNJ11 PNDM, the third visit involved the same procedure but without any 
food. 
Biochemical analysis 
All biochemical analyses were performed in the Royal Devon and Exeter NHS 
Foundation Trust Clinical Laboratory.  Serum glucose and paracetamol were 
analysed on the 702 module of the Cobas 8000 analyser, serum insulin was 
analysed on the 602 module of the Cobas 8000 analyser, and serum glucagon 
was analysed on the Dynex DS2 automated ELISA platform.   
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Statistical analyses 
Data were analysed in Stata 14.2 using non-parametric statistical methods; 
Wilcoxon signed-ranks test for paired continuous data and Mann-Whitney test 
for unpaired continuous data (independent samples).  For categorical data, 
Fisher’s exact test was used for between group comparisons.  Total area under 
the curve over 4 hours (tAUC0-4h) and incremental area under the curve (iAUC0-
4h) for insulin, glucagon and glucose were calculated using the trapezoidal rule.  
Values are reported as median (range) throughout unless stated otherwise.   
Glucose levels and hypoglycemia 
Glucose trends after meals and responses to hypoglycemia questionnaires 
were described and glucose tAUC0-4h and iAUC0-4h were compared between 
meals in controls and KCNJ11 cases. 
Post meal insulin secretion 
Insulin tAUC0-4h and iAUC0-4h were compared between meals in controls and 
KCNJ11 cases.  As baseline glucose values were different between cases and 
controls (Table 1, Supplementary figure 1), insulin was also adjusted for 
glucose by calculating ratios of total AUC for insulin and glucose (insulin 
tAUC/glucose tAUC)0-4h (18). 
Post meal glucagon secretion 
Glucagon tAUC0-4h and iAUC0-4h were compared between different meals in 
controls and KCNJ11 cases.   
Gastric emptying 
Maximum serum paracetamol concentration (pmax) and time to maximum 
concentration (tmax) were used to calculate the emptying index (tmax / pmax), 
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which was compared between different meals to check for differences in rates 
of gastric emptying as previously described (19).  Paracetamol tAUC0-4h was 
also compared between controls and KCNJ11 cases and between meals. 
 
Effect of sulfonylurea without food 
To examine the effect of sulfonylurea alone, the glucose, insulin and glucagon 
analyses were repeated in KCNJ11 cases after no food and compared to the 
responses to the carbohydrate and protein/fat meals.   
 
Data cleaning 
In the process of data analysis, for glucagon values <1.5 (limit of detection of 
the assay) a value of 1.4 was used.  For paracetamol values <1.2 (limit of 
detection of the assay) a value of 1.1 was used.  The baseline values for each 
analysis were an average of the minus-5-minute (-5m) and 0-minute (0m) 
values; if the -5m or 0m baseline value was missing, the single remaining 
baseline value was used. Where a value at a single time point was missing, an 
average of the values at the time points either side was imputed. On the 3 
occasions where a sample was delayed due to the participant requiring 







Different glucose levels after protein/fat and carbohydrate in KCNJ11 cases vs 
controls   
Glucose levels were higher in cases vs. controls after both carbohydrate 
(glucose tAUC 58.1 (45.9-62.0) mmol/L vs. 21.4 (19.3-25.7) mmol/L, p=0.009) 
and protein/fat (glucose tAUC 31.3 (23.5 – 35.3) mmol/L vs. 19.7 (17.7-21.2) 
mmol/L, p=0.009), figure 1a.   
 
Figure 1a - Glucose total AUC over 4 hours.  Controls are shown in light grey 
(diamonds are individuals and lines are group medians).  KCNJ11 cases are 
shown in dark grey (circles are individuals and lines are group medians). 
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Figure 1b - Insulin total AUC over 4 hours.  Controls are shown in light grey 
(diamonds are individuals and lines are group medians).  KCNJ11 cases are 
shown in dark grey (circles are individuals and lines are group medians).  
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Figure 2 (a-d) – incremental glucose (blue solid line), insulin (red solid line) and 
glucagon (black broken line) in controls without diabetes and sulfonylurea-
treated KCNJ11 cases with carbohydrate (upper panel) and protein/fat (lower 
panel) meals. Values shown are medians. 
 
In controls, glucose values were tightly regulated after the 2 meals, figures 1a, 2 
and Supplementary figure S1 (glucose tAUC after carbohydrate 21.4 (19.3-
25.7) mmol/L and after protein/fat 19.7 (17.7-21.2) mmol/L, p=0.08). In KCNJ11 
cases glucose levels were much higher after carbohydrate (glucose tAUC after 
carbohydrate 58.1 (45.9-62.0) mmol/L than after protein/fat 31.3 (23.5 – 35.3) 
mmol/L, p=0.04), figures 1a, 2 and Supplementary figure S1.  Similar trends 
were seen using iAUC (Supplementary table 1).   
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In cases, glucose increased 6.3 mmol/L from baseline in the first hour after 
carbohydrate and remained 2.6 mmol/L above baseline at 4 hours.  In contrast, 
after protein/fat, glucose fell reaching median 5.9 mmol/L below baseline at 4 
hours, figures 1 and S1.  Despite falling glucose after protein/fat, no cases 
became hypoglycemic in the 4-hour study period: the lowest glucose value 
recorded was 4.4mmol/L.  Consistent with these glucose profiles, all cases and 
controls had the lowest possible scores at all time points when screened for 
symptoms of hypoglycemia, indicating an absence of subjective symptoms.  
There were also no objective symptoms of hypoglycemia during observation of 
participants by the study nurse and doctor.  
 
Different glycemic responses to meals were explained by different patterns of 
insulin secretion in KCNJ11 cases vs controls 
Insulin secretion was higher in controls vs cases after the carbohydrate meal 
(insulin tAUC0-4h 727 (409-1302) vs. tAUC0-4h  327(175-647) pmol/l, p=0.03) but 
not after the protein/fat meal (insulin tAUC0-4h 335(241-722) vs. 378(228-508) 
pmol/l p=0.60), figure 1b.  In controls insulin secretion was greatly increased 
after the carbohydrate meal compared to the protein/fat meal (insulin tAUC0-4h 
727 (409-1302) vs 335(241-722) pmol/l, p=0.04, but in the KCNJ11 cases 
insulin secretion was similar with the 2 meals (insulin tAUC0-4h 327(175-647) 
after carb and 378(228-508) pmol/l after protein/fat) p=0.50, Figures 1b, 2 and 
Supplementary figure 1.   
The same pattern was observed using iAUC (Supplementary table 1) and when 
insulin secretion was adjusted for glucose (insulin tAUC/glucose tAUC)0-0.4h in 
controls after carbohydrate vs protein/fat, 33.9 (19.6-50.8) vs 18.9 (11.4-36.2), 
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p=0.04 and in KCNJ11 cases 6.2 (2.9-14.1) vs 11.7 (9.7-14.4), p=0.08), 
Supplementary figure 2. These results are consistent with KCNJ11 cases not 
being glucose responsive, in contrast to controls without diabetes.   
 
Glucagon secretion is increased in response to protein/fat compared to 
carbohydrate in both cases and controls  
Both controls and cases had higher glucagon secretion after protein/fat than 
carbohydrate (glucagon tAUC0-4h in controls 32.5 (13.8-37.9) vs 7.2 (5.6-11.2) 
pmol/l, p=0.04 and in cases 17.4 (7.8-28.3) vs 6.1 (5.7-8.9) pmol/l, p=0.04), 
Figures 2, 3 and Supplementary figure 1.  This is consistent with an alpha cell 
response to amino acids and / or fatty acids in both groups.  
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Figure 3 - Glucagon total AUC over 4 hours.  Controls are shown in light grey 
(diamonds are individuals and lines are group medians).  KCNJ11 cases are 
shown in dark grey (circles are individuals and lines are group medians). 
 
Paracetamol profiles indicate similar rates of gastric emptying  
Paracetamol concentration-time curves are shown in Supplementary figure 3.  
Emptying index (tmax/pmax) and tAUC were similar between controls vs cases 
(tmax/pmax for carbohydrate 0.03 vs 0.05, p= 0.46 and for protein/fat 0.04 vs 
0.03, p=0.60, paracetamol tAUC0-4h for carbohydrate 30.5 (21.9-55.5) vs 28.5 
(18.5-44.4) mg/L, p=0.75 and for protein/fat 28.4 (24.4-46.7) vs 36.5 (13.6-
40.4), p=0.92) mg/L. Emptying index and tAUC were also similar between 
meals in controls (emptying index p=0.89, tAUC0-4h p=0.45) and in cases 
(tmax/pmax p=0.50, tAUC0-4h p=0.92). 
 
Effects of sulfonylurea independent of food in KCNJ11 cases 
Glucose fell to a similar extent after both sulfonylurea only (no food) and 
protein/fat (Supplementary figures 4&5) and there was no difference in overall 
glucose levels (glucose tAUC0-4h with no food 34.6 (28.7-42.8) mmol/L vs and 
after protein/fat 31.3 (23.5 – 35.3) mmol/L, p=0.22).  In contrast, glucose levels 
were lower after sulfonylurea only vs carbohydrate ((glucose tAUC0-4h with no 
food 34.6 (28.7-42.8) vs 58.1 (45.9 – 62.0) mmol/L, p=0.04).  The same trends 
were seen using glucose iAUC (Supplementary table 1). 
Insulin secretion in the 4 hours after a meal was higher after carbohydrate vs. 
sulfonylurea only (insulin tAUC0-4h 327(175-647) vs. 174(129-280) pmol/l, 
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p=0.04, and insulin iAUC 205(104-480) vs. 39(13-101) pmol/l, p=0.04).  There 
was also a trend towards higher insulin secretion after protein/fat vs. 
sulfonylurea only (insulin tAUC0-4h 378(228-508) vs. 174(129-280) pmol/l, 
p=0.08, and insulin iAUC 183(109-316) vs. 39(13-101) pmol/l, p=0.04), 
Supplementary figures 4&5.  This supports a key role for food in triggering 
insulin release in the context of sulfonylurea-treated KCNJ11 PNDM.   
Glucagon secretion was similar in the absence of food vs. carbohydrate 
(glucagon tAUC0-4h 6.0 (5.6-18.7) vs 6.1 (5.7-8.9) pmol/l, p=0.69, and glucagon 
iAUC 0.2(-0.2-1.9) vs 0.5(0.1-1.2) pmol/l, p=0.50)) despite very different glucose 
levels.  In contrast, there was a trend towards lower glucagon secretion in the 
absence of food vs. protein/fat (glucagon tAUC0-4h 6.0 (5.6-18.7) vs 17.4 (7.8-
28.3) pmol/l, p=0.22, and glucagon iAUC0-4h 0.20 (-0.2-1.9) vs 11.8 (2.2-16.7) 
pmol/l, p=0.04).   
The rate of gastric emptying did not change with sulfonylurea only in 
comparison to the two meals (paracetamol tAUC0-4h with no food 34.6 (20.0-
43.4) mg/L and with carbohydrate 28.5 (18.5-44.4) mg/L, p=0.89, paracetamol 
tAUC0-4h with no food 34.6 (20.0-43.4) mg/L and with protein/fat 36.5 (13.6-40.4) 
mg/L, p=0.69).      
 
Discussion / Conclusions  
We have shown clear differences in glucose levels and insulin secretion after 
carbohydrate and protein/fat meals between controls without diabetes and 
individuals with sulfonylurea-treated KCNJ11 PNDM.   
Whilst controls show tightly regulated glucose levels after meals, individuals 
with KCNJ11 PNDM have lower glucose after protein/fat vs. carbohydrate.  
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These different glucose profiles have clinical implications in terms of dietary 
advice offered to patients with sulfonylurea-treated KCNJ11 PNDM.  In this 
specific type of diabetes, patients should avoid meals or diets completely 
lacking carbohydrate since blood glucose is likely to fall post-prandially in the 
context of a protein/fat meal.  Furthermore, they should avoid missing meals 
after taking sulfonylurea, as we also observed a fall in glucose with sulfonylurea 
in the absence of food.    
In addition to the practical implications, our data may provide a mechanistic 
explanation as to why patients with sulfonylurea-treated KCNJ11 PNDM report 
hypoglycemia after protein/fat-rich meals.  Insulin secretion after protein/fat and 
carbohydrate is similar in affected individuals despite very different glucose 
profiles. This supports insensitivity to glucose and lack of moderation of incretin 
and amino acid/fatty acid-stimulated insulin secretion after a protein/fat meal.  
Consistent with this is human and rodent data from previous studies 
demonstrating non-KATP-driven insulin secretion in the presence of normal or 
low glucose.  Humans with congenital hyperinsulinism (CHI) caused by 
recessively inherited inactivating (loss of function) KATP channel mutations have 
insensitivity to leucine, which acts through KATP pathways, but sensitivity to 
glutamine, which acts independently of ATP to drive insulin secretion and 
hypoglycemia after protein-rich meals (20).  Furthermore, SUR1 knockout mice 
are euglycemic but show amino acid-stimulated insulin secretion which is 
particularly sensitive to glutamine (21).   
The pattern of the insulin response to the different meals in sulfonylurea-treated 
KCNJ11 PNDM contrasts with the pattern in controls without diabetes where 
carbohydrate, acting through the classical ATP pathway, elicits a far greater 
insulin response than protein/fat and is quickly ‘switched off’ in response to 
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normalisation of blood glucose.  It also contrasts with the response in 
individuals with Type 1 diabetes on intensive insulin therapy, who show rises in 
post-prandial glucose 3-5 hours after a high protein/fat meal and in whom 
protein is protective against hypoglycemia (22).   
Our results are consistent with the previously hypothesised mechanism of 
insulin secretion in patients with sulfonylurea-treated KCNJ11 PNDM.  Pearson 
et al. reported a large reduction in insulin secretion following intravenous 
glucose vs oral glucose supporting predominance of non-KATP mediated 
amplifying pathways over the classical ATP pathway in these patients (4).  The 
small amount of insulin secretion and fall in glucose we observed in the 
absence of food contrasts with the idea of a purely permissive action of 
sulfonylureas on the beta-cell (4), although our experimental design differed 
from previous physiological studies limiting direct comparison.  The very high 
doses of sulfonylurea used to treat KCNJ11 PNDM do not result in severe 
hypoglycemia highlighting the possibility of a different pharmacological 
mechanism to the direct effects on the KATP channel seen in Type 2 diabetes.  
Further research is needed to improve understanding of the mechanism of 
sulfonylurea action in KCNJ11 PNDM. 
In our study, glucagon secretion was higher after protein/fat vs carbohydrate in 
both cases with KCNJ11 PNDM and controls without diabetes, consistent with 
the previously described stimulatory effect of amino acids on alpha cells (17).  
We did not test the glucose-responsiveness of alpha cells in this study as all 
individuals remained euglycemic throughout.  However, rodent models suggest 
defective glucagon secretion may occur in the presence of KATP channel 
mutations.  Specifically, SUR1 knockout mice show an alpha cell secretory 
defect at low levels of glucose (23), KCNJ11 knockout mice exhibit defective 
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glucagon secretion due to an impaired brain response to hypoglycemia (24), 
and intracerebroventricular perfusion of KATP channels with SU in conscious rats 
reduces glucagon responses to hypoglycemia (25).  In humans, the research 
and anecdotal clinical evidence to date suggests that these patients are 
protected from severe hypoglycemia, but the mechanisms of this remain 
unknown and future research will investigate in detail the counter-regulatory 
response to hypoglycemia in people with KCNJ11 mutations at the level of the 
alpha cell and the brain as previously described in the context of glucokinase 
mutations (26). 
Our study has important strengths.  To our knowledge, it is the first study to 
assess the impact of different food types on glucose levels and insulin and 
glucagon secretion in people with KCNJ11 PNDM, and to compare this with 
data from controls without diabetes.  Previous research has been limited to 
assessment of insulin secretion following oral and intravenous glucose 
tolerance tests in small groups of affected individuals without a control group for 
comparison (4, 5).   
Our study has some limitations.  Firstly, the numbers of cases and controls are 
small and only 2 mutations in the KCNJ11 gene (R201H and R201C) were 
studied, reflecting the rarity of the disease.  However, these are the most 
common mutations and both impact ATP binding.  Secondly, as the individuals 
in our study did not have glucose levels in the hypoglycemic range, we were 
unable to assess the alpha cell response in the presence of low glucose as 
discussed above.  Finally, the study was only done in adults, which may limit 
the generalisability of the findings, particularly for patients in the paediatric age 
range.  Additional studies in children with sulfonylurea-treated KCNJ11 PNDM 
will be required to investigate the beta and alpha cell responses to carbohydrate 
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and protein/fat and to establish whether these responses differ to those 
observed in adults. 
In conclusion, we have shown that individuals with sulfonylurea-treated KCNJ11 
PNDM produce similar levels of insulin in response to both carbohydrate and 
protein/fat meals despite carbohydrate meals resulting in much higher glucose 
levels and protein/fat meals being characterized by relatively low glucose levels. 
This suggests an apparent inability to modulate insulin secretion in response to 
both higher (carbohydrate) and lower (protein/fat) glucose levels, which is 
consistent with a dependence on non-KATP pathways for insulin secretion.  Our 
findings may provide a mechanistic explanation for the post-prandial 
hypoglycemia reported by patients with KCNJ11 PNDM.  Furthermore, glucose 
levels can fall with sulfonylureas in the absence of food.  We would therefore 
recommend that affected individuals avoid missed meals or meals lacking 
carbohydrate whilst on sulfonylurea treatment.  Finally, our data highlights the 
utility of KCNJ11 PNDM as a model for studying non-KATP-mediated pathways 
of insulin secretion and demonstrates the predominance of the classical ATP 
pathway in the non-diabetic state.   
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Supplementary Table 1.  Incremental area under the curve (iAUC) for glucose, insulin and glucagon after different meals in KCNJ11 
cases and controls.              
iAUC  = incremental AUC over 4 hours











Cases 16.7 (8.3-31.6) -10.9 (-29.1 - -
2.2) 
-7.6 (-11.8-3.9) 0.04 0.22 0.04 
Controls 1.00 (-0.7-3.3) -1.15 (-1.5- -0.9) N/A 0.04 N/A N/A 
Insulin iAUC 
(pmol/L) 
Cases 205 (104-480) 183 (109-316) 39 (13-101) 0.69 0.04 0.04 
Controls 472 (230-992) 70 (8-310) N/A 0.04 N/A N/A 
Glucagon iAUC 
(pmol/L) 
Cases 0.5 (0.1-1.2) 11.8 (2.2-16.7) 0.2 (-0.2-1.9) 0.04 0.04 0.50 
Controls 0.3 (-2.8-1.7) 18.4 (-6.9-26.3) N/A 0.14 N/A N/A 
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Figure S1 – absolute values insulin, glucagon and glucose in controls without 
diabetes and KCNJ11 cases in response to carbohydrate and protein meals. 
Values shown are medians. 
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Figure S2 - ratio of total AUC0-4h insulin / total AUC0-4h glucose.  Controls are 
shown in grey (diamonds are individuals and lines are group medians).  











Figure S3 – paracetamol absorption curves in controls and cases with the 





Figure S4 – incremental glucose, insulin and glucagon in KCNJ11 cases with 
sulfonylurea only in the absence of food in comparison to the carbohydrate and 









Figure S5 - absolute glucose insulin, and glucagon and in KCNJ11 cases with 
sulfonylurea only in the absence of food in comparison to the carbohydrate and 
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• This is the first study to systematically assess psychiatric morbidity in 
people with KCNJ11 mutations, using validated, standardised diagnostic tools. 
• The data show that KCNJ11 mutations, in addition to causing neonatal 
diabetes, also cause psychiatric disorders that are clinically unrecognised but 
have high impact on families. 
• This research highlights the need for early assessment and an integrated 






Mutations in the KCNJ11 gene, which encodes the Kir6.2 subunit of the 
pancreatic KATP channel, cause neonatal diabetes.  KCNJ11 is also expressed 
in the brain, and approximately 20% of those affected have neurological 
features, which may include features suggestive of psychiatric disorder.  No 
previous studies have systematically characterised the psychiatric morbidity in 
people with KCNJ11 neonatal diabetes. We aimed to characterise the types of 
psychiatric disorders present in children with KCNJ11 mutations, and explore 





The parents and teachers of 10 children with neonatal diabetes due to KCNJ11 
mutations completed the Strengths and Difficulties Questionnaire (SDQ) and 
DAWBA (Development and Wellbeing Assessment).  SDQ scores were 
compared with normative data.  Diagnoses from the DAWBA were compared 
with known clinical diagnoses.       
 
Results 
SDQ scores indicated high levels of psychopathology and impact.  Psychiatric 
disorder(s) were present in all 6 children with the V59M or R201C mutation, and 
the presence of more than one psychiatric disorder was common. Only 2 
children had received a formal clinical diagnosis, with a further one awaiting 
assessment, and coexistence of more than one psychiatric disorder had been 
missed.  Neurodevelopmental (attention deficit hyperactivity disorder and 
autism) and anxiety disorders predominated.   
 
Conclusions 
Systematic assessment using standardised validated questionnaires reveals a 
range of psychiatric morbidity in children with KCNJ11 neonatal diabetes.  This 
is under-recognised clinically and has a significant impact on affected children 
and their families.  An integrated collaborative approach to clinical care is 
needed to manage the complex needs of people with KCNJ11 neonatal 




Mutations in KCNJ11, which encodes the Kir6.2 subunit of the KATP channel, are 
the commonest cause of neonatal diabetes. These are important to diagnose as 
over 90% of people with these mutations can transfer from insulin treatment to 
an oral sulphonylurea, achieving excellent glycaemic control (1). KCNJ11 is 
expressed in the brain as well as the pancreas (2), explaining why 
approximately 20% of people with mutations in this gene have a neurological 
phenotype known as DEND (Developmental delay, Epilepsy and Neonatal 
Diabetes) syndrome (3).  Even those without an overt neurological phenotype 
have recently been shown to have attention deficits and developmental 
coordination disorder on neuropsychological testing (4). 
 
Case reports and animal data suggest that KCNJ11 mutations may be 
associated with childhood psychiatric disorders. Two people with the 
commonest DEND mutation, V59M, have been reported to have attention deficit 
hyperactivity disorder (ADHD) (5).  Mouse models with V59M mutations 
targeted to neuronal tissue have replicated the hyperactive phenotype, and 
show increased exploratory behaviour and reduced anxiety behaviour 
consistent with the inattention and impulsivity reported in humans, suggesting a 
role for KCNJ11 in emotional regulation (6).  Autism (comprising impaired 
language and social interaction and restricted/repetitive behaviours) has also 
been reported in one person with the V59M mutation (7).   No previous studies 
have systematically assessed the psychiatric morbidity in people with KCNJ11 
neonatal diabetes, or the impact that this has on families.   
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We aimed to characterise the types of psychiatric disorders present in children 
and adolescents with KCNJ11 mutations, and explore the impact of these on 




We recruited 10 children from the UK (median age 8.5, range 6-17 years) with 
neonatal diabetes due to a mutation in the KCNJ11 gene.    
 
Study Procedures  
Ethical approval 
Ethical approval was obtained for the study from the National Research Ethics 
Service Committee South West - Exeter.  
 
Recruitment and Consent 
Patients were recruited at a neonatal diabetes family event in Exeter.  Valid 
informed consent was obtained from parents (at the family event) and teachers 
(at a later date). 
 
Developmental and physical health history 
Parents reported the ages at which their child achieved major fine and gross 
motor, social and speech and language milestones, their child’s educational 
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attainment, and any interventions required e.g. speech and language therapy, 
extra support at school.  They also gave details of their child’s physical and 
mental health history and current diabetes medication.   
 
Psychiatric evaluation 
Parents and teachers completed the DAWBA and SDQ.  The DAWBA is a 
standardised diagnostic interview that combines structured and semi-structured 
approaches to generate DSM-IV (8) psychiatric diagnoses on 5-17-year-olds.  
Parallel versions exist for parents and young people aged 11-17 years, with a 
briefer questionnaire for teachers.  It covers common emotional, behavioural 
and hyperactivity disorders as well as less common but sometimes more severe 
psychiatric disorders.  Clinicians assess the data from all available informants to 
assign diagnoses according to DSM-IV.  The initial DAWBA validation study 
showed excellent discrimination between community and clinic samples in rates 
of diagnosed disorder (9).  Since then the DAWBA has been widely used in 
British national surveys and as a tool to aid clinical assessment in many 
countries. 
The SDQ consists of 25 items relating to emotional symptoms, conduct 
problems, hyperactivity/ inattention, peer relationships and prosocial behaviour.  
Scores across the first four subscales (5 items each) are summed to create a 
‘total difficulties score’ that ranges from 0-40.  The impact supplement 
measures distress and social impairment caused by the child’s difficulties.  The 
reliability and validity of the SDQ make it a useful screen for psychopathology in 




The total difficulties, impact scores and psychiatric diagnoses were compared 
with normative data for approximately 8000 school-age children from the British 
Child and Adolescent Mental Health Survey 2004 (11).   
  
RESULTS  
Clinical and Developmental History  
Parents reported high levels of developmental delay and learning difficulties 
(Table S1).  9/10 children required intervention to assist education or 
development. Psychiatric morbidity (Table S1) was recognised: 2 children had a 
clinical diagnosis of autism, one was awaiting assessment due to probable 
autism, and one had ‘autistic tendencies’.  Another child required psychological 
support for low mood.  
 
Strengths and Difficulties Questionnaire  
Both parents (Figure 1) and teachers (Figure S1) reported high levels of 
psychopathology.  Parent-reported median impact and median total difficulties 
Z-scores were 2.8 and 1.8 compared to the general school-age population (Z-
score >1.3 psychiatric evaluation suggested).  Problems were most marked in 
emotional difficulties and hyperactivity.  Prosocial behaviour scores were also 
reduced compared to the background population (median Z-scores -1 and -0.7 




Development And Wellbeing Assessment (DAWBA) 
Clinical evaluation of parents’ and teachers’ responses to the DAWBA 
questionnaire showed definite psychiatric disorder(s) were present in 6/10 
children, but only 2 had a clinical diagnosis, with a further one awaiting formal 
assessment (Table 1).  All children with either V59M (n=4) or R201C (n=2) had 
a definitive psychiatric diagnosis on the DAWBA. There was more than one 
disorder in 4/6 which was not recognised clinically.  The prevalence of 
psychiatric disorder in British school children using the DAWBA is 10% (11), so 
the level of psychiatric morbidity is this cohort is higher than the background 
population (p=0.0001 for a one-sample proportion test).    
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Table 1.  Clinical diagnoses and diagnoses obtained from DAWBA 
questionnaires 
Case Mutation Clinical 
diagnoses 
DAWBA diagnoses (DSM-IV classification) 
Neurodevelopmental 
disorders 
Anxiety disorders Behavioural 
disorders 





2 V59M - ADHD (combined) - - 












5 R201C - - Other anxiety 
disorder 
- 
6 R201C - Autism (probable) Separation anxiety Oppositional 
defiant disorder 
7 K170R - - -  
8 I182V - - - Other disruptive 
disorder 
(probable) 
9 K170N - - - - 
10 R201H - - - - 
 
Table 1.  Clinical diagnoses and diagnoses obtained from DAWBA 
questionnaires.  a Attention Deficit Hyperactivity Disorder  b (combined) denotes 
all three features (hyperactivity, impulsivity, inattention) present  
 
Neurodevelopmental disorders were prominent (autism and ADHD).  3/10 
children had both autism and ADHD; although DSM-IV criteria exclude ADHD 
as a diagnosis in the presence of autism, clinical practice and DSM-V has 
moved towards assigning both due to the high impact on families and need for 
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clinical intervention.    Anxiety disorders were common with 5/10 children being 
diagnosed with at least one anxiety disorder.  
 
Three children had additional probable diagnoses, but we could not make 
definitive diagnoses based on the DAWBA.  Case 6 (R201C) was assigned a 
probable diagnosis of autism (and is awaiting formal diagnostic assessment for 
autism by his local services), and Case 8 (I182V) had a probable diagnosis of 
other disruptive (conduct) disorder, but this related to behaviour more than 6 
months previously which was now resolving.  Finally, Case 9 (K170N) was 
supported by health psychology and a nurture group for low mood and self-




Neurodevelopmental disorders (autism and ADHD) and/or anxiety disorders 
were present in all 6 children with sulphonylurea-treated neonatal diabetes due 
to V59M or R201C KCNJ11 mutations.  Most of these psychiatric disorders had 
not been diagnosed in clinical practice.  
 
Definitive psychiatric diagnoses occurring only in those with the V59M or R201C 
mutation is consistent with the previous literature.  These are the two 
commonest mutations associated with neurological/developmental features, 
which are almost invariable in V59M and inconsistently reported in R201C (3).  
There is a clustering in the type of psychiatric disorder; ADHD is present in all 4 
children with the V59M mutation, consistent with previous reports of ADHD in 
188
people and hyperactivity, inattention and impulsivity in mice with the mutation 
(2, 5, 6).  Autism found in 4 children has previously been reported in a single 
patient (7).  The presence of anxiety disorders in 4 children differs to the 
reduced anxiety behaviour noted in the V59M mouse model (6). 
One of the most striking features of the assessment process was the impact on 
families of the difficulties identified.  In those most severely impaired, parents 
had become full-time carers for their children.  Some families reported that their 
children needed more support, which suggests that awareness of the 
psychological problems faced by such families should be raised amongst 
healthcare professionals involved in their care.  The complex pattern of needs 
that we identified requires a fully integrated and collaborative approach 
involving parents, carers, GPs, paediatric endocrinologists, occupational 
therapists, clinical / educational psychologists, teachers, special educational 
needs coordinators and child and adolescent mental health services.   
 
Limitations of the study 
Due to the rarity of the condition, the number of participants recruited was small.  
In addition, the families who attended our family day may not be representative 
of all people with KCNJ11 neonatal diabetes.  Psychiatric difficulties could make 
patients more reluctant to attend a public meeting with considerable travelling or 
make them more likely to attend to seek advice.  The total number of UK 
patients aged 5-17 with KCNJ11 mutations at the time of the study was 21, 
therefore 48% of those eligible for inclusion in the study took part.  Furthermore, 
our cohort did have significantly more V59M and R201C mutations than in the 
total UK paediatric cohort (60% v 26% p=0.049).  For these reasons, we have 
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been unable to use this study to provide prevalence data on the psychiatric 
features associated with KCNJ11 mutations.  However our systematic and 
detailed assessments found considerable unrecognised psychiatric morbidity in 
this group.  
 
Further work 
Our research suggests that psychiatric morbidity predominantly affects people 
with V59M and R201C mutations and most of these mutation carriers are 
affected.  A larger study assessing more patients with these and other 
mutations will give information on prevalence and the extent to which 
psychiatric morbidity forms part of a specific phenotype/genotype relationship.  
In addition, further studies are needed to assess the effects of sulphonylurea 
therapy on psychiatric symptoms in people with KCNJ11 mutations.   
 
Conclusions/Implications 
Systematic assessment using standardised validated questionnaires reveals a 
range of psychiatric morbidity in children with KCNJ11 neonatal diabetes.  This 
is under-recognised clinically and has a significant impact on affected children 
and their families.  An integrated and collaborative approach to clinical care is 
needed to ensure early identification and appropriate management of the 
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Parental Report of Developmental Milestones  
(Interventions) 
Psychiatric history / epilepsy / other relevant 
clinical history 
Current diabetes treatment 









Age of transfer to 
sulphonylureas (if 
applicable) 
1 14 M V59M 
(KCNJ11) 
Delayed – current mental age 4 (attends 
Special School)  
‘Some autistic tendencies’ noted as a younger 
child.  Epilepsy diagnosed aged 10 years; 
treatment Epilim (sodium valproate) 400mg BD.  
Glibenclamide 10mg TDS 
(0.7mg/kg/day) 
36 (5.4) 1 4 years 
2 6 M V59M 
(KCNJ11) 
Delayed – current mental age 3 (1:1 support at 
school, SENd statement) 
Younger brother of case 3. Glibenclamide 10mg BD 
(1mg/kg/day)  
30 (4.9) 9 On SU since 
diagnosis 
3 17 M V59M 
(KCNJ11) 
Delayed – current mental age 3 (attends 
Special School) 
Autism diagnosis.  Under local gCAMHS team. Glibenclamide 30mg breakfast, 
35mg dinner (1mg/kg/day) 
33 (5.2) 1 10 years 
4 6 F V59M 
(KCNJ11) 
Delayed – current mental age 3 (25 hours/week 
1:1 support at school, SEN statement, uses 
Makaton to aid communication) 
Autism diagnosis July 2014.  Speech improved 
following recent increase in SU from 2.6mg / 
day. 
Glibenclamide 11mg BD 
(1mg/kg/day) 
38 (5.6)  12 12 months 
5 16 F R201C 
(KCNJ11) 
Developmental concerns re: social interaction, 
learning difficulties at school (on enhanced 
learning programme – current mental age 12) 
Difficulties with language expression / 
comprehension and mathematics. 
Glibenclamide 20mg breakfast, 
15mg lunch, 20mg dinner 
(1.1mg/kg/day)  
55 (7.2)  11 10 years 
6 9 M R201C 
(KCNJ11) 
Speech delay (speech and language therapy 
when younger, support at school from teaching 
assistant) 
Probable autism – awaiting formal assessment. Glibenclamide 4.2mg breakfast, 
3mg lunch, 3.7mg dinner 
(0.3mg/kg/day) 
 37 (5.5) 1 4.5 months 
7 8 M K170R 
(KCNJ11) 
Speech delay (speech & language therapy, 20 
hours/week support from SENCOf, IEPe) 
Being assessed for dyslexia (difficulties with 
maths/ literacy/ spellings /letter and shape 
formation).   
Glibenclamide 5mg breakfast, 
5mg lunch, 2.5mg dinner 
(0.48mg/kg/day) 
32 (5.1)  33 15 months 
8 15 F I182V 
(KCNJ11) 
 
Mild speech delay (some 1:1 support at school, 
particularly during examinations) 
Diagnosed with ‘borderline’ dylsexia. Spent 
some time on gliclazide; found concentration 
improved when switched to glibenclamide. 
Glibenclamide 15mg breakfast, 
10mg dinner; noted to not be 
taking her medication regularly 
(0.5mg/kg/day) 
127 (13.8)  1 N/Ac (TNDMh); 
Insulin 8-9 
months, no Rx 
then SU aged 11 
years 
9 8 M K170N 
(KCNJ11) 
Mild speech and motor delay (speech and 
language therapy as toddler) 
Attends ‘nurture group’ at school to help 
confidence.  Excels academically.  Under 
paediatric diabetes psychology service due to 
low mood related to diabetes. 
Glibenclamide 5mg breakfast, 
2.5mg dinner (0.29mg/kg/day) 
33 (5.2)  11 5 months 
10 6 F R201H 
(KCNJ11) 
Normal Nil Glibenclamide 2.5mg TDS 
(0.4mg/kg/day)  
42 (6.0) 12 12 months 
aWhere no recent weight available, weight calculated based upon CDC paediatric growth charts using 50 th percentile (http://www.cdc.gov/growthcharts 2000) b Most recently 
available result    cN/A = Not applicable dSEN = special educational needs  eIEP = Individualised education program  fSENCO = special educational needs coordinator 
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We support the findings of Carmody et al who offered new insights into the 
neurological phenotype of people with KCNJ11 neonatal diabetes[1]. 
Neurological features result from the K-ATP channel affected by these 
mutations being expressed in the brain as well as the pancreas [2].  Past work 
has characterised developmental delay associated with specific mutations e.g. 
V59M, known as DEND syndrome (developmental delay, epilepsy, and 
neonatal diabetes) [3, 4].  Affected individuals also have impaired visuomotor 
performance [5] and psychiatric (predominantly neurodevelopmental) disorders 
[6].  Carmody et al described neuropsychological impairments in children with 
KCNJ11 mutations and compared their cognitive functioning with unaffected 
sibling controls, concluding that affected children without global developmental 
delay had lower IQs and performed worse on a range of assessments of 
academic achievement and executive function than their unaffected siblings [1].   
Characterising the neuropsychological profiles in this rare form of diabetes is 
important to enable appropriate educational support to be implemented early for 
affected individuals.  Here we report the results of neuropsychological testing in 
10 individuals with KCNJ11 neonatal diabetes who received a molecular genetic 
diagnosis in Exeter, UK.   
Ethical approval for the study was obtained from the Devon and Torbay 
Research Ethics Committee. 
We recruited 10 children (median age 8.8 years (range 5.9-17.0 years)) with 
neonatal diabetes due to a mutation in the KCNJ11 gene (4 V59M, 2 R201C, 
K170R, K170N, R201H, I182V), and 7 unaffected siblings (median age 11 
years, range 4-15 years).  All children with neonatal diabetes were 
sulphonylurea-treated at the time of testing (median dose 0.56 mg/kg/day, 
range 0.09-1.15mg/kg/day).  Nine children had permanent neonatal diabetes 
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(PNDM) and one (with the I182V mutation) had transient neonatal diabetes 
(TNDM) which had relapsed 4 years prior to taking part in this study.  Informed 
consent was obtained from parents.  Parents were asked about their child’s 
developmental milestones, educational attainment, and any interventions at 
school.  Children were assessed by clinicians in the research team using 8 tests 
selected from specific batteries to measure a wide range of functioning.  The 
‘narrative memory’ subscale of the Developmental Neuropsychological 
Assessment (NEPSY-II) was used to test episodic memory, and the ‘verbal 
fluency’ subtest of the Delis-Kaplan Executive Function System (DKEFS) was 
used to test letter fluency.  The ‘symbol search’, ‘digit span’, and ‘vocabulary’, 
subtests of the Wechsler Intelligence Scale for Children, fourth edition (WISC-
IV) were used to test processing speed, memory capacity/working memory, and 
verbal comprehension.  Finally, all three subtests of the Beery-Buktenica Test of 
Visual Motor Integration (VMI), (‘visual perception’, ‘motor coordination’ and 
‘visual motor integration’ tests), were used to assess fine motor skills and hand-
eye coordination.  On completion the tests were marked by a Paediatric Clinical 
Neuropsychologist and scores were converted to Z-scores using normative data 
for the school age population.   
 
All four children with the V59M mutation had severe developmental delay and 2 
had a clinical diagnosis of autism; 2 attended a special school and 2 had 
statements of special educational needs with one to one support required at 
school.  Two were untestable using our neuropsychological battery and 2 
scored the lowest of all participants in the few tests they did complete (Z-scores 
≤ -3).  The remaining 6 children did not have mutations consistently associated 
with severe developmental delay, however parents reported speech delay or 
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learning problems requiring support at school in 5 individuals.  Specifically, 3 
children had required speech and language therapy (R201C, K170R, K170N), 
and  4 children required support at school in the form of enhanced / 
individualised learning programmes and / or one to one support from a teaching 
assistant or special educational needs coordinator (2 R201C, K170R, I182V).  
Median Z-scores in these 6 children were below school-age population average 
in all tests (figure 1), and were particularly low (>1SD below population 
average) in tests of executive function (verbal fluency), verbal comprehension 
(vocabulary) and visuo-motor performance (VMI).  Only 1 child (K170N) scored 
within the average range in all tests completed.  In 7 sibling controls, median 
scores were within the normal range in all tests. 
 
Our findings using a different battery of tests are consistent with the study by 
Carmody, where only 2/9 individuals with global developmental delay were able 
to complete any neuropsychological tests and scores in tests they did complete 
were the lowest of the group.  In those individuals without global developmental 
delay, compared to unaffected sibling controls, Carmody reported lower scores 
in the WISC-IV digit span test (working memory); these were also evident in our 
assessments.  Carmody’s study showed impairments in vocabulary assessed 
using the WASI-II; similarly, we found impairments in the vocabulary subtest of 
the WISC.  The low scores we observed in the various components of the VMI 
were consistent with impaired visuo-motor performance in people with KCNJ11 
mutations reported by the same group [5]. 
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Other published studies also suggest difficulties are not restricted to individuals 
with known DEND mutations.  Landmeier reported disturbances in parent-
reported social-emotional and regulatory behaviours, attention, sleep and 
learning that occurred in all KCNJ11 mutation subtypes studied [7].  
Furthermore, Busiah found attention deficits in all patients and dyspraxia in 81% 
of people with KCNJ11 mutations not previously known to have neurological 
sequelae [8].   
 
Due to the rarity of the disease the numbers in our study are small, but 
nevertheless this work supports Carmody et al and provides further evidence of 
neuropsychological dysfunction in people with KCNJ11 mutations, not limited to 
those with known DEND mutations.  We advocate early neuropsychological 
assessment as part of the multidisciplinary care of these individuals to facilitate 
provision of targeted educational support.  Further research in this area is 
needed to assess the impact of high dose sulphonylurea and timing of initiation 




Figure 1.  Neuropsychological test scores represented as Z-scores.  X-axis represents school age population mean.  Large black squares 
are KCNJ11 group medians, large black circles are sibling control group medians.  Small grey squares / circles represent individual 
scores for KCNJ11 participants (n=3-6) and sibling controls (n=5-7).  
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Central nervous system (CNS) features in children with permanent neonatal 
diabetes (PNDM) due to KCNJ11 mutations have a major impact on affected 
families.  Sulfonylurea therapy achieves outstanding metabolic control, but only 
partial improvement in CNS features.  The effects of KCNJ11 mutations on the 
adult brain and their functional impact are not well described.  We aimed to 
characterise the CNS features in adults with KCNJ11 PNDM, compared to adults 
with INS PNDM.   
 
Research Design and Methods 
Adults with PNDM due to KCNJ11 mutations (n=8) or INS mutations (n=4) 
underwent a neurological examination, and completed standardised 
neuropsychological tests/questionnaires about development/behavior.  Four 
individuals in each group underwent a brain MRI scan.  Test scores were 
converted to Z-scores using normative data, and outcomes compared between 
groups.   
 
Results 
In individuals with KCNJ11 mutations, neurological examination was abnormal in 
7/8; predominant features were subtle deficits in coordination/motor sequencing. 
All had delayed developmental milestones and/or required learning 
support/special schooling.  Half had features and/or a clinical diagnosis of autism 
spectrum disorder.  KCNJ11 mutations were also associated with impaired 
attention, working memory and perceptual reasoning, and reduced IQ (median 
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IQ KCNJ11 vs INS mutations 76 vs 111, p=0.02).  However, no structural brain 
abnormalities were noted on MRI. The severity of these features was related to 
the specific mutation and they were absent in individuals with INS mutations.   
 
Conclusions 
KCNJ11 PNDM is associated with specific CNS features which are not due to 
long-standing diabetes, persist into adulthood despite sulfonylurea therapy, and 
represent the major burden from KCNJ11 mutations.   
 
Introduction 
KCNJ11 gene mutations are the commonest cause of permanent neonatal 
diabetes (PNDM), which presents in the first 6 months of life and affects 1 in 
100,000 live births (1).  KCNJ11 is expressed in the pancreas and brain as well 
as other tissues, and encodes the Kir6.2 subunit of the ATP-dependent 
potassium (KATP) channel.  In the pancreas, the KATP channel links increasing 
blood glucose to insulin secretion, but activating KCNJ11 mutations prevent 
channel closure in response to metabolically generated ATP and result in 
diabetes (2).  Clinically, patients present in an insulin-deficient state and prior to 
discovery of disease-causing variants in the KCNJ11 gene they required insulin 
therapy.  It was later shown that KCNJ11 PNDM could be treated with 
sulfonylurea tablets, which bind and close the channel allowing insulin secretion, 
excellent metabolic control and reduced glycaemic variability (3).  For many 
patients and their families transferring from insulin to oral sulfonylureas vastly 
improved quality of life in relation to their diabetes (4).   
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Central nervous system (CNS) features occur in children with KCNJ11 PNDM in 
addition to diabetes. These are thought to result from expression of aberrant KATP 
channels in the brain. The precise role(s) of KATP channels in the human CNS has 
not been fully elucidated, but rodent studies suggest that they play a role in 
glucose sensing and homeostasis as well as seizure propagation (5; 6).  KCNJ11 
is expressed in many brain areas but there are particularly high levels of 
expression in the cerebellum (7; 8). The cerebellum is well known for its role in 
motor learning and coordination (9), but it also has functions relating to language, 
executive function and to mood; furthermore, cerebellar abnormalities have been 
linked with autism (10; 11).  Documented CNS features in children with KCNJ11 
mutations range from subtle neuropsychological impairments that specifically 
affect attention, praxis and executive function to the severe and overt 
DEND/intermediate DEND syndrome (developmental delay, epilepsy and 
neonatal diabetes) (12-15).  Other associated features may include psychiatric 
morbidity, specifically neurodevelopmental disorders and anxiety disorders, 
visuomotor impairments, and sleep disturbance (16-18).  The severity of the CNS 
phenotype is related to the genotype.  For example, the V59M mutation is 
frequently associated with iDEND syndrome and neurodevelopmental features 
whereas the R201H mutation, previously associated with diabetes alone, has 
been more recently linked with subtle neuropsychological features (12).  
Historically, the severity of CNS features was thought to be related to the 
functional severity of the specific mutation in vitro, although functional 
interpretation also has to take into account the impact of the mutation on the open 
probability of the KATP channel which will depend on whether it affects channel 
gating or ATP binding (19-22). 
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Sulfonylurea treatment results in partial improvement in the CNS features (23-
26), and resolution of functional cerebellar and temporal lobe abnormalities on 
single-photon emission computed tomography (SPECT) scanning (24; 27).   The 
improvement in CNS features may be limited as a result of poor penetration of 
the sulfonylurea across the blood brain barrier or active transport back out of the 
brain, leading to sub-therapeutic concentrations in the cerebrospinal fluid (CSF) 
(28).  This, and anecdotal clinical experience of greater CNS response with higher 
doses of sulfonylurea, has prompted clinical recommendations of glyburide doses 
of ~1mg/kg/day in people with severe neurological features secondary to KCNJ11 
mutations (29).  However, the neurobehavioral features continue to have a huge 
impact on families despite sulfonylurea treatment (16).  This contrasts markedly 
with the outstanding metabolic response that changed lives by alleviating the 
anxiety associated with poor metabolic control (4).  A key question is whether the 
CNS features continue to represent the major burden from KCNJ11 mutations in 
adult life.  To date all studies characterising CNS features in KCNJ11 PNDM have 
been conducted in predominantly paediatric cohorts (12-14; 16; 23).  However, 
brain development continues beyond childhood and adolescence (30; 31).  No 
study has comprehensively assessed the CNS outcomes in adults with KCNJ11 
mutations.   
 
Mutations in the INS gene are a less common cause of neonatal diabetes, 
accounting for around 10% of cases (1).  Heterozygous dominant negative INS 
mutations often affect protein synthesis resulting in production of structurally 
abnormal preproinsulin and proinsulin within the beta cell, endoplasmic reticulum 
(ER) stress and cell death.  Individuals with these mutations also typically present 
with insulin deficiency, but unlike KCNJ11 PNDM, require lifelong treatment with 
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replacement doses of insulin (32).  The INS gene is not expressed in any 
significant levels in the brain, therefore it is very unlikely that individuals with INS 
mutations would display a characteristic CNS phenotype as a direct result of their 
mutations (33).  In fact, there have not been any reports of any such neurological 
issues, in contrast to those with KCNJ11 PNDM. 
 
Individuals with PNDM may have long-term CNS sequelae secondary to diabetic 
ketoacidosis at diagnosis, as seen in Type 1 diabetes (34; 35).  However, cerebral 
oedema in KCNJ11 PNDM gives rise to a pattern of neurological impairment 
distinct from that seen as a direct result of brain KATP channel dysfunction (36).  
More subtle neurocognitive problems also occur in the presence of diabetes per 
se, particularly if metabolic control is poor and diabetes is diagnosed before age 
7 (37).  Further, individuals with Type 2 diabetes are at increased risk of 
developing Alzheimer’s disease in later life, and this may be in part due to chronic 
metabolic disturbance and changes in insulin signalling (38).  Indeed, there is 
evidence from both animal and human studies that insulin plays a key role in 
central processes including memory and learning (38).  The non-specific 
diabetes-related cognitive features could confound assessment of CNS 
phenotype in people with KCNJ11 mutations, however people with INS mutations 
are well placed to control for them.  There has been no previous detailed 







The aims of the study were to characterise the neurological and 
neuropsychological features in adults with KCNJ11 PNDM, and to compare these 




Ethical approval was obtained from the National Research Ethics Service 
Committee South West-Exeter. 
 
Sample size and patient recruitment 
We identified 34 patients >16 years old with KCNJ11 mutations and 9 patients 
>16 years old with INS mutations who had received a molecular genetic diagnosis 
in Exeter and who had been diagnosed with permanent neonatal diabetes under 
6 months of age. We approached potential participants either directly at a 
neonatal diabetes family event in Exeter or via the Consultants in charge of their 
clinical care. We invited 17 individuals with KCNJ11 mutations to join the study; 
of these, 10 agreed to participate.  However, 2 individuals were excluded from 
the analysis due to possible confounding factors: one individual (mutation L164P) 
was excluded because he was taking antipsychotic medication to treat a 
psychotic illness at the time of the study and had had a particularly severe initial 
presentation with diabetic ketoacidosis and 3 days in a coma, and a second 
individual (mutation V59M) was excluded due to severe neurological impairment 
following initial presentation with diabetic ketoacidosis (further clinical 
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characteristics of excluded participants are available in online supplemental 
Table S1).  We approached 9 individuals with INS mutations and 4 agreed to take 
part.  All participants were from the UK apart from one who was from Canada. 
 
Tests 
All participants were visited at home or assessed in the Exeter Clinical Research 
Facility by the same Consultant neurologist and Consultant clinical 
neuropsychologist who carried out the history taking using a standard proforma, 
neurological examination, neuropsychological assessments, mood questionnaire 
and neurodevelopmental screen.  If possible an informant or carer was also 
present to facilitate information gathering.  The severity of intellectual impairment 
and behavioral disturbance in one individual (KCNJ11-8 [V59M]) meant that it 
was not possible for him to attempt any of the cognitive tests.  Another individual 
(KCNJ11-6 [V252G]) did not wish to attempt the Controlled Oral Word 
Association Test (COWAT) and was unable to understand instructions for the 
Colour Trails Test (CTT).  In 8 participants (4 with KCNJ11 mutations and 4 with 
INS mutations), T2-weighted brain magnetic resonance imaging (MRI) scans 
were performed using a 1.5T MRI scanner.  The scans were reviewed and 
interpreted by a radiologist and a neurologist who were blinded to the mutation 
status of the individuals concerned. 
Medical / developmental history, educational and professional attainment 
Participants and informants were asked for a standard medical history, the ages 
at which major milestones were attained, whether learning support was required 




A full neurological examination was performed.  This included assessment of 
cranial nerves, limb tone, power, reflexes, coordination, sensation, and simple 
tests of motor sequencing and praxis, comprising 2 tests of bimanual 
coordination, one unilateral motor sequencing task (the Luria three hand position 
test), copying unfamiliar hand positions and manual miming, both tested in each 
hand.  
 
Psychiatric and neurodevelopmental screen 
Current psychological distress was assessed using the Hospital Anxiety and 
Depression Scale (HADS) questionnaire.  The Autism Spectrum Quotient (AQ) 
was administered to screen for autistic traits. 
 
Cognitive function 
A battery of neuropsychological tests were administered to assess a variety of 
cognitive domains.  The Wechsler Abbreviated Scale of Intelligence (WASI) was 
used as a brief measure of current IQ.  The Verbal Paired Associates and Visual 
Reproduction subtests of the Wechsler Memory Scale (WMS-IV) were used to 
give a verbal and non-verbal (visual) measure of memory.  Subtests of the 
Wechsler Adult Intelligence Scale, 4th edition (WAIS-IV) were administered: 
cancellation to assess processing speed and digit span (forwards and 
backwards) to assess working memory.  Subtests of the Visual Object and Space 
Perception battery (VOSP) assessed visuospatial function; incomplete letters and 
object decision to test object perception, and dot counting and cube analysis to 
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test spatial perception.   The Controlled Oral Word Association Test (COWAT) 
was used to assess aspects of executive function including verbal fluency, self-
monitoring and ability to assimilate and adhere to stipulated rules.  The Colour 
Trails Test (CTT) 1 and 2 were used as measures of sustained and divided 
attention, hand eye motor coordination and speed.  Finally, the Addenbrooke’s 
Cognitive Examination-Revised (ACE-R) was used as a broad screening 
measure of cognition, providing an assessment of the following cognitive 
domains; attention/orientation, memory, fluency, language, and visuospatial 
function.  
 
Functional assessment  
The Cambridge Behavioral Inventory Revised (CBI-R) questionnaire was used to 
complement the information obtained from the history taking. This measure seeks 
the opinion of the informant e.g. carer or family member on the frequency of a 
range of behaviors in the domains of memory and orientation, everyday skills, 
self-care, abnormal behavior (e.g. tactlessness, impulsiveness), mood, unusual 
beliefs, altered eating habits, disturbed sleep, stereotypic and motor behaviors, 
and altered motivation.  For each behavior the informant assigned a score of 0-4 
based on the frequency: scores of 3 (occurring daily) or 4 (occurring constantly) 
denote a significant behavioral deficit. 
 
Statistical analysis 
Data were analysed using Excel 2010 and Stata 14.  Qualitative data were 
presented descriptively.  Where population normative data were available, 
neuropsychological test scores were converted to Z-scores.  For VOSP subtests, 
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a pass was a score ≥5th population percentile.  To compare characteristics and 
outcomes between the KCNJ11 and INS groups, data were analysed using non-
parametric methods (Mann-Whitney test for numerical variables and Fisher’s 
exact test for categorical variables).  Data are presented as median (range) 




Baseline clinical characteristics of the participants are outlined in Table 1; these 




Abnormalities on neurological examination were identified in 7/8 KCNJ11 
participants and only one INS participant (Table 2).   
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Table 1. Baseline characteristics in individual participants, KCNJ11 cases and INS controls and group characteristics summary. 
Table 1. Summary numerical data are presented as median (range) and categorical variables are presented as n (%).  Mutations were presumed 
to have arisen de novo if there was no parental history of diabetes but the mutation status of the parents had not been confirmed with a genetic 
test.  HbA1c values are the results available closest to the time of the neurobehavioral assessment. N/A = not applicable, NK = not known. 
Case  Mutation Inheritance Sex Age Age at diabetes 
diagnosis 
(weeks) 
Age at genetic 
diagnosis 
(years) 
Age at transfer 
to SU (years) 






KCNJ11 1 G53S Autosomal 
dominant 
M 32 2 23 23 Glyburide 30mg, 
metformin 1g  
9.3 78 
KCNJ11 2 R201H Presumed de 
novo 
F 22 4  15 15 (attempted) Insulin (restarted after 
trial of glyburide) 
8.1 65 
KCNJ11 3 R201H De novo M 36 10  29 29 Gliclazide (120mg) 8.1 65 
KCNJ11 4 R201C Presumed de 
novo 
F 36 5  27 34 Glyburide (40mg) 7.0 53 
KCNJ11 5 R201C De novo M 19 6  13 13 Glyburide 27.5mg  5.4 36 
KCNJ11 6 V252G De novo M 28 8 21 21 Glyburide (85mg)  10.8 95 
KCNJ11 7 V59M De novo F 25 15  17 17 Glyburide (7.5mg) 8.1 65 
KCNJ11 8 V59M De novo M 17 5 10 11 Glyburide (55mg) 5.9 41 
INS 1 C43F Autosomal 
dominant 
F 35 78 31 N/A Insulin  NK NK 
INS 2 F48C Presumed de 
novo 
F 50 5 42 N/A Insulin NK NK 
INS 3 G75C De novo M 28 8 26 N/A Insulin 7.9 63 
INS 4 H29D De novo F 20 26 12 N/A Insulin (pump)   8.2 66 
    
KCNJ11 
group 
N/A De novo = 7 
(87.5%) 
Autosomal 
dominant = 1 
(12.5%) 
M = 5 
(63%) 





5.5 (2-15) 19 (10-29) 21 (11-34) Insulin treated = 1/8 8.1 (5.4-
10.8) 
65 (36-95) 
INS group N/A De novo = 3 
(75%) 
Autosomal 
dominant = 1 
(25%) 
M = 1 
(25%) 





17 (5-78) 28.5 (12-42) N/A Insulin treated = 4/4 8.1 (7.9-
8.2) 
65 (63-66) 
P value N/A 1.0 0.55 0.44 0.15 0.23 N/A 0.01 0.79 0.79 
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Table 2 - History and examination findings for individual KCNJ11 cases and INS controls.   
Case 
(mutation)  















status (job) of 








D (speech and 
motor)  























until age 15, 
Maths for 1 
year) 
US F – E (accountant) 
M – E (nurse) 
Nil Intermittent mild 
head titubation. Brisk 
reflexes, 
questionable 
increase in tone in 













and Maths).  
E (baker) NK Nil Normal Bilateral high 
T1 signal in 
pons – artefact 
KCNJ11 4 
(R201C) 






E (pubs, shops, 
hotel) 
B – E (operations 





















MS then C 
(for people 
with ID) 
LS (from age 
10).   
CS (college for 
people with ID). 
F – E (company 
manager), M - UE 
(housewife), B – E 
(aviation engineer), 
B – US (political 
science) 
Anxiety (social 







D (speech, fine 
motor). Speech 
therapy. 




















MS then C 





E (SS teaching 
assistant) 
M – E (SS teaching 
assistant), F – E 
(lecturer), B – E 
(trainee lawyer) 









D (global).  Yes – 
hypoglyca
SS Unable to 
read/write. 
UE S – E (museum 
curator) 
Autism Ritualistic, clumsy, 




Table 2. NK = not known, ND = not done, D=delayed, N=normal, MS = Mainstream school, SS = Special school, U = University, C = College, LS 
= learning support, E = employed, UE = unemployed, ID = intellectual disability, US = university student, CS = college student, OCD = obsessive 









N Yes  U (pharmacy 
degree)  
No E (hospital 
pharmacist)  








No support.  UE (ill health). 
Clerical / carer 
jobs in past 









with known diabetic 








N No  MS  No support.  E (dept. of work 
and pensions) 
F – E (carpenter, 
transport manager), 
B – E (marketing 
agency) 
Nil N N 
INS 4 
(H29D) 
N Yes – 
DKA 
MS LS (Maths & 
English 4 
years). 
E (bank call 
centre)  
F – E (carpenter) Anxiety, panic 
attacks 
(Escitalopram in the 
past) 







Developmental History, Educational and Professional Attainment 
Developmental histories, level of educational support and employment history 
reported for each participant are described in Table 2.  Developmental delay and 
/ or learning difficulties were present in all KCNJ11 participants and they 
continued to require high levels of support as adults.  In contrast, the INS group 
did not report major learning difficulties in keeping with their subsequent 
employment history and independence in adulthood.  
 
Neurodevelopmental and Psychiatric Features  
4/8 with KCNJ11 mutations, but none of the participants with INS mutations, had 
features of autistic spectrum disorder, either via a clinical diagnosis of autism or 
an AQ score at or above the threshold suggestive of clinically significant autistic 
traits (Table 2 and S3).  Two individuals in the KCNJ11 group and one in the INS 
group required treatment either at the time of the study or in the past for 
depression or anxiety.  HADS scores for anxiety and depression were similar in 
KCNJ11 vs INS participants (Table S3).  One individual in the KCNJ11 group and 
2 individuals in the INS group scored above the HADS clinical threshold (11) for 
anxiety (Table 2, Table S3).   
 
Cognitive Function  
IQ was lower in the KCNJ11 group vs the INS group (IQ 76(55-101), n=7 and 
111(90-124), n=4, p=0.02).  Three individuals in the KCNJ11 group had IQs <70 
(Table S2) and impairments in adaptive behaviors in-keeping with a clinical 
diagnosis of intellectual disability (39). 5/7 individuals in the KCNJ11 group 
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scored below the clinical cut-point for cognitive impairment on the ACE-R (Figure 
S1). CTT1 scores suggested reduced attention (CTT1 Z-score -1.7(-3.0- -0.1), 
n=6 vs 0.4(-1.1-1.2), n=4, p=0.03, CTT2 Z-score -0.8(-3.0-0.8), n=6 vs. 0.7(-1.0-
1.2), n=4, p=0.13 (Figure 2, Table S2)). 
 
In the KCNJ11 group but not the INS group median scores in the WASI, WAIS 
and WMS were below population average in all subtests apart from the verbal 
paired associates subtest of the WMS (Figure 1).  Scores were particularly low 
(≤2SD below population average) in the matrix reasoning component of the WASI 
(Z-score -3.2(-4.8- -0.9) vs. 0.6(-0.7-0.8), p=0.008) and the digit span component 
of the WAIS-IV (Z-score -2.0(-3.0-0.3) vs 0(-1.0-0.3), p=0.046).  Cancellation 
scores, although not as markedly reduced compared to population norms, were 
significantly lower in the KCNJ11 group (Z-score -1(-3-0) vs 2.8(0.7-3.0), 
p=0.007).  COWAT and VOSP scores showed a trend towards reduced executive 
function and visuospatial function respectively in the KCNJ11 group (Table S3), 
although these did not reach statistical significance.   
 
Behavioral / functional impact 
In the KCNJ11 group, 6 individuals had severe behavioral features which 
clustered in the domains of everyday skills (5/6), stereotypic behavior (5/6), 
memory and orientation (4/6), abnormal behavior (3/6), mood (3/6), and 
motivation (3/6).  Specific everyday skills highlighted included writing (3/5) and 
dealing with money/bills (2/5).  The most frequent stereotypic behaviors were 
being rigid / fixed (3/5) and having fixed routines (4/5).  Poor concentration was  
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Figure 1: Neuropsychological testing in KCNJ11 patients (blue, n=7) and INS patients (orange, n=4).  WMS: Verbal paired associates I/II 
(immediate/delayed) – auditory memory, Visual reproduction I/II (immediate/delayed) – visual memory (both components of working memory) 
WASI: Vocabulary - word knowledge and verbal concept formation, matrix reasoning – non-verbal/perceptual reasoning.  Digit span – working 
memory, cancellation – processing speed. *denotes p<0.05 for difference between KCNJ11 and INS groups.
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highlighted as a specific feature in all 4 individuals who had memory and 
orientation problems.  Two individuals had significant difficulties with self-care 
and 2 reported disturbed sleep.  
 
Neuroimaging 
Structural brain MRI was normal in participants with KCNJ11 mutations.  In INS 
controls, 2 were normal, and 2 had minor abnormalities which were not clinically 
significant (Table 2).  
 
Severity of impairments associated with the specific mutation 
Performance in the cognitive tests was better in the 2 individuals with the R201H 
mutation.  These individuals consistently had scores equal to or greater than the 
KCNJ11 group medians (Figures 1 and 2, Table S2), and no significant 
behavioral features were reported.  
 
Discussion 
We have characterised for the first time the profile of neurological, 
neuropsychological and behavioral features present in adults with PNDM due to 
KCNJ11 mutations.  The key features were learning difficulties, features of ASD, 
subtle motor deficits affecting coordination and motor sequencing, and reduced 
IQ.  Specific cognitive domains most affected were perceptual/non-verbal 
reasoning, working memory, and attention, with a trend towards executive 
dysfunction and impaired visuospatial abilities.  Verbal paired associate memory
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Figure 2: Colour Trails Test 1&2 scores represented as Z-scores in the KCNJ11 group (blue, n=6) and INS group (orange, n=4).  Lines 
show group medians for each subtest; dots represent individuals. *denotes p<0.05 for difference between KCNJ11 and INS groups. 
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was relatively preserved.  The impact on everyday functioning was significant; 2 
participants were severely impaired, requiring support with activities of daily 
living.  A comparison group of patients with neonatal diabetes of similar duration 
due to INS mutations did not show any of these specific features indicating that 
they are unlikely to be a non-specific effect of metabolic disturbance from birth.  
Furthermore, as both groups were insulin treated from diagnosis as infants, the 
differences observed are unlikely to have been influenced by variation in the 
timing or duration of action of insulin on insulin and IGF receptors in the brain.   
 
Our findings are consistent with studies in paediatric cohorts with KCNJ11 
neonatal diabetes.  Specifically, the motor features noted on neurological 
examination, together with impairments of attention, working memory, 
visuospatial ability and executive function are consistent with the previously 
reported high prevalence of developmental coordination disorder, inattention, 
executive dysfunction and poor visuomotor performance in children with KCNJ11 
mutations (12-14; 17; 18; 23; 40).  ASD features in 4 individuals with KCNJ11 
mutations is consistent with previous research reporting high rates of 
neurodevelopmental disorders in affected children (16; 18; 41).  Dyspraxia, 
visuomotor impairment, autism and impaired executive function may be related 
to the high levels of expression of dysfunctional KATP channels in the cerebellum 
in KCNJ11 PNDM (7; 10).   
 
Importantly, the abnormal findings we report in the KCNJ11 group were mutation-
specific; the 2 individuals with the R201H mutation had no overt features and only 
some subtle abnormalities on neuropsychological testing (Table S2).  As a result, 
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both were able to live independently and support themselves financially.  Those 
with more severe features required high levels of support from family members 
and professionals in healthcare, education and social care.  This is consistent 
with previous studies showing the severity of the CNS phenotype is related to the  
specific mutation; for example, the V59M mutation results in more severe 
features, greater impairment in daily living skills (13) and greater impact on 
families (16).  Interestingly, however, there was a relatively good level of social 
integration from all patients with KCNJ11 mutations even when the 
neurobehavioral features were severe. 
 
Some of our findings contrast with previous research.  To our knowledge 
choreiform movements have not been previously associated with KCNJ11 PNDM 
but were observed in one individual with the V59M mutation in our study.  We did 
not identify abnormal tone in our cohort, which contrasts with the hypotonia 
previously reported, particularly in the context of DEND/iDEND syndrome (42).  
This may be explained by 7/8 individuals in our study being sulfonylurea-treated; 
improvement in tone to near-normal following transfer from insulin to 
sulfonylureas has been observed in a recent study of children with KCNJ11 
PNDM (23).  Similarly, improvement of visuospatial abilities and attention 
following transfer to sulfonylureas was noted in the paediatric study (23), which 
could account for the attention deficits and visuospatial impairment being less 
marked in our cohort of sulfonylurea-treated adults than might have been 
expected given previous descriptions (17; 23).  Our neuroimaging findings 
contrast with this paediatric study in which there were non-specific findings in 
12/17 who underwent brain MRI, largely comprising white matter abnormalities 
(23).  However, these scans were performed at baseline prior to transfer to 
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sulfonylureas (23).  It is not known whether the abnormalities would have 
improved after a period of sulfonylurea treatment, as has been shown in SPECT 
studies (24; 27).  
 
Sulfonylurea treatment may influence the CNS phenotype in KCNJ11 PNDM.  
Two studies have suggested that an earlier age of initiation of sulfonylureas can 
lead to better CNS outcomes (17; 23).  We were unable to assess this in our 
study because median age at transfer to sulfonylureas was 18 years (range 11-
34).  However, the persistence of CNS features in some patients even after early 
initiation of treatment (16; 23) suggests other factors are involved.  Specifically, 
active transport of glyburide out of the brain across the blood-brain barrier, as has 
been demonstrated in a rodent model (28), may result in suboptimal 
concentrations in the CSF, thereby limiting therapeutic efficacy in the human 
CNS.  Anecdotal clinical experience suggests that this can be partially addressed 
by increasing the dose of glyburide to ~1mg/kg/day; however there have been no 
cases of complete resolution of CNS features in a patient with iDEND.  Another 
possible reason for the partial response is that pathways that can fully restore 
KATP channel function in other tissues are not available in the CNS to interact with 
brain KATP channels.  For example, restoration of pancreatic KATP channel 
function resulting in excellent glycaemic control with sulfonylurea treatment is 
dependent on the activity of incretin hormones (3).  Furthermore, there is a 
theoretical impact of insulin deficiency in utero and / or C-peptide deficiency prior 
to sulfonylurea transfer on the brain as an indirect consequence of KCNJ11 
mutations, but more studies are needed to explore this in humans.  Indeed, given 
the complexities of human neurodevelopmental processes, it is likely that several 
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factors contribute in some way to the response of CNS features to sulfonylureas 
in KCNJ11 PNDM.   
 
Strengths, Limitations and future work 
This study has important strengths.  It is the first to assess in detail the CNS 
manifestations of KCNJ11 mutations in adults and to control for the non-specific 
effects of PNDM by comparing the features in individuals with INS mutations.  
Limitations of the study, which relate to the rarity of the disease, are the small 
number of individuals in each group, the broad range of mutations studied, and 
the variable timing of initiation and duration of treatment with sulfonylureas in the 
KCNJ11 group.  Studies in larger cohorts with single specific mutations would be 
valuable.  Furthermore, exploration of the impact of treatment-specific factors, 
such as age of initiation, dose and CNS handling of sulfonylureas in humans, on 
CNS features in KCNJ11 PNDM is warranted.   
 
Conclusion 
The CNS phenotype in adults with KCNJ11 mutations comprises learning 
difficulty, autistic features, subtle motor dysfunction, moderately reduced IQ, and 
impaired attention, perceptual reasoning and working memory.  The severity of 
these features varies with the causative mutation. They persist despite long term 
sulfonylurea therapy, at least when this is started after the first decade of life, and 
represent the major burden from KCNJ11 mutations once glycemia is well 
controlled on sulfonylureas.  These CNS features are not present in individuals 
with INS mutations, which indicates that they do not occur as a result of the 
lifelong metabolic disturbance imposed by PNDM, but as a consequence of 
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impaired KATP channel function in the brain.  Clinicians in adult and paediatric 
medicine should be aware of the potential impact of CNS features in patients with 
KCNJ11 mutations and should consider multidisciplinary management to ensure 
appropriate support is provided.   
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Figure S1; ACE-R in KCNJ11 individuals (blue), n=7 and INS individuals (orange), n=4.  Scores are presented as percentages of maximum possible 




Table S1 – Clinical characteristics of participants with KCNJ11 mutations excluded from analysis 
NK = not known, D=delayed, MS = Mainstream school, SS = Special school, LS = learning support, E = employed, UE = unemployed, MR = 
medically retired 
 
Table S2 - Individual scores on subtests of the Wechsler Memory Scale 4th edition (WMS-IV), Wechsler Abbreviated Scale of Intelligence 
(WASI), Wechsler Adult Intelligence Scale 4th edition (WAIS-IV), and Colour Trails Test (CTT) I and II. ND = Not done. 




























KCNJ11 1 G53S -1.67 -2 -3 -1.67 -2.3 -1.8 65 -2.33 -2.33 -1 -2.5 -1.7 
KCNJ11 2 R201H 0 0.33 0 0.33 0.5 -2.3 101 0.067 0.33 0 -0.9 0.8 
KCNJ11 3 R201H 0.33 1 0.67 1.33 1.6 -3.2 99 -0.067 -1.33 0 -0.1 0.6 
KCNJ11 4 R201C 0 0.33 -1.33 -1.33 -0.9 -0.9 86 -0.933 -2 -1 -1.3 0.1 
KCNJ11 5 R201C -1.67 -1.67 -1.33 -0.33 0.1 -4 76 -1.6 -1.67 -1 -2.1 -3 
KCNJ11 6 V252G -2 -2.67 -3 -3 -3.2 -4.8 55 -3 -3 -3 ND ND 
KCNJ11 7 V59M 0 0.66 -3 -2.33 -1.1 -4.4 65 -2.33 -3 -2 -3 -1.9 
KCNJ11 8 V59M ND ND ND ND ND ND  ND ND ND ND ND ND 
INS 1 C43F 0.67 1.33 0.33 1 2.1 0.6 124 1.6 0.33 2.67 0.13 0.6 
INS 2 F48C 1.67 1.33 0.67 0 0.9 0.6 113 0.867 0 3 0.6 0.8 
INS 3 G75C -1 -0.67 1 0 0.2 0.8 109 0.6 -1 3 1.2 1.2 










































Psychiatric history  Neurological features 
KCNJ11 9 
(V59M) 












UE Nil  Spastic tetraparesis, able to follow 1-
step commands only, unable to speak 
but able to vocalise noises. 
KCNJ11 10 
(L164P) 
M 44 16 39 40 Glyburide 









E - Post 
Office)  
Bipolar disorder – two 
hospital admissions. On 
ziprasidone, fluoxetine, 
metoclopramide. 
Cogging pursuit eye movement, 
hypomimia, reduced arm swing, 
cogwheel rigidity of arms, mild rigidity 
of legs. Difficulty with motor sequences. 
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Table S3 - Individual scores on Autism Spectrum Quotient (AQ), Hospital Anxiety and Depression Scale (HADS), Controlled Oral Word 
Association Test (COWAT), and subtests of the Visual Object and Space Perception battery (VOSP) and Addenbrooke’s Cognitive Examination-
Revised (ACE-R). ND = Not done. 
Patient Mutation AQ 
raw 
score 
HADS raw score COWAT 
Z-score 
VOSP Score (Pass/Fail) ACE-R raw score 

























KCNJ11 1 G53S 33 9 1 -2.21 F P P F 69 16 20 7 18 8 
KCNJ11 2 R201H 12 6 6 -1.31 P P P P 89 17 23 10 23 16 
KCNJ11 3 R201H 17 9 2 0.79 P P P P 92 18 21 13 25 15 
KCNJ11 4 R201C 32 9 7 -1.91 P F P P 76 18 16 8 20 14 
KCNJ11 5 R201C 24 10 5 -1.72 P F P F 79 16 18 9 20 16 
KCNJ11 6 V252G  ND 14 8  ND P F F F 28 7 5 2 9 5 
KCNJ11 7 V59M 25 9 7 -1.92 P P F F 76 17 24 8 19 8 
KCNJ11 8 V59M  ND ND  ND ND  ND ND ND ND ND ND ND ND ND ND 
INS 1 C43F 5 1 0 -0.77 P P P P 95 18 24 11 26 16 
INS 2 F48C 15 12 4 -0.86 P P P P 89 15 25 10 25 14 
INS 3 G75C 26 6 1 -0.42 P P P P 94 17 22 14 25 16 





























Chapter 1 is an international cohort study that followed 81 patients with KCNJ11 
PNDM over a median of 10.2 years and assessed the efficacy and safety of 
sulphonylurea treatment, as well as the impact on neurological features.   
Conclusions 
The study showed that sulphonylureas are highly effective,  with 93% patients 
remaining independent of insulin at most recent follow-up and maintaining 
excellent glycaemic control (median HbA1c 6.4% (46.4mmol/mol) at 10 years).  
Importantly, sulphonylureas are safe and do not result in severe hypoglycaemia 
or significant side-effects, even at doses 2-10 times greater than those used in 
Type 2 Diabetes.  If present, neurological features persist in sulphonylurea-
treated KCNJ11 PNDM long-term, although there is partial improvement in 
these features in ~half of affected patients on transfer from insulin to 
sulphonylurea therapy.  This research confirms that sulphonylureas are the 
treatment of choice in KCNJ11 PNDM and emphasises the importance of 
prompt genetic testing of all individuals who develop diabetes in the first 6 
months of life, to facilitate rapid transfer from insulin to sulphonylureas in those 
with KCNJ11 mutations.   
Impact  
This research has significant implications for individuals with KCNJ11 PNDM 
and their clinicians, as it is the only study to address the question of long-term 
outcomes of sulphonylurea treatment.  The study has been acknowledged in a 
recent review article as being of major importance in the field (1).  It provides 
reassurance that sulphonylureas continue to work extremely well in achieving 
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outstanding metabolic control for at least 10 years in KCNJ11 PNDM with no 
safety concerns.  Clinicians can therefore be confident in prescribing high dose 
sulphonylureas for patients with KCNJ11 PNDM and can provide accurate 
counselling in relation to the predicted long-term outcomes of this treatment.  
For affected individuals and the parents of children with KCNJ11 PNDM, the 
knowledge that sulphonylureas are the optimum therapy for the condition is 
likely to provide peace of mind and potentially improved quality of life.  This is 
illustrated by responses from affected individuals and families when they were 
told the outcomes of the study: 
“Amazing to think that 10 years ago I was asked to do test for which I was told 
would change my diabetes care. In which changed my course of treatments 
from insulin to sulphonylureas which in turn amazingly changed my life from day 
to day worries of blood glucose and insulin injection time to never worrying 
about have hypoglycaemia attack . And that the length time I've been on 
sulphonylureas gives hope to all those young and old that the team at Exeter 
are able to treat like me.” (Patient GR) 
"When S first transitioned from insulin injections over ten years ago we were 
amazed by the improvements in blood sugar control and the greater 
independence this brought.   Life became more flexible, less of a worry and no 
longer a juggling act between measuring food intake against judging the insulin 
required. Knowing sulphonylureas is a 'fix for life', has had huge positive impact 
on the whole family." (parents of patient ST) 
The study also has wider implications.  Whilst many examples of precision 
medicine result in good short-term outcomes, treatment failure is common in the 
medium-long term particularly in fields such as oncology where, over time, 
cancers are able to acquire new mutations that confer resistance to 
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pharmacological therapies (2).  In the case of KCNJ11 PNDM, there is a fixed 
genetic defect that does not change over time, and therapy targeted to this 
specific defect results in excellent clinical outcomes for at least 10 years.  
Sulphonylurea-treated KCNJ11 PNDM therefore represents an excellent 
example of precision medicine and demonstrates how effective specific targeted 
treatments can be in monogenic disease.   
Future Research 
It will be crucial to continue to follow the progress of large cohorts of patients 
with sulphonylurea-treated KCNJ11 neonatal diabetes beyond 10 years, with 
longitudinal assessments of glycaemic and neurological outcomes, to 
investigate longer-term durability of sulphonylurea therapy.  More in-depth 
neuropsychological, psychiatric and behavioural assessments undertaken at 
multiple time points throughout life will be important to map the 
neurodevelopmental trajectories of affected individuals, and to provide more 
information on the impact of specific genetic variants as well as sulphonylurea 
treatment.   
In addition, the effects of specific physiological states e.g. puberty, pregnancy, 
on metabolic control and sulphonylurea efficacy will require investigation, 
particularly as clinical experience suggests that dose requirements increase 
during puberty.  The use of cell-free fetal DNA (cffDNA) for in utero diagnosis of 
monogenic diabetes (3) will be extremely useful in identifying cases for 
prospective follow-up at an early stage of development, in those families with a 
history of neonatal diabetes.  Furthermore, sulphonylurea therapy is 
recommended in mothers with KATP channel mutations when the variant has 
been inherited by the fetus (4), and it will be important to assess the impact of in 
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utero sulphonylurea treatment on both insulin-mediated growth and 
neurodevelopment.   
The influence of genetic factors in relation to research into sulphonylurea 
handling and bioavailability should also be considered.  For example, there is 
evidence from the T2D literature that genetic variants in cytochrome P450, 
family 2, subfamily C, polypeptide 9 (CYP2C9) can influence the rate of 
metabolism of sulphonylureas, with specific alleles resulting in reduced 
clearance, longer plasma half-life and higher AUC (5).  An impact of CYP2C9 
on drug response has also been reported.  Specifically, carriers of the 
CYP2C9*2 or CYP2C9*3 variants, which have a loss-of-function effect, had a 
0.5% larger reduction in HbA1c than wild-type carriers in a retrospective study 
of over 1000 individuals with T2D resulting in greater likelihood of achieving 
therapeutic targets for glycaemic response (6).  Furthermore, interactions 
between these variants and POR*28, a variant in the P450 oxidoreductase 
gene, have been shown to result in improved response to sulphonylureas but 
with greater odds of hypoglycaemia in T2D (7).  Such studies suggest that 
genetic factors other than the primary mutation in KCNJ11 might have the 
potential to affect sulphonylurea treatment response in people with neonatal 
diabetes, but small cohort sizes have limited the ability to formally test this.  As 
research cohorts increase in size in the future, there may be sufficient power to 
conduct pharmacogenetics studies specific to KCNJ11 neonatal diabetes.   
Qualitative research with patients with KCNJ11 mutations represents another 
key future direction.  A hugely positive impact on quality of life was reported by 
affected patients and families in the short-term following transfer from insulin to 
sulphonylureas (8).  Initial responses from patients and families suggest that 
this is also the case long-term (see quotes above), but it will be important to 
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establish this formally, by undertaking interviews and focus groups exploring the 
impact of sulphonylurea treatment.  Also of interest will be qualitative work with 
those few individuals with KCNJ11 PNDM who do require reintroduction of 
insulin, to explore the biopsychosocial factors that may contribute to treatment 
failure. 
Further research in related genes and phenotypes and comparison of these 
with KCNJ11 PNDM will also be important to inform future clinical guidelines 
relating to KATP channel neonatal diabetes.  The ABCC8 gene encodes the 
regulatory subunits of the KATP channel and contains the binding site for 
sulphonylureas (9).  ABCC8 mutations are the second commonest cause of 
permanent neonatal diabetes (10) and 85% of patients can be treated with 
sulphonylureas in the short-term (11).  Clinical experience and preliminary 
research evidence (Bowman, unpublished) suggests that the long-term 
response to sulphonylureas is also excellent in this group of patients.  However, 
detailed analysis of long-term outcomes in sulphonylurea-treated ABCC8 
PNDM and comparison with those reported in KCNJ11 PNDM is crucial to 
expand the evidence base and inform clinical management.   
Similarly, patients with transient neonatal diabetes (TNDM) and adult-onset 
diabetes due to KCNJ11 or ABCC8 mutations, represent an understudied yet 
fascinating group in which sulphonylurea therapy is effective (11); lower doses 
are recommended for individuals with TNDM mutations than those required for 
KATP channel PNDM (12, 13).  Longitudinal research including physiological 
studies during remission and relapse are needed to address key clinical and 
mechanistic questions relating to the role of pharmacological, genetic and 
environmental factors in the pathophysiology and natural history of KATP channel 




Chapter 2 is a physiological study that assesses the insulin, glucose and 
glucagon response to carbohydrate and protein/fat in patients with 
sulphonylurea-treated KCNJ11 PNDM and non-diabetic controls.  The study 
also assesses the response in the absence of food (with sulphonylurea only) in 
those with KCNJ11 PNDM. 
Conclusions 
People with sulphonylurea-treated KCNJ11 PNDM have similar insulin secretion 
after a protein/fat and carbohydrate meal, despite lower glucose values after a 
protein/fat meal and higher glucose values after a carbohydrate meal.  This is in 
contrast to non-diabetic controls in whom insulin secretion is greater after a 
carbohydrate meal than after a protein/fat meal, and in whom glucose remains 
tightly controlled after both meals.  The relatively low glucose values after 
protein/fat in individuals with KCNJ11 PNDM may put them at risk of post-
prandial hypoglycaemia following meals lacking carbohydrate.   
The results emphasise the lack of response to glucose and predominance of 
non-KATP-channel pathways of insulin secretion (e.g. incretins, direct effect of 
amino acids and fatty acids) in the context of sulphonylurea-treated KCNJ11 
PNDM, whilst non-diabetic individuals remain glucose-responsive with insulin 
secretion driven primarily through KATP-channel pathways.  Consistent with a 
dependence on food for insulin secretion, insulin levels in the absence of a meal 
are lower in individuals with sulphonylurea-treated KCNJ11 PNDM.  However, 
glucose levels in this situation are also relatively low, suggesting there is some 
direct effect of the sulphonylurea drug in the absence of food.  In both cases 
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and controls, glucagon secretion was higher after a protein/fat meal than after a 
carbohydrate meal, supporting the direct stimulation of alpha cells by amino and 
/ or fatty acids. 
Impact  
This research is impactful for clinicians and patients with sulphonylurea-treated 
KCNJ11 PNDM as it can be used to inform the clinical care of affected 
individuals.  We observed a fall in glucose after a protein/fat meal and with no 
meal at all (sulphonylurea only).  Clinical recommendations therefore include 
ensuring all meals contain some carbohydrate, and not missing meals whilst 
taking sulphonylureas.   
The study also has impact in terms of providing a mechanistic explanation as to 
why people with sulphonylurea-treated KCNJ11 PNDM can experience mild-
moderate hypoglycaemia after meals lacking carbohydrate.  In the presence of 
a mutation, which confers insensitivity to rising or falling ATP, there is a relative 
inability to ‘switch off’ insulin secretion in response to falling glucose after 
protein/fat meals.  Understanding mechanism is helpful for clinicians and 
patients but also for the scientific community studying this and related fields. 
More broadly, this research demonstrates how individuals with KCNJ11 
mutations can be used as a human model to study non-KATP-mediated 
pathways of insulin secretion.  This may have relevance for other forms of 
diabetes where such pathways represent known and potential drug targets. 
Future Research 
Future directions of study will include replication of this research in paediatric 
cohorts, in whom there will be a shorter duration of diabetes and an earlier age 
of sulphonylurea initiation than in adults; it is not known if this affects beta cell 
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function in the context of different food stimuli.  It will be also be important to 
conduct further research into hypoglycaemia and counter-regulatory responses 
in individuals with sulphonylurea-treated KCNJ11 PNDM through further 
physiological studies as well as pragmatic clinical studies.   
The lack of severe hypoglycemia despite very high doses of sulphonylurea is 
not yet fully understood.  KATP channels are present on glucagon-secreting 
alpha cells (14) and in the brain (15).  It is thought that both have roles to play in 
counter-regulation, although the exact function of KATP channels in this context 
remains uncertain (16, 17).  Future research will investigate these counter-
regulatory responses in detail via hypoglycaemic clamp studies.      
Furthermore, the effects of sulphonylurea dose, timing of treatment, and 
exercise on the risk of mild-moderate hypoglycaemia is not known. These are 
key clinical questions as they have implications for the treatment and lifestyle 
advice offered to patients with this condition.  Importantly, such issues have 
been specifically raised by the patients themselves during their interactions with 
clinicians and researchers.  Future studies will address these questions in both 
controlled laboratory conditions and in the ‘real-life’ context e.g. via the use of 
relatively non-invasive methods such as flash glucose monitoring (FGM) (18).  
Another important line of research for the future will be further assessment of 
the role of incretin hormones in the context of sulphonylurea-treated KCNJ11 
PNDM.  The evidence to date suggests that this pathway remains intact and 
indeed predominates in affected individuals.  The only study to measure the 
glucagon‐like peptide‐1 (GLP-1) response to oral glucose in 4 patients with 
KCNJ11 PNDM showed similar levels of the hormone before and after 
sulphonylurea transfer (19).  However, no studies have measured gastric 
inhibitory polypeptide (GIP) or assessed the impact of different types of food on 
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incretin hormone secretion in these patients.  In addition, it would be of interest 
to investigate the impact of pharmacological augmentation of the incretin 
pathway through the administration of GLP-1 receptor agonists, GLP-1 
analogues or DPP-4 inhibitors.  In the few individuals with KCNJ11 PNDM 
whose glycaemic control on sulphonylureas in suboptimal, this may represent a 
logical next step in treatment, although it would also be important to establish 
whether the risk of hypoglycaemia would be increased by enhancing stimulation 




The chapter comprises 2 parts which describe the psychiatric and 
neuropsychological manifestations of KCNJ11 mutations in children with 
sulphonylurea-treated KCNJ11 neonatal diabetes (9 PNDM and 1 TNDM).  In 
part A the psychiatric morbidity is explored using validated questionnaires and 
compared with UK school-age population norms.  In part B a battery of specific 
standardised neuropsychological tests is used to assess cognitive performance 
across several key domains and outcomes in affected individuals are compared 
with their unaffected siblings. 
 
Conclusions 
In part A, we showed that there is significant psychiatric morbidity in children 
with sulphonylurea-treated KCNJ11 neonatal diabetes, particularly in 
association with specific mutations e.g. V59M, R201C.  Our data support at 
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least one psychiatric diagnosis in 6/10 children tested, which is significantly 
higher than that seen in school-age children in the general population (10% 
using the same standardised assessments).  The types of disorders observed in 
children with KCNJ11 mutations are predominantly neurodevelopmental e.g. 
autism, ADHD, but anxiety disorders are also frequently seen.  Despite SDQ 
scores indicating high impact of these disorders at home and at school, many 
are unrecognised clinically, with only 2/14 diagnoses having been made in 
clinical practice.   
In part B, we showed that in children with KCNJ11 neonatal diabetes who do 
not have mutations known to cause DEND or iDEND, there are cognitive 
impairments in comparison to non-diabetic siblings that can be identified using 
standardised neuropsychological tests.  These affect a range of domains but 
particularly executive function, verbal comprehension and visuomotor 
performance.  This is consistent with what has been reported elsewhere in the 
literature (20-22) and supports early and comprehensive neuropsychological 
testing in individuals with KCNJ11 neonatal diabetes even in the absence of 
overt severe neurological features. 
 
Impact  
Both studies in this chapter have scientific and clinical impact through 
expanding our knowledge of the CNS manifestations of KCNJ11 mutations.  
Part A is the first study to formally assess and describe the psychiatric morbidity 
in children with sulphonylurea-treated KCNJ11 neonatal diabetes, and the high 
impact this has on patients’ lives, particularly in association with specific 
genotypes e.g. V59M.  The findings have recently been supported in an 
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observational study that used the SDQ to assess 8 children with KCNJ11 
neonatal diabetes (23).   
Part B provides additional evidence for the presence of specific 
neuropsychological impairments in children with KCNJ11 mutations who do not 
have the severe DEND / iDEND phenotype.     
This research is of importance for the clinical care of affected individuals and 
their families.  Specifically, healthcare professionals are now better placed to 
counsel families regarding the neurological aspects of this condition, which 
frequently represent the greatest challenge given the excellent glycaemic 
control obtained on sulphonylurea therapy.  Furthermore, clinicians can refer 
affected patients to the appropriate specialists for neuropsychological testing, 
clinical diagnostic assessments and ongoing support.  Ultimately this will result 
in joined up multi-professional care for children with KCNJ11 PNDM so that the 
metabolic and neurological aspects of their condition can be treated, and 
appropriate educational interventions provided as early as possible.  In-keeping 
with this, some individuals have sought diagnostic clinical assessments 
following participation in this research or been able to use the results of the 
research to obtain improved educational support.   
Future Research 
The studies in this chapter provide a crucial foundation for future research both 
clinically, in terms of further exploration of genotype-phenotype relationships 
and development of improved treatments for the neurological sequelae, and 
mechanistically, in terms of investigating the role of the KATP channel in the 
brain. 
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Most of the children assessed in these studies had one of the commoner 
mutations seen in KCNJ11 neonatal diabetes e.g. V59M, R201H, R201C.  
However, some had rarer mutations which make the interpretation and 
generalisability of the findings relating to CNS features more challenging.  
Future studies in larger cohorts containing more patients with each genetic 
variant will be required to further develop our understanding of how specific 
genotypes influence the neurological phenotype and the possible reasons for 
this.  In addition, the impact of TNDM mutations on the CNS can be explored.  
Only one patient assessed in our cohort had TNDM and this individual had mild 
speech delay and required learning support.  Other studies have also 
suggested the presence of neuropsychological impairments in association with 
TNDM mutations (21), but this has not been assessed in detail and will be an 
important future direction for research.  Similarly, the impact of ABCC8 
mutations causing either PNDM or TNDM on CNS functioning requires 
investigation in larger cohorts of affected patients.  An interesting research 
question is whether there are any specific differences in the neurological 
phenotype and treatment response between patients with neonatal diabetes 
due to KCNJ11 vs ABCC8 mutations. 
Although glibenclamide treatment can result in partial improvement of the 
neurobehavioural features in KCNJ11 neonatal diabetes (24), our studies and 
others show that such features persist in children on sulphonylurea treatment 
and indeed represent a significant disease burden.  Many research questions 
about the impact of sulphonylurea treatment on the CNS remain unanswered.  
Firstly, the penetration of sulphonylureas across the blood-brain barrier (BBB) 
has not been studied in humans.  In rats, glibenclamide crosses into the brain 
and is rapidly pumped back out across the BBB such that therapeutic 
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concentrations of the drug are not achieved in the cerebrospinal fluid (CSF) 
(25).  Currently clinicians are advised to prescribe larger doses (~1mg/kg/day 
glibenclamide) in the presence of severe neurological features, but this is based 
on research in rodents and anecdotal clinical evidence of improvements in 
humans on such high doses.  Future research will focus on measurement of 
sulphonylurea levels in human CSF and how these relate to blood levels, for 
glibenclamide and other sulphonylureas.  It will be important to also consider 
the effects of pharmacogenetics in relation to this, as described for study 1.  
Such research will provide an evidence base to help inform prescribing in 
clinical practice in individuals with KCNJ11 neonatal diabetes, particularly if 
there is a significant neurological component to the presentation.   
Another factor that may play an important role in the neurological response in 
KCNJ11 PNDM is the age of initiation of sulphonylurea treatment.  Some 
preliminary research evidence in small cohorts of patients with KCNJ11 
mutations (one cross sectional and one prospective study) has suggested that 
earlier treatment results in better CNS outcomes (24, 26).  This may relate to 
increased neuroplasticity in the younger brain and therefore an ability to recover 
greater function if KATP channels are targeted at a very early stage of 
development e.g. within the first 6 months of life, a so-called ‘sensitive period’ 
(27).  Such an hypothesis is supported by neurodevelopmental studies in 
Romanian adoptees; long-term follow-up showed that those children who 
experienced severe deprivation due to institutionalisation for greater than 6 
months had high rates of autism, inattention, overactivity and disinhibited social 
engagement which persisted through childhood into early adulthood.  In 
contrast, children adopted under 6 months of age had lower rates of all 
disorders at all ages and these were comparable to rates observed in a UK 
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adoptee control group (28, 29).  Although one recent cross-sectional study did 
not find a significant correlation between the age of initiation of sulphonylureas 
and neuropsychological outcomes in patients with KCNJ11 neonatal diabetes, 
this was based on an analysis of only 5 patients and a 6 month cut-off for 
treatment initiation was not applied (23).  Future studies will focus on the 
neurodevelopmental outcomes in larger cohorts of patients treated with 
sulphonylureas in the first 6 months of life and will compare these with the 
outcomes in those who transferred later.   
Furthermore, recent advances in laboratory techniques have resulted in the use 
of cell free fetal DNA (cffDNA) to detect neonatal diabetes-causing mutations in 
utero in those fetuses with an affected parent (3).  Glibenclamide crosses the 
placenta and is detectable in umbilical venous blood after delivery (30), 
although thus far studies have been done in women with gestational diabetes 
(GDM) who would be on lower doses of glibenclamide than those with KCNJ11 
PNDM.  Using cffDNA, there will be opportunities in the future to identify 
affected fetuses early and assess the impact of glibenclamide treatment during 
pregnancy if they have inherited a KCNJ11 mutation from their mother. 
Finally, there have been no clinical trials assessing the efficacy of other drugs 
targeted to brain KATP channels.  Carbamazepine inhibits KATP channels in vitro 
via a similar mechanism to sulphonylureas (31) and is already used as an anti-
epileptic drug in clinical practice.  Memantine inhibits hippocampal KATP 
channels expressing Kir6.2 and this is thought to be a major mechanism by 
which the drug has therapeutic efficacy in Alzheimer’s disease (32).  It will be 
important to explore in future research studies whether repurposing of these 
drugs can provide benefits for individuals with KCNJ11 mutations in addition to 




This chapter is the first study to assess in detail the neurological, 
neuropsychological and behavioural profile of adults with KCNJ11 PNDM (n=8), 
and to compare this with adults with diabetes from birth due to INS mutations 
(n=4), thereby controlling for metabolic disturbance from an early age.   
Conclusions 
Adults with KCNJ11 mutations have a range of neurobehavioural and 
neuropsychological features that persist with sulphonylurea treatment and have 
a significant functional impact on activities of daily living.  Specific features 
identified in this study were similar to those observed in children with KCNJ11 
neonatal diabetes and include autistic traits, reduced IQ, and impaired attention, 
reasoning and working memory.  There was also impaired motor sequencing 
and coordination, and a trend towards impaired visuospatial and executive 
functions.  The severity of these features related to the genotype, with most 
difficulties associated with the V59M and R201C mutations.  The impairments 
observed in the KCNJ11 group were not present in individuals with INS 
mutations, suggesting they are directly related to the genetic abnormality as 
opposed to a consequence of the early and ongoing metabolic disturbance(s) 
associated with diabetes.  
Impact  
This research is impactful in that it enhances our understanding of the nature 
and aetiology of CNS features in KCNJ11 neonatal diabetes.  The presence of 
CNS features in the individuals with KCNJ11 mutations but not INS mutations 
supports a direct role of dysfunctional KATP channels in the brain as opposed to 
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a non-specific effect of hyperglycaemia from birth.  The specific impairments 
observed are different to those seen in patients with KATP channel neonatal 
diabetes who suffered cerebral oedema secondary to diabetic ketoacidosis at 
initial presentation (33).  Furthermore, both the KCNJ11 and INS groups were 
treated with insulin from diagnosis as infants (until successful transfer to 
sulphonylureas in 7/8 KCNJ11 patients at a median age of 21 years); both 
genetic subtypes are insulin deficient and require replacement doses.  
Therefore, variation in the action of insulin on brain insulin and insulin-like 
growth factor (IGF) receptors would not explain the presence of specific defects 
in the KCNJ11 group and not in the INS group.   
Future Research 
Future studies in this area will assess the longitudinal progression of the CNS 
features in adults with KCNJ11 mutations and the impact of these mutations in 
older adults.  In people with T1D neuropsychological impairments show 
progression over time (34).  In those with T2D, cognitive deficits are more 
pronounced in individuals aged >60-65 years (35) and there is an increased risk 
of dementia with poor metabolic control accelerating the rate of cognitive 
decline; specific domains affected include executive function, learning and 
memory, psychomotor speed and attention (36).  This has a significant impact 
on daily life including the ability to adhere to medication regimes and function 
independently (37).  Although the pathophysiology and treatment response in 
KATP channel neonatal diabetes is clearly different from T1D and T2D, the 
extent to which the CNS features in people with KCNJ11 mutations progress 
throughout adult life is not known.  Longitudinal follow-up studies with repeated 
testing are needed to assess this.  In addition, it would be valuable to perform 
health economic analyses as part of future research.  Current estimates of the 
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cost saving made per individual on switching treatment from insulin to 
sulphonylureas in KCNJ11 neonatal diabetes are in the region of $30,000 over 
30 years (38).  However, this model is based on the American healthcare 
system and additional studies are needed to accurately identify the cost 
effectiveness of genetic diagnosis and treatment change within the UK National 
Health Service (NHS).  
Further future directions for research will include the areas outlined above for 
chapter 3: the impact of sulphonylurea-related factors (age of initiation, dose, 
type, BBB permeability) and the potential repurposing of other drugs that act on 
CNS KATP channels are all relevant for adults with KCNJ11 mutations as well as 
children.  Furthermore, pancreatic physiology in KCNJ11 neonatal diabetes 
relies predominantly on non-KATP channel amplifying pathways such as incretin 
hormones; to what extent such pathways are used in the brain is not known.  
GLP-1 receptors are present in the brain and have been associated with 
neuroprotection and improved learning and memory in rats (39).  Interestingly, 
the neuroprotective role of GLP-1 has also been observed in humans with 
neurodegenerative disorders but no diabetes treated with GLP-1 agonists 
suggesting a glycaemia-independent effect (40).  It will be important to consider 
the potential for drugs targeted at GLP-1 pathways in the brain to be trialled in 









Summary and dissemination of research findings  
The research described within this thesis has advanced knowledge relating to 
both the glycaemic and CNS response to sulphonylureas in people with 
KCNJ11 mutations.  We have shown that sulphonylureas are a very effective 
and safe long-term treatment in individuals with KCNJ11 permanent neonatal 
diabetes, who maintain excellent glycaemic control for at least 10 years without 
severe hypoglycaemia.  The key pathways for endogenous insulin secretion in 
this context are non-KATP-channel mediated amplifying pathways; this differs 
from individuals without diabetes in whom the classical ATP pathway 
predominates.  In addition we have shown that a range of neurological, 
neuropsychological, psychiatric and behavioural features are present in 
individuals with KCNJ11 neonatal diabetes.  The severity of these features is 
genotype-specific and normal functioning is not fully recovered with 
sulphonylurea treatment, despite an initial improvement in some patients.  For 
many families, managing the ongoing CNS abnormalities represent the main 
challenge since metabolic control is optimal following transfer from insulin to 
sulphonylurea therapy.  The findings from all studies in this thesis have been 
widely disseminated through peer-reviewed publications, oral presentations at 
national and international conferences, and education events including the 
Exeter monogenic diabetes symposium for healthcare professionals, genetic 
diabetes nurse education days and family education days for patients and 
families with neonatal diabetes. 
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Translational impact of the research and future clinical care 
The studies in this thesis have had clinical impact for both affected families and 
their clinicians, by providing a greater evidence base for the clinical 
management of KCNJ11 neonatal diabetes.  This supports UK NHS strategies 
that aim to improve healthcare for individuals with rare disease by facilitating 
earlier diagnosis and intervention, improving care coordination and promoting 
research (41).  Specifically, highlighting the existence and impact of the CNS 
features associated with KCNJ11 mutations and raising awareness of these 
amongst clinicians facilitates earlier recognition and intervention.  The aim will 
be to promote better care coordination amongst healthcare professionals which 
is frequently poor for families affected by rare disease (42).  In-keeping with 
this, in Exeter we are currently developing a specialist national service for 
patients with KATP channel neonatal diabetes which will involve multidisciplinary 
team assessments and integration of findings into comprehensive individualised 
care plans that will be fed back to local teams for implementation.   
However, the provision of clinical interventions is dependent on patients having 
a genetic diagnosis of KATP channel neonatal diabetes in the first place, and the 
efficacy of such interventions is likely to increase the earlier the genetic 
diagnosis is made.  Clinical referrals for genetic testing for monogenic diabetes 
have increased over time (10) and therefore it will be important to ensure that 
ascertainment of existing cases and prompt identification of new cases continue 
to increase in the future.  This would be greatly assisted by the incorporation of 
glucose into the UK newborn screening programme; encouragingly research 
has shown that glucose is easily detectable on Guthrie cards and is raised even 
on day 5 of life in individuals with neonatal diabetes (43).  Furthermore, the use 
of targeted next generation sequencing (tNGS) as an alternative to the 
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traditional Sanger sequencing approach has revolutionised genetic testing in 
neonatal diabetes by reducing the time and cost involved (44).   
Taking these factors into account, the future vision for people with KCNJ11 
mutations will be early, rapid genetic diagnosis, prompt initiation of 
sulphonylurea therapy, multidisciplinary assessment and ongoing care involving 
relevant clinical specialties.  Importantly, research and education should be 
integrated into this approach facilitating a translational model whereby research 
findings are rapidly incorporated into clinical practice resulting in improved 
patient care.    
 
Modelling precision medicine: implications for monogenic disease  
Sulphonylurea-treated KCNJ11 neonatal diabetes remains the best example of 
precision medicine in diabetes.  It exemplifies the utility and durability of 
precision approaches in the context of monogenic disease where the specific 
genetic defect is amenable to targeted treatment with a given drug.  Unlike the 
situation in oncology, where precision approaches often have some initial 
success but fail long term, the evidence from the studies in this thesis suggest 
that this is not the case in KCNJ11 PNDM.  This is most likely due to the fixed 
genetic change in KCNJ11 neonatal diabetes and the absence of additional 
acquired mutations which, in cancers, can confer resistance to targeted 
pharmacotherapy (2).  Implementation of precision medicine for other types of 
monogenic disease has been successful to an extent.  For example, in cystic 
fibrosis specific therapies can be targeted at the various defects in ATP Binding 
Cassette (ABC) transporters but the efficacy of such drugs is genotype-specific 
and will therefore only work for a proportion of affected patients (45).  A further 
caveat is cost; novel drug development not only takes a significant amount of 
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time but the final product is frequently expensive (45) and for this reason may 
not be offered to all individuals with a given disease in the context of the 
resource-limited UK NHS.  The efficacy of sulphonylureas in KCNJ11 neonatal 
diabetes demonstrates how a relatively cheap and widely used class of drugs 
can be repurposed for specific conditions if they target the correct pathway(s).  
Furthermore, although genotype can affect the chances of successful transfer 
from insulin (46, 47), for the 90% who do transfer the efficacy of sulphonylurea 
therapy does not appear to be dependent on the specific mutation and its 
effects on protein function i.e. ATP sensitivity or KATP channel gating.  Given the 
success of the precision approach to treatment in patients with KCNJ11 
mutations, it will be important to consider drug repurposing as well as novel 
drug development to improve future clinical care in other forms of neonatal 
diabetes and monogenic disease more generally.   
 
Scientific impact of the research and broader implications 
The research in this thesis and the future studies that build upon it can be useful 
in a much broader context than KCNJ11 neonatal diabetes alone.  This is 
because we can use what we learn from studying patients with KCNJ11 
mutations to achieve improved understanding of normal physiological 
mechanisms and apply findings to other conditions with shared biological 
pathways, both monogenic and polygenic.  Animal models have some utility but 
their generalisability of to human disease is limited for the reasons outlined in 
Part 2 of the introduction to the thesis.  Patients with KCNJ11 mutations 
represent a natural experimental human model of monogenic disease; given the 
tissue expression of the KCNJ11 gene this provides a unique opportunity to 
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study the roles of KATP channel-mediated pathways relating to both the 
pancreas and the CNS. 
Specifically, future research will involve further investigation of the physiology of 
insulin, glucagon and incretin hormone secretion in patients with KCNJ11 
neonatal diabetes.  Pathways associated with these hormones are targets for 
current and potential drug therapies and dietary interventions in T2D, but many 
aspects of human physiology remain poorly understood.  For example, 
scientists have as yet been unable to reach a consensus on the regulation of 
glucagon secretion from alpha cells and the role(s) of KATP channels in this 
process (48).  Further physiological studies in individuals with KCNJ11 
mutations may allow a more sophisticated understanding of such mechanisms 
by highlighting the differences in response when KATP channel pathways are 
‘knocked out’, as is the case in this unique group of patients.  An important 
aspect of such work will be attempting to understand the relative contribution(s) 
of brain KATP channels in glucose sensing and counter-regulatory responses to 
hypoglycaemia, as well as the role(s) of pancreatic KATP channels on both alpha 
and beta cells.  Gaining a better mechanistic understanding will not only have 
direct implications for the care of patients with neonatal diabetes but will be 
valuable for informing research and possibly clinical care relating to common 
polygenic subtypes of diabetes. 
Similarly, patients with KCNJ11 mutations have potential to offer new insights 
into neurodevelopmental disorders.  Clearly neurodevelopmental processes and 
the disorders associated with them are highly complex and are influenced by 
many factors including genetics, environment, socioeconomic context, physical 
co-morbidities, and clinical and educational interventions.  Single gene causes 
of neurodevelopmental disorders are rare e.g. they account for only ~1% of 
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autism (49).  However, monogenic disease again offers a unique platform for 
examining the role(s) of specific proteins in biological pathways, in this case 
those involved in neurodevelopment.  Studying patients with KCNJ11 neonatal 
diabetes allows investigation of the potential role(s) of KATP channels in the CNS 
and the therapeutic window of time for targeting these pathways with drug 
therapies.  This may assist our understanding of developmental processes in 
the CNS more broadly as well as in the context of KATP channel-related 
syndromic diabetes.  Importantly, in clinical practice it may assist in driving a 
precision medicine approach to developmental disorders.        
 
Research collaborations and new study cohorts of the future 
This research has facilitated successful collaboration with other centres 
internationally, which is of particular importance given the rarity of KCNJ11 
neonatal diabetes.  These collaborations will be crucial in the future as we 
endeavour to address the large number of additional research questions in the 
field, many of which have arisen as a result of our studies.  As discussed above, 
it is likely that ascertainment of existing cases and prompt identification of new 
cases will continue to increase in the future, particularly if neonatal diabetes is 
adopted into the newborn screening programme (43).  This will give rise to 
larger research cohorts facilitating replication of existing findings as well as 
additional analyses that have not yet been possible given the small number of 
individuals available to study.  An example of this would be using mendelian 
randomisation to investigate the impact of CYP450 genotype on glycaemic and 
CNS response to sulphonylureas in individuals with KCNJ11 mutations.  
Furthermore, the number of monogenic pregnancies that can be followed up will 
rise over time.  Technological advances such as cffDNA that make it possible to 
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genetically diagnose affected fetuses in utero will provide a valuable opportunity 
to further decipher the roles of insulin and KATP channels during early 
development, as well as the impact of sulphonylurea treatment of affected 
mothers (and by default their unborn children) in pregnancy.   
 
Final conclusion 
It has been an enormous privilege to have worked with patients with KCNJ11 
neonatal diabetes during the course of my research.  The studies in this thesis 
have offered novel insights into the treatment response to sulphonylureas in 
affected individuals as well as the CNS phenotype, and have had a significant 
impact on clinical care.  Importantly, the work has also provided a foundation for 
future research in the field, which will have utility in further refining care 
pathways specific to neonatal diabetes and more broadly in relation to 
understanding precision medicine and biological pathways related to KATP 
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Date Sulphonylurea started:      Date insulin stopped  
 
Before Transfer - Please give 1-2 values prior to transfer from insulin.  








Other medication (please give names and 
doses) 
      
      
 
 
After Transfer - Please give one set of values per year as close to anniversary of transfer date as possible.  
Year  Date of 
visit 






















6 mo           
1           
2           
3           
4           
5    .       
6    .       
7           
8    .       
9    .       
10           
11           
12           
 
 
  Patient details:   
  Name    Gender Female 
  MODY number    Ethnicity  
  Date of birth  Gene (mutation)  
Any other current medication? If yes 
please give names and doses. 
 
 
Number of episodes of severe hypoglycaemia* in 12 months prior to transfer  
Number of episodes of ketoacidosis in 12 months prior to transfer  
*Severe Hypoglycaemia =  Semi-conscious / unconscious or in coma ± convulsions or needs assistance e.g. 
parenteral therapy (glucagon or IV glucose).  Ketoacidosis= Needs admission to hospital for hyperglycaemia. 
 
Side effects whilst on SU treatment (YES/NO/NK(not known) for each) 
 
 
Gastrointestinal  Abnormal liver function  
Hypersensitivity  Abnormal kidney function  
Photosensitivity   Tooth discolouration  
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If YES to any of above  
please give details  
including dates and  
action taken 











Neurological features (YES/NO/NK(not known) for each) 
 
 
Developmental Delay  Muscle weakness  
Learning Difficulties  Epilepsy  
Sleep problems  Anxiety  
ADHD (attention deficit 
hyperactivity disorder)  
 Autism  
Other    
Did neurological features 
change with sulphonylurea 




Cardiovascular risk factors (Please enter value for each from most recent assessment) 
 
Date reviewed  
Blood Pressure (mmHg)  HDL Cholesterol 
(mmol/L) 
 
Triglycerides (mmol/L)  LDL Cholesterol 
(mmol/L) 
 
Total Cholesterol (mmol/L)  
 
Puberty and Development (Please enter value from most recent assessment) 
 
Date reviewed    
Present pubertal stage  Age of Tanner 5 if 
appropriate (years, months) 
 
Age of Tanner 1 if appropriate 
(years, months) 




Other co-morbidity (YES/NO/NK (not known) for each) 
 
Coeliac disease  Hypothyroidism  
Other  
  
Please give details 




    Any other comments:   





Proteinuria / Raised creatinine   Stroke  
Retinopathy   Neuropathy  
Other    
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Thank you very much in advance for your help. Please don’t hesitate to contact me if you need any assistance. 
If YES to any of above please give 
details and dates e.g. if retinopathy 
state whether proliferative, non-
proliferative or pre-proliferative and 
when first observed: 
 






FoND Study Meal Compositions 
 
Table 1. High carbohydrate meal composition. 
 
 
Table 2a. High protein meal composition with Danepak ham. 
 
 




High Carb Meal  Weight (g) or 
volume (ml) 
Calories Fat (g) Protein (g) Carbs (g) 
White toast 2 x 40g = 80g 186.4 1.4 7.0 35.7 
Jam 30g 77.7 0 0.1 19.1 
Orange juice  250ml 107.5 0 2.0 22.3 
TOTAL  371.6 1.4g 9.1g 77.1 
High Protein Meal 1 Weight 
(g) 
Calories Fat (g) Protein (g) Carbs (g) 
Low fat cheddar cheese (be 
good to yourself) 4 slices  
96 272.6 16.3 28.5 3.0 
Lean ham (Danepack), 4 
slices 
80 96.8 2.0 17.2 2.4 
TOTAL  369.4 18.3 45.7 5.4 
High Protein Meal 2 Weight 
(g) 
Calories Fat (g) Protein (g) Carbs (g) 
Low fat cheddar cheese (be 
good to yourself) 4 slices  
96g 272.6 16.3 28.5 3.0 
Lean ham (Welly), 7.1 slices 91g 96.4 2.1 17.3 2.55 
TOTAL  369.0 18.4 45.8 5.55 
FoND Study Visit X 





















Any changes in health / medication since last 






























Patient Name; ___________________    Visit 1 / 2 / 3 (please circle) 
FoND hypoglycaemia screening questions     Time -5 
 
 Absent    Severe 
Neuroglycopenic symptoms        
difficulty speaking 1 2 3 4 5 6 7 
confusion 1 2 3 4 5 6 7 
dizziness 1 2 3 4 5 6 7 
irritability 1 2 3 4 5 6 7 
drowsiness 1 2 3 4 5 6 7 
        
Autonomic symptoms        
sweating 1 2 3 4 5 6 7 
anxiety 1 2 3 4 5 6 7 
tremor 1 2 3 4 5 6 7 
palpitations 1 2 3 4 5 6 7 
feeling hot  1 2 3 4 5 6 7 
        
        
TOTALS   Neuroglycopenic ____   














Patient Name; ___________________     Visit 1 / 2 (please circle) 
FoND hypoglycaemia screening questions     Time 30 
 
 Absent    Severe 
Neuroglycopenic symptoms        
difficulty speaking 1 2 3 4 5 6 7 
confusion 1 2 3 4 5 6 7 
dizziness 1 2 3 4 5 6 7 
irritability 1 2 3 4 5 6 7 
drowsiness 1 2 3 4 5 6 7 
        
Autonomic symptoms        
sweating 1 2 3 4 5 6 7 
anxiety 1 2 3 4 5 6 7 
tremor 1 2 3 4 5 6 7 
palpitations 1 2 3 4 5 6 7 
feeling hot  1 2 3 4 5 6 7 
        
        
TOTALS   Neuroglycopenic ____   














Patient Name; ___________________     Visit 1 / 2 (please circle) 
FoND hypoglycaemia screening questions     Time 60 
 
 Absent    Severe 
Neuroglycopenic symptoms        
difficulty speaking 1 2 3 4 5 6 7 
confusion 1 2 3 4 5 6 7 
dizziness 1 2 3 4 5 6 7 
irritability 1 2 3 4 5 6 7 
drowsiness 1 2 3 4 5 6 7 
        
Autonomic symptoms        
sweating 1 2 3 4 5 6 7 
anxiety 1 2 3 4 5 6 7 
tremor 1 2 3 4 5 6 7 
palpitations 1 2 3 4 5 6 7 
feeling hot  1 2 3 4 5 6 7 
        
        
TOTALS   Neuroglycopenic ____   













Patient Name; ___________________     Visit 1 / 2 (please circle) 
FoND hypoglycaemia screening questions     Time 90 
 
 Absent    Severe 
Neuroglycopenic symptoms        
difficulty speaking 1 2 3 4 5 6 7 
confusion 1 2 3 4 5 6 7 
dizziness 1 2 3 4 5 6 7 
irritability 1 2 3 4 5 6 7 
drowsiness 1 2 3 4 5 6 7 
        
Autonomic symptoms        
sweating 1 2 3 4 5 6 7 
anxiety 1 2 3 4 5 6 7 
tremor 1 2 3 4 5 6 7 
palpitations 1 2 3 4 5 6 7 
feeling hot  1 2 3 4 5 6 7 
        
        
TOTALS   Neuroglycopenic ____   














Patient Name; ___________________     Visit 1 / 2 (please circle) 
FoND hypoglycaemia screening questions          Time 120 
 
 Absent    Severe 
Neuroglycopenic symptoms        
difficulty speaking 1 2 3 4 5 6 7 
confusion 1 2 3 4 5 6 7 
dizziness 1 2 3 4 5 6 7 
irritability 1 2 3 4 5 6 7 
drowsiness 1 2 3 4 5 6 7 
        
Autonomic symptoms        
sweating 1 2 3 4 5 6 7 
anxiety 1 2 3 4 5 6 7 
tremor 1 2 3 4 5 6 7 
palpitations 1 2 3 4 5 6 7 
feeling hot  1 2 3 4 5 6 7 
        
        
TOTALS   Neuroglycopenic ____   














Patient Name; ___________________     Visit 1 / 2 (please circle) 
FoND hypoglycaemia screening questions            Time 150 
 
 Absent    Severe 
Neuroglycopenic symptoms        
difficulty speaking 1 2 3 4 5 6 7 
confusion 1 2 3 4 5 6 7 
dizziness 1 2 3 4 5 6 7 
irritability 1 2 3 4 5 6 7 
drowsiness 1 2 3 4 5 6 7 
        
Autonomic symptoms        
sweating 1 2 3 4 5 6 7 
anxiety 1 2 3 4 5 6 7 
tremor 1 2 3 4 5 6 7 
palpitations 1 2 3 4 5 6 7 
feeling hot  1 2 3 4 5 6 7 
        
        
TOTALS   Neuroglycopenic ____   














Patient Name; ___________________     Visit 1 / 2 (please circle) 
FoND hypoglycaemia screening questions            Time 180 
 
 Absent    Severe 
Neuroglycopenic symptoms        
difficulty speaking 1 2 3 4 5 6 7 
confusion 1 2 3 4 5 6 7 
dizziness 1 2 3 4 5 6 7 
irritability 1 2 3 4 5 6 7 
drowsiness 1 2 3 4 5 6 7 
        
Autonomic symptoms        
sweating 1 2 3 4 5 6 7 
anxiety 1 2 3 4 5 6 7 
tremor 1 2 3 4 5 6 7 
palpitations 1 2 3 4 5 6 7 
feeling hot  1 2 3 4 5 6 7 
        
        
TOTALS   Neuroglycopenic ____   














Patient Name; ___________________     Visit 1 / 2 (please circle) 
FoND hypoglycaemia screening questions            Time 210 
 
 Absent    Severe 
Neuroglycopenic symptoms        
difficulty speaking 1 2 3 4 5 6 7 
confusion 1 2 3 4 5 6 7 
dizziness 1 2 3 4 5 6 7 
irritability 1 2 3 4 5 6 7 
drowsiness 1 2 3 4 5 6 7 
        
Autonomic symptoms        
sweating 1 2 3 4 5 6 7 
anxiety 1 2 3 4 5 6 7 
tremor 1 2 3 4 5 6 7 
palpitations 1 2 3 4 5 6 7 
feeling hot  1 2 3 4 5 6 7 
        
        
TOTALS   Neuroglycopenic ____   














Patient Name; ___________________     Visit 1 / 2 (please circle) 
FoND hypoglycaemia screening questions                     Time 240 
 
 Absent    Severe 
Neuroglycopenic symptoms        
difficulty speaking 1 2 3 4 5 6 7 
confusion 1 2 3 4 5 6 7 
dizziness 1 2 3 4 5 6 7 
irritability 1 2 3 4 5 6 7 
drowsiness 1 2 3 4 5 6 7 
        
Autonomic symptoms        
sweating 1 2 3 4 5 6 7 
anxiety 1 2 3 4 5 6 7 
tremor 1 2 3 4 5 6 7 
palpitations 1 2 3 4 5 6 7 
feeling hot  1 2 3 4 5 6 7 
        
        
TOTALS   Neuroglycopenic ____   
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FIND SOP: Blood sample handling, transport and analysis       Version 2.0:  15th July 2016 
Procedure for Visits 1 & 2  
Blood Samples Handling, Transport & Analysis 
To be used in conjuction with Protocol: CRF 227 FoND Study Version 1 29/04/16 
 
1.  Purpose.  
The purpose of this SOP is to outline the procedure for the blood sample handling, transport and analysis 
in the FIND Study (Impact of Food on Insulin Secretion in Neonatal Diabetes). 
 
2. Applicability.  
This SOP applies to; study personnel involved in the blood sampling of patients. 
3. Procedure.  
Patients will fast from 10pm the night before the visits. They can take water, but no other drinks. They 
will be asked, if applicable, to avoid excessive alcohol and exercise for 48 hrs prior to this appointment. 
 
Patients will attend between 0700 and 1000am.  Following the (optional) application of topical 
anaesthetic cream, a standard gauge cannula will be placed into a forearm vein for blood sampling.  
 
Blood Samples 
Ensure you have the correct sample collection kit (and barcode set FN-XX-XXXX) and correct blood tube 
types (see table 1). Label appropriate labels or barcodes on the blood collection tubes. Collect all blood 
tubes as indicated in table 1. This should total 2 primary blood tubes (serum and BD-P800).  Ensure all 
primary blood tubes are mixed at collection by 10x gentle inversion. 
 
Flush cannula with 3-5ml sterile normal saline if there is 30 minutes or more until the next sample is due.  
If cannula has been flushed, before next blood sample withdraw 0.5ml of blood and discard prior to filling 
tubes.   
 
At each time point (-5, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 mins) collect 3ml blood in a 5ml 
syringe.  Decant 2ml into 1 BDP-800 tube using a blunt fill needle.  Eye protection may be worn when 
decanting blood to avoid blood splash injury.  Use the remining blood in the syringe to measure blood 
glucose on the YSI and record this reading.  At each time point also use an adaptor to fill one serum tube 
(4.9ml).  Time point 0 is immediately before eating the meal and time point 15 mins is 15 minutes after 
starting to eat the meal.  Participants will only be allowed 15 minutes to eat the meal therefore will have 




It is important that all baseline blood samples are centrifuged (as appropriate/ necessary) and processed 
as soon as possible after sample collection.   
 
Centrifuge the BDP-800 tubes indicated in table 1 at room temperature for 10 minutes at 1300G.  
Centrifuge the serum tubes at room temperature for 10 minutes at 2500G.  Once centrifuged, transfer 
separated plasma promptly into labelled storage tubes, or 2D barcode tubes and transfer into appropriate 
storage racks. See table 1. 
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Table 1: Sample handling procedure for baseline bloods 
 
Barcodes 
Samples should be identifiable by the bar code.  Use only the bar codes provided for the study (FN-XX-
xxxx). 
 
Transport of samples to laboratory 
Sample shipments can be organized at any time (weekday collection and delivery only).  It is preferable 
to transfer full sample storage boxes only.  Where possible, samples should be batched together for 
convenience and economy. Samples must be shipped on dry ice. 
A summary of the sampling tubes to be used and the processing requirements is provided in Figure 1.  The 
tube lid colour may vary according to the manufacturer supplying the tubes. 
 






Stick labels / 




Stick labels / 
















2d barcode tube 
aliquots
directions for primary 
tube
urine label no 3 x small label none
x3 into urine 
storage box at 
−80 °C
dispose after having 
made aliquots
BDP800 label yes 2 x small label none
x1 into GLP1-
1/glucagon box 
at −80 °C;               
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxx                        
x1 into storage 
box at −80 °C
dispose after having 
made aliquots
1 x barcode
1 x 500 uL into 
insulin/c-peptide 
box at −80 °C
1 x barcode
1 x 500 uL into 
metabolomics box 
at −80 °C




6 x small label
x6  into storage 
box at −80 °C
2 x small EDTA barcode no none none none
store in DNA box at 
−80 °C
1 x PAXgene barcode no none none none
store in RNA box at 
−80 °C
Blood Spot card for  
HbA1c
barcode no none none none






are used dispose after having 
made aliquots
none
Fill aliquot tubes →



























































Label primary tubes and 



























































Centrifuge tubes at 
1300g for 10 mins. 
Decant 500 µL of plasma 
into c-pep/ insulin, 
metabolomics and 
proteomics tubes. Decant 




















































































































Centrifuge tubes at 
1300g for 10 mins. 
Decant 500 µLinto GLP-1  
tube and GLP1 storage 
tubes and put into GLP-1 



































Pregnancy test + 
Storage tubes 
Dip for hCG and 
mulitstix
Collect 3x 2D 
barcode storage 












































HbA1c Blood spot 
card
Primary tube type Primary tube 







Large aliquots 2d barcode tube 
aliquots 
 Directions for 
primary tube 
Serum (4.9ml for 
adult participants 











1x Elkay into 
insulin box 
x4 2D aliquots 
into storage box
at -80C  (X2 2D 
aliquots for 
childre ) 
 Dispose after 
having made 
aliquots 
BDP-800 (2ml) – 
collected in syringe 
and decanted 
(same size for 
adults and children) 
label Yes 2 x small label none x1 into GLP-1 box 
at -80C 
 Dispose after 
having made 
aliquots 
x1 into GIP box at 
-80C 
Centrifuge  tubes at 2500G for 
10 minutes.  Decant 500uL into 
large aliquot (Elkay) for insulin, 
glucose, paracetamol.  Decant 
300 uL into 2D aliquot tubes x4 
(x2 for children) for storage box. 
Centrifuge  tubes at 1300G 
for 10 minutes.  Decant  
500 uL into GLP-1  tube / 
storage box and 500 uL 








FoND Study Flowchart 
 
Patient Name_______________________________ Date______________ 
 













-5 YES YES _______________ YES  
      
0 YES  YES _______________ NO Start Breakfast 
      
15 YES YES _______________ NO Finish Breakfast 
      
30 YES YES _______________ YES  
      
45 YES YES _______________ NO  
      
60 YES YES _______________ YES Flush cannula 
      
90 YES YES _______________ YES Flush Cannula 
      
120 YES YES _______________ YES Flush cannula 
      
150 YES YES _______________ YES Flush cannula 
      
180 YES YES _______________ YES Flush cannula 
      
210 YES YES _______________ YES Flush cannula 
      
240 YES YES _______________ YES  
      
 
END OF STUDY. REMOVE CANNULA.  PATIENT HAS LUNCH. 
      
 
Name of researcher collecting samples________________________________  
 
Please tick off each blood sample / questionnaire on flowchart as it is taken / completed 
and write glucose value from YSI in space provided at each time point.  Please note any 
other events in the comments section, state time and give details e.g. participant went to 
toilet, extra flush used etc.  
 
Blood sampling 
 At each time point collect 
o One standard (4.9ml) serum tube 
o 3ml of blood in a 5ml syringe 
 Decant 2ml into standard BDP-800 tube (only fill as much as vacuum 
draws into tube through needle), mix by gentle inversion   
 Use remaining blood to get BG reading from YSI 
 For paediatric participants collect blood in syringe for BDP-800 bottle and YSI and one 
small (2.9ml) serum tube.   
 Flush cannula with 3-5ml normal saline if there is 30 minutes or longer until the next 
blood sample is due, or if cannula stops working and needs a flush at any other point 
(please document this on flowchart if it occurs).   
o Withdraw and discard 0.5ml of blood before filling sample tubes if cannula has 
been flushed at previous time point.   
 Samples will be collected from bedside and transferred to technicians for processing.   
 Please ensure all samples are appropriately labelled with printed label prior to 
collection.   
 
Questionnaires 
 Complete a separate questionnaire at -5 minutes, 30 minutes then every half an hour to 
screen participant for symptoms of hypoglycaemia. 
 
Heights and Weights 
 Please measure the height and weight of the study participant during one of the half 
hour intervals between blood tests (or at the end of the study) and add these values to 
the flowchart in the spaces provided. 
 
Meals 
 Meals will be either high protein or high carbohydrate – order will be allocated at 
random.  
 Encourage patient to eat all food in 15 minutes.  When 15 minutes finished and / or 
patient has finished eating, ensure leftovers are kept and returned to kitchen for 
weighing.   
 
Management of severe hypoglycaemia 
We expect that blood glucose readings may drop lower than normal.  No clinical 
intervention is needed unless 
1. Blood glucose <3mmol/l 
AND 
2. Neurological symptoms present 
a. Confusion 
b. Drowsiness / reduced consciousness 
c. Seizures 
If intervention is needed please use attached flowchart to manage hypoglycaemia.  Participation 
in study will end at point of intervention, if treatment is required following doctor review. 
 
Discharge from CRF 
Cannula can be removed 10 minutes after the last blood sample provided there are no clinical 
concerns.  Patients can go home after lunch (which we will provide) if they feel well and there 




Thank you for taking the time to read this information. Before you make a decision about participating 
in this study, you may want to discuss the project with your GP or family members.  If you decide that 
you wish to take part, please contact Dr Pamela Bowman (Principle Investigator)  on 01392 408325 
or Dr Bea Knight (Research Nurse) on 01392 408172.                                                  
9.  What will happen to the samples I provide? 
You will be asked for blood samples at each visit . Your samples will be stored using a code, without 
your name or other personal details (anonymised) and stored for the specialist tests. Access to 
samples or information related to samples is restricted to members of the research team only.  You 
will be given the option to donate any spare samples available at the end of the study and the 
anonymised research data related to your samples to an approved tissue bank (Peninsula Research 
Bank) for use in future biomedical research.  Your identity will remain anonymous to researchers 
using these samples/data. 
10. Will I be told about the results of the study? 
We expect the project to take 1-2 years to complete. At the end of the project, a copy of the study 
findings will be made available to participants. We will write up the results for publication. When 
published, copies of any publications will be available to be viewed and downloaded from our 
diabetesgenes.org website. You will not be identifiable in these publications.  
12. Do I have to take part in this study? 
No, participation is entirely voluntary. It is up to you to decide to join the study. If you agree to take 
part, we will ask you to sign a consent form, and you will be given the opportunity to discuss any 
questions with a member of the research team. You are also free to withdraw from the study at any 
point without giving reason, and this would not affect your clinical care. If you do decide to take part, 
you will be asked to consent to the following statements with a member of the research team present: 
 
 I confirm that I have been provided with an information sheet for the above study.  I have had 
opportunity to consider the information, ask questions and have had these questions answered 
satisfactorily.  
 I understand that my participation is voluntary and that I am free to withdraw at any time without 
giving any reason, without my medical care or legal rights being affected.  
 I am happy to have an intravenous cannula inserted and multiple blood samples taken.  
 I am happy to take a one-off standard dose of paracetamol/calpol before each meal.  
 I give permission for NHS staff within the Exeter Clinical Research Facility to access my medical 
records.  
 I understand that relevant sections of my medical notes and data collected during the study may 
be looked at by individuals from regulatory authorities or from the NHS Trust, where it is 
relevant to my taking part in this research. I give permission for these individuals to have access 
to my records.  
 I agree to take part in this study.   
 
OPTIONAL STATEMENTS 
 I am happy to gift any spare samples available at the end of the study and the research data 
relating to this study to the Peninsula Research Bank so that they can be used in future 
research studies providing that my identifying information is not shared with other researchers 
or organisations. 
 I give permission for my contact details to be kept on a secure database to be contacted about 
other research in the future.  
11. Will I be reimbursed for any expenses during the study? 
Yes, all reasonable expenses incurred by your participation in the study will be reimbursed. 
 
 
 The FoND study 
Assessing the effect of Food composition on postprandial insulin secretion in 
KCNJ11 Neonatal Diabetes  
What participation would involve:  
 2 visits to our research facility (2-3 days 
apart) each lasting approx. 5 hours. 
 Donation of blood samples before and 
after a meal. 
 On one visit the meal will be a high 
protein/low carbohydrate mix and on the 
other visit it will be a low protein/high 
carbohydrate mix (e.g. cheese and ham or 
eggs / meat alternative for one meal and 
orange juice and white bread toast with 
jam for the other meal).   
 Taking a one-off dose of sugar free 
paracetamol with each meal. 
Contents: 
 
1. Why are we doing this research? 
2. Am I eligible to take part? 
3. Are there any risks in taking part? 
4. What if I don’t like/can’t take the food options 
5. What are the benefits of taking part? 
6. Will my participation be confidential? 
7. What will I need to do if I take part? 
8. Who is organising this study? 
9. What will happen to the samples I provide? 
10. Will I be told about the results of the study? 
11. Will I be reimbursed for any expenses during 
the study? 
12. Do I have to take part in this study? 
 
 Before you decide whether to take part, it is important to understand why the research 
is being done and what it will involve. 
 Please take the time to read the following information carefully.   
 You are free to decide if you want to take part in this research study.  
 You can decide to stop taking part in the study at any time without giving a reason. 
 Please ask us if anything is not clear or if you would like more information. 
How to contact us: 
If you have any questions about this study or would like to be involved, please contact  Dr. Pam 
Bowman (Principle Investigator)  on 01392 408325 or Dr Bea Knight (Research Nurse) on 01392 
408172.  
Can you help us to see if different amounts of protein and sugar in food can 
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3.   Are there any risks in taking part?  
We do not anticipate there being any risks to your health by taking part in the study.   
 
 As some people with neonatal diabetes have reported mild hypoglycaemia (blood 
sugar going low) after food containing little carbohydrate you will be closely 
monitored during your visits to ensure this does not cause you any problems.  
 Blood sampling can be uncomfortable and may cause bruising but this will be 
carried out by researchers who have had lots of practice in these procedures to 
reduce these risks.  
 If we happen to discover anything unexpected, we will inform your GP or the 
relevant healthcare professional. Entering into the study is unlikely to affect your 
current treatment. 
2. Am I eligible to take part? 
 
You will be able to take part if  you have: neonatal diabetes treated with sulphonylureas, 
Type 2 diabetes treated with sulphonylureas or do not have diabetes.  You will not be 
able to take part if you have any known allergies to paracetamol. 
1. Why are we doing this research?  
People with neonatal diabetes who switch from insulin to sulphonylurea treatment have 
better blood glucose control, including fewer episodes of low blood sugars 
(hypoglycaemia).  If hypoglycaemia does occur it is usually mild and self-limiting and may 
be related to the type of food being eaten.  We would like to explore this idea in more 
detail. We can do this by looking at the effect of eating different combinations of protein 
and carbohydrate on the amount of insulin, glucose and incretin hormone in the blood 
afterwards. By also comparing the results from people without diabetes and those with 
Type 2 diabetes who are also treated with sulphonylureas (our control groups) we hope 
to be able to understand how sulphonylureas work in different types of diabetes  and 
improve the advice we give to patients about their diet and reducing the risk of 
hypoglycaemia.  
5. What are the benefits of taking part?  
There may be no direct benefits to you from taking part in this study, but your contribution 
will help us to understand more about the effects of different foods on insulin release and 
the role of other hormones in this process.  This will be important for providing advice 
about diet and hypoglycaemia risk to people with neonatal diabetes who are on 
sulphonylurea treatment.   
6. Will my participation be confidential? 
Any information you provide will be held in the strictest confidence. If you take part in the 
study, your information will be coded. All information that is collected about you will be 
held on a password-protected computer. Access to data will be available to the research 
team only. Anonymous data will be stored for five years, or indefinitely if you give 
permission for the data to be transferred to the Peninsula Research Bank (PRB).  This 
data may be made available for future research projects.    
4.   What if I don’t like or can’t take the food options? 
 
We will discuss any special dietary needs you may have and try to accommodate these 
and provide alternatives to our standard offerings. 
 
 
7. What will I need to do if I take part? 
 
The study involves 2 appointments. Details of what will happen at each visit and how you 
will be asked to prepare are shown below.  
 
  Avoid excessive exercise or alcohol for 48 hours before taking part. 
 Arrive at the Exeter Clinical Research Facility (CRF) having fasted 
overnight  (continue to take your regular medicines if appropriate but 
nothing containing paracetamol for 24 hours before taking part). 
 Provide written consent for participation.  
 Baseline information obtained: height and weight measured  and 
questions asked about your health and any current treatments. 
 A needle will be used to introduce a small plastic tube (cannula) into 
one of the veins in your hand or arm. The needle is removed 
immediately leaving only the soft cannula in place.  All blood samples 
will then be taken easily and painlessly through this tube which will 
be left in your hand or arm throughout your  study visit.    
 Blood samples will be taken to measure levels of glucose and the 
hormones involved in controlling blood sugar levels.  
 You will then be given a breakfast to eat which will either be high 
protein/low carbohydrate or low protein/high carbohydrate (you  will 
not be told which it is).   
 After the meal. you will have more blood samples taken at regular 
intervals over 4 hours, to measure the same things that were 
measured in the first blood test. This will allow us to see how the 
levels change over time.  
 You will also be asked to take some sugar free paracetamol with the 
meal, and paracetamol levels will be measured with each blood test 
to tell us how quickly the stomach is emptying. 
 Your will also regularly be asked some questions to see how you are 
feeling.  If you feel unwell at any point, help will be immediately 
available from a member of the research team.  
Minimum 2-day interval 
  The procedure will be the same as visit 1, but at this visit you will be 
given a breakfast of the opposite combination to the one eaten at 
visit 1.   
 This will then complete the sample collection part of the study. 
Research 





8.   Who is organising this study? 
This project is being run at the NIHR Exeter Clinical Research Facility (at the Royal Devon 
and Exeter Hospital, Wonford, site) with the University of Exeter. It has been reviewed by a 
Research Ethics Committee (REC) prior to starting (South West—Cornwall & Plymouth 
REC). The Patient Advice and Liaison Service (PALS) can provide independent advice 
about research participation, and can provide assistance if you have any concerns: (tel: 





Thank you for taking the time to read this information. Before you make a decision about 
participating in these additional parts of the FoND study, you may want to discuss the project 
with your GP or family members.  If you decide that you wish to take part, please contact Dr 
Pamela Bowman (Principle Investigator)  on 01392 408325 or Dr Bea Knight (Research 
Nurse) on 01392 408172.                                                  
10. Will I be told about the results of the study? 
We expect the project to take 1-2 years to complete, including these additional tests. At the 
end of the project, a copy of the study findings will be made available to participants. We will 
write up the results for publication. When published, copies of any publications will be 
available to be viewed and downloaded from our diabetesgenes.org website. You will not be 
identifiable in these publications.  
11. Do I have to take part in these extra tests? 
No, participation is entirely voluntary. It is up to you to decide whether you would like to take 
part in one or both of the additional tests. If you agree to take part, we will ask you to sign a 
consent form, and you will be given the opportunity to discuss any questions with a member 
of the research team. You are also free to withdraw from the study at any point without giving 
reason, and this would not affect your clinical care. If you do decide to take part, you will be 
asked to consent to the following statements with a member of the research team present: 
 
 I confirm that I have been provided with an information sheet for the additional tests for 
the FoND study.  I have had opportunity to consider the information, ask questions and 
have had these questions answered satisfactorily.  
 I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected.  
 I am happy to have an intravenous cannula inserted and multiple blood samples taken.  
 I am happy to take a one-off standard dose of paracetamol at each of the visits.  
 I give permission for NHS staff within the Exeter Clinical Research Facility to access my 
medical records.  
 I understand that relevant sections of my medical notes and data collected during the 
study may be looked at by individuals from regulatory authorities or from the NHS Trust, 
where it is relevant to my taking part in this research. I give permission for these 
individuals to have access to my records.  
 I agree to take part in visit 3 involving blood sampling without a breakfast. 
 I agree to take part in visit 4 involving blood sampling before and after a breakfast.   
 
OPTIONAL STATEMENTS 
 I am happy to gift any spare samples available at the end of the study and the research 
data relating to this study to the Peninsula Research Bank so that they can be used in 
future research studies providing that my identifying information is not shared with other 
researchers or organisations. 
 I give permission for my contact details to be kept on a secure database to be contacted 
about other research in the future.  
 
 
 The FoND study 
Optional Additional Tests 
Assessing the effect of Food composition on postprandial insulin secretion in 
KCNJ11 Neonatal Diabetes  
What participation would involve:  
 
 1 or 2 additional visits to our research 
facility (2-3 days apart) each lasting 
approx. 5 hours. 
 Donation of blood samples. 
 On one visit there would be no meal 
and on the other there would be a 
mixture of protein, fat and 
carbohydrate (e.g. ham, cheese, bread 
and orange juice).  
 Taking a one-off dose of sugar free 
paracetamol at each visit. 
Contents: 
 
1. Why are we doing this extra piece of research? 
2. Am I eligible to take part? 
3. Are there any risks in taking part? 
4. What are the benefits of taking part? 
5. Will my participation be confidential? 
6. Who is organising this study? 
7. What will I need to do if I take part? 
8. What will happen to the samples I provide? 
9. Will I be reimbursed for any expenses during 
the study? 
10. Will I be told about the results of the study? 
11. Do I have to take part in these extra tests? 
 Before you decide whether to take part, it is important to understand why the extra piece 
of research is being done and what it will involve. 
 Please take the time to read the following information carefully.   
 You are free to decide if you want to take part in the additional tests for this study.  
 You can decide to stop taking part in the study at any time without giving a reason. 
 Please ask us if anything is not clear or if you would like more information. 
How to contact us: 
If you have any questions about this study or would like to be involved, please contact  Dr. Pam 
Bowman (Principle Investigator)  on 01392 408325 or Dr Bea Knight (Research Nurse) on 01392 
408172.  
Can you help us to understand even more about the glucose and insulin 
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3.   Are there any risks in taking part?  
We do not anticipate there being any risks to your health by taking part in the study.   
 As one of the additional tests would involve taking your usual sulphonylurea 
medication (if applicable) in the absence of food, your blood glucose will be closely 
monitored during your visit(s) to ensure this does not cause you any problems.  
 Blood sampling can be uncomfortable and may cause bruising but this will be 
carried out by researchers who have had lots of practice in these procedures to 
reduce these risks.  
 If we happen to discover anything unexpected, we will inform your GP or the 
relevant healthcare professional. Participating in these extra tests is unlikely to 
affect your current treatment. 
2. Am I eligible to take part? 
 
You will be able to take part if you have previously participated in the FoND study.  
1. Why are we doing this extra piece of research?  
You have already helped us to look at the effect of eating different combinations of 
protein and carbohydrate on the amount of insulin, glucose and incretin hormone in the 
blood afterwards.  We would now like to do some additional tests to help understand 
these responses even better.  We would like to know if the sulphonylurea tablet on its 
own has any effect on insulin and glucose levels, in the absence of a meal.  We would 
also like to know if a mixture of protein and carbohydrate causes a different response to 
the individual protein and carbohydrate meals.  By comparing the results in people with 
sulphonylurea-treated neonatal diabetes to people without diabetes and those with 
sulphonylurea-treated Type 2 diabetes (our control groups) we hope to be able to better 
understand how sulphonylureas work in different types of diabetes.  We also hope to 
improve the advice we give to patients about their diet and reducing the risk of 
hypoglycaemia.  
4. What are the benefits of taking part?  
There may be no direct benefits to you from taking part in these additional tests, but your 
contribution will help us to understand more about the effects of different foods and 
sulphonylurea medication on insulin release and the role of other hormones in this 
process, which could help the clinical care of people with neonatal diabetes.   
5. Will my participation be confidential? 
As before, any information you provide will be held in the strictest confidence. If you take 
part in the extra tests, your information will be coded. All information that is collected 
about you will be held on a password-protected computer. Access to data will be 
available to the research team only. Anonymous data will be stored for five years, or 
indefinitely if you give permission for the data to be transferred to the Peninsula 
Research Bank (PRB).  This data may be made available for future research projects.    
6.   Who is organising this study? 
This project is being run at the NIHR Exeter Clinical Research Facility (at the Royal 
Devon and Exeter Hospital, Wonford, site) with the University of Exeter. It has been 
reviewed by a Research Ethics Committee (REC) prior to starting (South West—Cornwall 
& Plymouth REC). The Patient Advice and Liaison Service (PALS) can provide 
independent advice about research participation, and can provide assistance if you have 
any concerns: (tel: 01392 402093 or email: rde-tr.PAL@nhs.net)  
 
 
7. What will I need to do if I take part? 
 
You have already completed 2 research visits.  The extra tests are optional and would 
involves another 1 or 2 appointments.  Details of what will happen at each visit and how you 
  Avoid excessive exercise or alcohol for 48 hours before taking part. 
 Arrive at the Exeter Clinical Research Facility (CRF) having fasted 
overnight  (continue to take your regular medicines if appropriate but 
nothing containing paracetamol for 24 hours before taking part). 
 Provide written consent for participation.  
 Baseline information obtained: height and weight measured  and 
questions asked about your health and any current treatments. 
 A needle will be used to introduce a small plastic tube (cannula) into 
one of the veins in your hand or arm. The needle is removed 
immediately leaving only the soft cannula in place.  All blood samples 
will then be taken easily and painlessly through this tube which will 
be left in your hand or arm throughout your  study visit.    
 Blood samples will be taken to measure levels of glucose and the 
hormones involved in controlling blood sugar levels.  
 You will not be given anything to eat but you can continue to drink 
water.  You will have blood samples taken at regular intervals over 4 
hours, to measure the same things that were measured in the first 
blood test. This will allow us to see how the levels change over time.  
 You will also be asked to take some sugar free paracetamol, and 
paracetamol levels will be measured with each blood test to tell us 
how quickly the stomach is emptying. 
 Your will regularly be asked some questions to see how you are 
feeling.  If you feel unwell at any point, help will be immediately 
available from a member of the research team.  
Minimum 2-day interval 
  The procedure will be the same as visit 3, but at this visit you will be 
given a breakfast which will be a mixture of protein, fat and 
carbohydrate.  Blood samples will be taken before and after the meal 
in the same way as your previous breakfast tests.    
 This will then complete the sample collection part of the study. 
Research 





8.  What will happen to the samples I provide? 
You will be asked for blood samples at each visit . Your samples will be stored using a code, 
without your name or other personal details (anonymised) and stored for the specialist tests. 
Access to samples or information related to samples is restricted to members of the 
research team only.  You will be given the option to donate any spare samples available at 
the end of the study and the anonymised research data related to your samples to an 
approved tissue bank (Peninsula Research Bank) for use in future biomedical research.  
Your identity will remain anonymous to researchers using these samples/data. 
9. Will I be reimbursed for any expenses during the study? 






The NIHR Exeter Clinical Research Facility is a partnership between 
The University of Exeter Medical School and the Royal Devon and Exeter NHS Foundation Trust 
Assessing the effect of food composition on postpra ndial insulin secretion 
in KCNJ11 neonatal diabetes ( the FoND Study) 
 
Chief Investigator: Andrew Hattersley      REC No: 16/SW/0150  
 
Consent Form – Participants aged 16 and over 
Please initial  the box if you agree with the statement below; 
 
1. I confirm that I have been provided with an information sheet for the above 
study.  I have had opportunity to consider the information, ask questions and 
have had these questions answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw  
at any time, without giving any reason, and without my medical care or legal 
rights being affected.  
 
3. I am happy to have an intravenous cannula inserted and multiple blood  
samples taken.  
 
4. I am happy to take a one-off standard dose of paracetamol with each of the 
meals.  
 
5. I give permission for NHS staff within the Exeter Clinical Research Facility to 
access my medical records. 
  
6. I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by individuals from regulatory authorities 
     or from the NHS Trust, where it is relevant to my taking part in this research. 
     I give permission for these individuals to have access to my records.  
 
7. I agree to take part in this study.   
 
OPTIONAL STATEMENTS 
8. I am happy to gift any spare samples available at the end of the study and the 
research data relating to this study to the Peninsula Research Bank so  
that they can be used in future research studies providing that my identifying 
information is not shared with other researchers or organizations. 
 
9. I give permission for my contact details to be kept on a secure database to be 
contacted about other research in the future.  
 
Participant’s Name:                                        Date:                  Signature 
(Please print) 
 
Researcher’s Name:                                       Date:                  Signature  
(Please print) 
 
Once completed: one original to be kept by the participant, one original to be kept by 
researcher. 






The NIHR Exeter Clinical Research Facility is a partnership between 
The University of Exeter Medical School and the Royal Devon and Exeter NHS Foundation Trust 
Assessing the effect of food composition on postprandial insulin secretion 
in KCNJ11 neonatal diabetes (the FoND Study) – optional additional tests 
 
Chief Investigator: Andrew Hattersley      REC No: 16/SW/0150  
 
Consent Form – Participants aged 16 and over who have already 
participated in FoND Study visits 1&2 
Please initial the box if you agree with the statement below; 
 
1. I confirm that I have been provided with an information sheet for the additional tests  
for the FoND study.  I have had an opportunity to consider the information, ask 
questions and have had these questions answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw  
at any time, without giving any reason, and without my medical care or legal rights  
being affected.  
 
3. I am happy to have an intravenous cannula inserted and multiple blood samples  
taken.  
 
4. I am happy to take a one-off standard dose of paracetamol at each of the visits.  
 
5. I give permission for NHS staff within the Exeter Clinical Research Facility to access  
my medical records. 
  
6. I understand that relevant sections of my medical notes and data collected during  
the study may be looked at by individuals from regulatory authorities or from the  
NHS Trust, where it is relevant to my taking part in this research.  I give permission  
for these individuals to have access to my records.  
 
7. I agree to take part in visit 3 involving blood sampling without a breakfast.   
 




9. I am happy to gift any spare samples available at the end of the study and the  
research data relating to this study to the Peninsula Research Bank so that they  
can be used in future research studies providing that my identifying information is  
not shared with other researchers or organizations. 
 
10. I give permission for my contact details to be kept on a secure database to be  
contacted about other research in the future.  
 
Participant’s Name:                                        Date:                  Signature 
(Please print) 
 
Researcher’s Name:                                       Date:                    Signature  
(Please print) 
 
Once completed: one original to be kept by the participant, one original to be kept by 
researcher. 
Consent form over 16s/FoNDExtra/V1/200916                                        IRAS Project ID 205255 
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Date of Birth: 
 
 
















The first step is to administer the P4-16 Strengths and Difficulties Questionnaire (SDQ) and then score the 
front page, ringing the scores below.  Subtract the prosocial score from the peer score – this will often be a 
negative number (because the prosocial score is usually higher than the peer score), but remember to show 
this as negative.  Only positive scores of 2 or more are relevant to the DAWBA skip rule. 
 
SDQ Emotion Score  
 
0      1      2       3 || 4      5      6      7      8      9      10 
SDQ Hyperactivity Score 
 
0      1      2       3      4       5|| 6      7      8      9      10 
SDQ Conduct Score 
 
0      1      2 || 3      4       5      6      7      8      9      10 
SDQ Peer Score 
 
0      1      2       3      4       5      6      7      8      9      10 
SDQ Prosocial Score 
 
0      1      2       3      4       5      6      7      8      9      10 
Peer minus Prosocial  
 
                 (positive score reflects peer score > prosocial score) 
                 (negative score reflects peer score < prosocial score) 
  
 
Social Aptitudes Score  
 
 
                 (from Social Aptitudes Scale on page 2) 
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Social Aptitudes Scale 
 
How does [Name] compare with other children/people of his/her age in the following situations: 
 




















SAS1 Able to laugh around with others, for 
example accepting light-hearted 












SAS2 Easy to chat with, even if it isn’t on a 












SAS3 Able to compromise and be flexible 
 
0 1 2 3 4 
SAS4 Finds the right thing to say or do in 













SAS5 Graceful when s/he doesn’t win or get 

























SAS7 By reading between the lines of what 
people say, s/he can work out what 












SAS8 After doing something wrong, s/he’s 
able to say sorry and sort it out so that 












SAS9 Can take the lead without others 












SAS10 Aware of what is and isn’t appropriate 













copyright Robert Goodman, 2001 
 
Now score up the scale by adding all ten items, and enter the score on the first page. 
 








Finds it easier 
than average 







Fr2 What is [Name] like at keeping the friends s/he 
has made? 




Finds it easier 
than average 








Fr3 At present, how many friends does s/he have that s/he  None One 2-4 5-9  10+ 
 fairly often spends time with, for example chatting, or 











  ↓ 1442443 





Fr4 Do [Name] and his/her friends have interests in common? No A little A lot 








Fr5 Do [Name] and his/her friends take part in joint activities such No A little A lot 










Fr6 If [Name] were very stressed or had some secret worry, do  No Perhaps Definitely 
 you think s/he’d be able to talk about this with a friend and 









Fr 7 By and large, do you approve of his/her friends? No A little A lot 








Fr8 Are many of his/her friends the sorts of 
children/young people who often get into trouble 
Not at 
all 
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Development Section 
 
R1 Thinking about his/her school work and about  Ahead Average Behind 
 his/her ability to reason things out, is s/he about 




1         
 
2         
  1442443 ↓ 
  R3 R2 
 
 
R2  At present, roughly what sort of age level is s/he at in his/her school 
work and ability to reason things out?  (Optional: For example like an 
average [insert an age 2 years younger than the child’s chronological 
age] year old?) 
 
If under 12 month level, code as ‘0’ 





R3 Is his/her ability to use language – to say what s/he 












1         
 
2         
  1442443 ↓ 
  R6 R4 
 
 
R4  At present, roughly what sort of age level is s/he at in his/her use and 
understanding of language? (Optional: For example like an average 
[insert an age 2 years younger than the child’s chronological age] 
year old?) 
 
If under 12 month level, code as ‘0’ 





R5  Can s/he get round difficulties in explaining what s/he wants 














R6  Going back to his/her first 3 years of life, was there anything that 
























the way his/her pretend or make-believe play developed? 
 
0 





any odd rituals or unusual habits that were very hard to interrupt? 
 
0 





his/her ability to learn and do new things – things such as puzzles or 
helping get dressed? 
 
0 
      
1 
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Only ask if R6a, R6b, R6c,R6d orR6e = ‘Yes’ 
R7  Have the things that seriously worried you or someone else 







   
0 
 
1           
 
 
Skip rule for the rest of this section 
Only continue if SAS score is 12 or less, if R7 = ‘Some continuing problems’, or if the SDQ peer problem 
score is 2 or more points higher than the prosocial score.  Otherwise go to next section. 
 
 
If R6a = ‘Yes’ continue with R8, else skip to R10 
R8 Could s/he use any real words other than ‘mama’ or ‘dada’ 





 (Baby words such as ‘bikkie’ for ‘biscuit’ do  count.  








R9 After using single words, children go on to join them up into phrases or short sentences 
like ‘Go park see ducks’ or ‘Mama give biscuits’. 
 
 Did [Name] join words together into phrases or short 





 (Do not count set phrases like ‘Thank you’ or ‘Night night’ 









R10 Toddlers often communicate through physical gestures such as waving goodbye, pointing to 
things, blowing a kiss, or bringing a finger to their mouth and saying Shh!  
 
 When s/he was a toddler, did [Name] use these sorts of 



















R11 Some children like playing nursery games like Ring a Ring a Roses, Round and Round the 
Garden, Peekaboo or Peepo. 
 
 Did [Name] ever like these games? No A little A lot 
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R12 Young children often try to share their enjoyment or interests or achievements, for example by 
pointing out something that they think you will enjoy seeing or find interesting.  
 
 As a toddler and young child, did [Name] want to share 







 other people?  
0 
 
1         
 
2        
 
R13 Some children spend a lot of their play time repeating the same action over and over again, for 
example spinning the wheels on a toy car, turning taps or light switches on and off, or opening 
and shutting doors. 
 
 Has this ever been true of him/her? No A little A lot 








R14 Children are sometimes very interested in unusual aspects of toys or other things.  For 
example, rather than playing with a toy, they may spend their time sniffing it, or running their 
fingers over its surface, or holding it to their face to feel any vibration that it makes. 
 
 Has this ever been true of him/her? No A little A lot 








R15 Make-believe play is important to some children.  This can include pretend games with other 
children – games such as cops and robbers, or mummies and daddies.  Even when they are by 
themselves, children may act out stories with dolls, action men or make-believe objects. 
 
 If aged under 11: As a preschool child and more recently, has 








 If aged 11 or more: Thinking about when s/he was younger 





1         
 
2        
 
 
R16 If aged under 11: At present, can [Name] make allowances 
according to who s/he is playing with? For example, not being 
too rough when playing with younger children, and not being 







 If aged 11 or more: When s/he was younger (say around 10), 
could [Name] make allowances according to who s/he was 
playing with? For example, not being too rough when playing 
with younger children, and not being too bossy when playing 
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R17 When s/he’s with other children/teenagers, does s/he have 














R18 Some children/teenagers enjoy putting a lot of time into collecting things, or get a lot of 
pleasure out of focusing on just one topic, such as sport, cars or a particular pop group.  In 
everyday language, we often say that these children/teenagers are ‘obsessed’ by their interest, 
but this is not an unpleasant obsession – this is something they like and usually enjoy talking 
about. 
 
 Has [Name] had any long-lasting obsessions of this sort? No A little A lot 
   
0 
 
1         
 
2        
  1442443 ↓ 
  R24 R19 
 
 
R19 Obsessions may be about common or unusual topics.   For example, it is fairly common for an 
8 year old to be obsessed by dinosaurs, but it is unusual for an 8 year old to be obsessed by 
Victorian fireplaces, bar codes or street lamps. 
 
 Is or was the topic of his/her obsession unusual? No A little A lot 








R20 Does or did the obsession dominate his/her life? No A little A lot 








R21 Does or did it tend to dominate his/her conversation with  No A little A lot 








R22 Does or did it stop him/her doing other important things in 
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R24 Is [Name] able to start conversations with other people? No A little A lot 









R25 If other people start conversations with him/her, can [Name]  No A little A lot 








R26 Is [Name] genuinely interested in chatting with other people 


















R27 Some children/teenagers have trouble adjusting their language to suit different social 
occasions.  For example they may speak too casually to a teacher or too formally to other 
children. 
 
 Does [Name] change the way s/he speaks according to 







   
0 
 
1         
 




R28 It is relatively easy to tell what some children/teenagers are feeling by observing their facial 
expressions, their tone of voice and their body language.  It is harder to tell with other 
children/teenagers, particularly if you don’t know them very well. 
 
 Do most people have difficulty knowing what [Name] is  No A little  A lot 











R29 The other way round, children/teenagers vary in their ability to know what other people are 
feeling.  Some children/ teenagers are good at recognising subtle clues in body language, 
facial expressions, or tone of voice.  For example, they can immediately tell when their mother 
is starting to get a little cross, or when another child/teenager is feeling a bit embarrassed.  
Other children/teenagers find this much harder. 
 
 Does [Name] have difficulty recognising the clues in other 
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R30 When we’re talking with someone face-to-face, eye contact is very important.  It generally 
makes us feel uneasy, or as if there’s something wrong, if the other person makes too little eye 
contact, or too much, or makes it at the wrong time. 
 
 Has [Name] ever been through a phase of making too little or 







   
0 
 
1        
 




R31 Many young children go through a phase of repeating what someone has just said to them. For 
example, if you said, “We’ll be going home in a few minutes”, they might parrot back “We’ll 
be going home in a few minutes”.  Or they might echo back the last word, “minutes”, in your 
tone of voice. Some young people do this a lot. 
 






   
0 
 
1         
 




R32 Some children/teenagers ask the same questions over and over again.  For example, “When are 
we going to the park?” or “What’s for dinner?” or “Are we going swimming this weekend?”  
They keep repeating these questions even though they’ve already been told the answers many 
times.  The questions that are repeated may not be exactly the same from week to week. 
 






   
0 
 
1         
 




R33 Another way in which young people repeat themselves is by using the same catch-phrase or 
cliché over and over again.  For example, almost every sentence may begin “If you want my 
opinion …” or “Logically speaking …”  Occasionally the phrase is appropriate, but it is used 
far more than is really needed. 
 
 Has [Name] ever filled his/her speech with these fairly empty 







   
0 
 
1         
 
2        
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R34 Some children enjoy routines and want things to be the same every day.  For example, they 
may want to eat the same food off the same plate while sitting in the same chair every single 
day.  Or there may be very fixed routines for dressing or undressing.  
 
 Has [Name] ever had strong or unusual routines that 







 that way?  
0 
 
1         
 
2           
  1442443 ↓ 
  R36 R35 
 









R36 Some children are easily upset by small changes in their routines. For example, they may be 
very upset by having to go to school a different way, by having to take a bath at a slightly 
different time, or by the furniture being moved around. 
 
 Has [Name] ever been easily upset by changes in routine? No A little  A lot 








R37 Some preschool children go through a phase of flapping or waving their hands or arms up and 
down if they are excited or upset. Some continue doing this for years. 
 
 Since [Name] has been going to school, has s/he tended to 




A little  
 
A lot 








R38 You have answered a lot of questions about his/her pattern of development – focusing  
particularly on language, play, routines and his/her ability to get along with other people. 
 
 Are you concerned at present about any of these  No A little A lot 
 aspects of his/her development?  
0 
 
1         
 
2           
  ↓ 1442443 
  Next 
section 
tick Development on the 
check list in M1 (p.55) 
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R39 Thinking about the last 12 months, have difficulties 



















R40  Have difficulties with language, routines, play, or 














a) how well s/he gets on with you and the rest         


















































Have these difficulties put a burden on you or the 



















R42 Some children’s development is unusual from birth onwards.  With hindsight, their parents 
realise that development was never quite normal.  That’s not always the case, though.  
Sometimes parents are sure that development was completely normal for a while and then there 
was a relatively sudden change. 
 
 Which was true for him/her? Always there 
to some extent 
Sudden 
change 




       ↓  ↓ 
  Next section R43 
 
 
R43  How old was [Name] when this change happened? 
 
If during the first 12 months, code as ‘0’ 
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Section A    Separation Anxiety 
 
Most children are particularly attached to a few key adults, looking to them for security and comfort, and 
turning to them when upset or hurt.  
 




a) Mother (biological or adoptive) 
  
0 1 
b) Father (biological or adoptive) 
    
0 1 







d) Another father figure (stepfather, foster father, mother’s partner) 
 
0 1 
e) One or more grandparents 
 
0 1 
f) One or more other adult relatives (e.g. aunt, uncle, grown-up 






g) Childminder, nanny, au pair 
 
0 1 
h) One or more teachers 
 
0 1 











If A1j was ticked, ask A1k and A1l; otherwise continue with A2 
 
Is (Child ) specially attached to the following children or young people? 
 




k) One or more brothers, sisters or other young relatives 
 
0 1 
l) One or more friends 
 
0 1 




if A1m is ticked, then skip to section B.  Otherwise continue: 
 
A2 You’ve just told me who [Name] is specially attached to: If you want, you can list all from 
A1a to A1i  (or from A1k to A1l) that were answered ‘Yes’.  From now on, I am going refer to 
these people as his/her ‘attachment figures’ 
 
What I’d like to know next is how much [Name] worries about being separated from his/her 
attachment figures.  Most children have some worries of this sort, but I’d like to know how 
[Name] compares with other children of his/her age. I am interested in how s/he is usually - 
not on the occasional ‘off day’. 
 
 Overall, in the last 4 weeks, has s/he been particularly worried  No Yes 





If A2 = Yes or if SDQ emotion score is ≥ 4 then continue. If neither, then skip to section B. 




Over the last 4 weeks, and compared with other 
children of the same age... 
 












a) has s/he worried either about something  
unpleasant happening to his/her attachment figures, or 
about losing them? 
 
      





b) has s/he worried unrealistically that s/he might be taken 
away from his/her attachment figures, e.g. by  
being kidnapped, taken to hospital or killed? 
 
      





c) Has s/he not wanted to go to school in case something 
nasty happened to his/her attachment figures while s/he 
was away at school?  (Do not include reluctance to go 
to school for other reasons e.g. fear of bullying or 
exams) 
 
      





d) has s/he worried about sleeping alone?       





e)   has s/he come out of his/her bedroom at night to check 
on, or to sleep near, his/her attachment figures? 
 
      





f) has s/he worried about sleeping in a strange place?       





g) (Only ask if aged under11) 
 has s/he been afraid of being alone in a room at home 
without his/her attachment figures even if they are close 
by? 
 
      








h) (Only ask if aged 11 or more) 
has s/he been afraid of being alone at home if his/her 
attachment figures pop out for a moment? 
 
      





i) has s/he had repeated nightmares or bad dreams about 
being separated from his/her attachment figures? 
 
      





j) has s/he had headaches, stomach aches or felt sick when 
s/he had to leave his/her attachment figures or when 
s/he knew it was about to happen? 
 
      





k) has being apart from his/her attachment figures, or the 
thought of  being apart from them led to worry, crying, 
tantrums, clinginess or misery? 
      





                           
If any of the items in A3 have been answered “A lot more than others” then tick Separation Anxiety on the 
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A5 How old was s/he when his/her worries about separation began? 
 
(if since birth, enter 0) 
   
years old 
 
           
  
 



















   










a) how well s/he gets on with you and the rest         

















































A8 Have these worries put a burden on you or the      
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Section B    Fears of specific things or situations  
 
This section of the interview is about some things or situations that children are often scared of, even 
though they aren’t really a danger to them.  I’d like to know what [Name] is afraid of.  I am interested in 
how s/he is usually - not on the occasional 'off day'.  Not all fears are covered in this section – some are 
covered in other sections, e.g. fears of social situations, dirt, separation, crowds. 
     




Animals:  Dogs, spiders, bees and wasps, mice and rats, 










































Blood - injection - injury:  Set off  by the sight  




































Using particular types of transport, e.g. cars, buses, boats, 






























Specific types of people, e.g. clowns, people with beards, with 
































If any of the items in B1 have been answered “a lot”, then continue with B2. Otherwise, go to section C. 
 















 If B2 = “Definitely” or if SDQ emotion score is ≥ 4 then continue. If neither, then skip to section C. 
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B3 How long has this fear or the most severe of these 
fears been present? 
Less than 
1 month 











B4 When [Name] comes up against the things s/he is  No A little A lot 
 afraid of, or when s/he thinks s/he is about to come up 












B5 Does s/he become anxious or upset every time, or almost 










B6 How often do his/her fears result in his/her 













 N.B. if [Name] is afraid of something that is 
only there for part of the year (e.g. wasps), this 










B7 Do his/her fears lead to him/her avoiding the things 




















Does this avoidance interfere with  
















  No Perhaps Definitely 
B9 
 











And what about him/her? Does s/he think that his/her 
fears are over the top or unreasonable? 
 
0 1 2 
  
If B2 = “Definitely” or B4 = “A lot” or B7 = “A lot”, then tick Specific Phobia on check list in M1(p.55). 
 
B11 Have his/her fears put a burden on you or the 
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Section C    Fear of social situations  
 
I am interested in whether (Child ) is particularly afraid of social situations.  This is as compared with other 
children of his/her age, and is not counting the occasional ‘off day’ or ordinary shyness.  
 
       
 
C1 Overall, does [Name] particularly fear or avoid social 
situations that involve a lot of people, meeting new people, or 












          
         
   If C1 = “Yes” or if SDQ emotion score is ≥ 4, then continue. If neither, then skip to section D. 
 
 
C2 Has [Name] been particularly afraid of any of the 


















b) Meeting a lot of people, such as at a party? 0 
 
1 2 
c) Eating in front of others? 0 
 
1 2 
d) Speaking in class? 0 
 
1 2 
e) Reading out loud in front of others? 0 
 
1 2 




                   
If none of the items in C2 have been answered “A lot”, then skip to section D. 
 
 
C3 Most children are attached to a few key adults, feeling more secure when they are around. Some 
children are only afraid of social situations if they don't have one of these key adults around. 
 
Other children are afraid of social situations even when they are with one of these key adults. 
 
 Which is true for him/her?
  
Mostly fine in social situations as 
long as key adults are around 
Social fears are marked even 
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C4 Is [Name] just afraid with adults, or is s/he also afraid 
















C5 Outside of these social situations, is [Name] able to get 












C6 Do you think his/her dislike of social situations is    

















C7 (Only ask if C2d = ‘A lot’, or C2e = ‘A lot’, or C2f = ‘A lot’) 
 
 Is his/her dislike of social situations related to specific 














          
  
 


















C9 How old was s/he when this fear of social situations began? 
 
(if since birth, enter 0) 






   19
 
C10 When [Name] is in one of the social situations s/he 
fears, or when s/he thinks s/he is about to come up 
against one of these situations, does s/he become 


























C11 How often does his/her fear of social 
situations result in him/her becoming  



























































  No Perhaps Definitely 
C14 Does s/he think that this fear of social situations is 

















If C10 = “A lot” or C12 = “A lot”, then tick Social Phobia on check list in M1(p.55). 
 
C16 Has his/her fear of social situations put a  
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Section D    Panic Attacks and Agoraphobia 
 
Many children have times when they get very anxious or worked up about silly little things, but some 
children get severe panics that come out of the blue - they just don’t seem to have any trigger at all. 
 
 
D1 In the last 4 weeks, has [Name] had a panic attack 





 reason at all, without even a little thing to set him/her 







If D1 = “Yes” then tick the box for Panic on the check list in M1 (p.55). 
 
     
 
D2 Over the last 4 weeks, has [Name] been very 
afraid of, or tried to avoid, the following 
situations? 
 








































If any of the items in D2 have been answered “Yes”, then tick the box for Agoraphobia on the check list in 
M1 (p.55) and continue with D3. Otherwise skip to section E. 
 
 
D3 Do you think this fear or avoidance of (Situation) is 





 or something like that, s/he would find it difficult or 
embarrassing to get away, or wouldn’t be able to get  
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Section E    Post Traumatic Stress 
 
The next section is about events or situations that are exceptionally stressful, and that would really upset 
almost anyone. For example being caught in a burning house, being abused, being in a serious car crash or 
seeing you being mugged at gunpoint.  
 











If E1 = “Yes” then continue. Otherwise skip to section F. 
 






Child involved in a disaster   
a) A serious and frightening accident, e.g. being run over  



















Violence to child 
  










Sexual assault of child 
  










Child witnessed something very upsetting 
  
h) Witnessed severe domestic violence, e.g. saw mother being  





Saw a family member or a friend severely attacked or threatened, 








Witnessed a sudden death, a suicide, an overdose, a serious 






Other severe trauma 
  








If any of the items in E2 have been answered “Yes”, then continue with E3. Otherwise, go to section F. 
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E3 At the time, was [Name] very distressed or   No Yes 





E3A At present, is it affecting his/her behaviour,  No Yes 




       ↓  ↓ 













































tried to avoid thinking or talking about  










tried to avoid activities, places or people  









































expressed a smaller range of feelings than in the past,  




























































jumped at little noises or been easily  








If any part of E4 is answered “A lot”, then tick the box for Post Traumatic Stress on the check list in M1 
(p.55)  and continue with E5. Otherwise, skip to section F. 




You have told me about (Definite Symptom/s). How 






More than 6 
months after event 




          
     
E6 How long has s/he been having these problems? Less than 
1 month 












E7 How upset or distressed is s/he by the problems that 





























a) how well s/he gets on with you and the rest         













































          
 
 
E9 Have these problems put a burden on you or the      
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Section F    Compulsions and Obsessions 
 
Many children have some rituals or superstitions, e.g. not stepping on the cracks in the pavement, having to 
go through a special goodnight ritual, having to wear lucky clothes for exams, or needing a lucky mascot 
for school sports matches. It is also common for children to go through phases when they seem obsessed by 
one particular subject or activity, e.g. cars, a pop group, a football team. But what I want to know is 




F1 Does [Name] have rituals or obsessions that upset him/her, 
waste a lot of his/her time, or interfere with his/her ability to  
 
No 
    
Yes 










F2 Over the last 4 weeks, has s/he had any of the following rituals (doing any of the following 
things over and over again even, though s/he has already done them or doesn’t need to do them at 
all)? 
 
  No A little A lot 
a) Excessive cleaning: hand washing, baths,  








b) Other special measures to avoid dirt, germs 








c) Excessive checking: electric switches, gas taps, 








d) Repeating the same simple activity many times in a 
row for no reason, e.g. repeatedly standing up or 
sitting down or going backwards and forwards 








e) Touching things or people in particular ways 
 
0 1 2 
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F3 Over the last 4 weeks, has [Name] been 







 poisons – not being able to get thoughts  








If any of the items in F2 or F3 have been answered “A lot”, then tick Obsessions and Compulsions on the 
check list in M1 (p.55). 
 
F4 Over the last 4 weeks, has [Name] been obsessed 
by the worry that something terrible will happen 




















  144424443 ↓ 
  Skip rule at the start of F7 F6 
         
 
F6 Is this obsession about something terrible happening to 
him/her or to others just one part of a general concern 
about being separated from his/her key attachment 






A problem  
in its own     
 right 




   
If F6 = “A problem in its own right” then tick Obsessions and Compulsions on the check list in M1 (p.55). 
 
 
F7 If the Obsessions and Compulsions box is ticked in M1, then continue.  
Otherwise skip to section G 
 
 Have his/her rituals or obsessions been present on most 












F8 Does s/he think that his/her rituals or obsessions are 
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Yes 

















a) how well s/he gets on with you and the rest         
















































F13 Have the rituals or obsessions put a burden on you 
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Section G    Generalized Anxiety 
 
This section is about worrying 
 
 
G2 Does [Name] ever worry? No Yes 




       ↓  ↓ 






Some children worry about just a few things, sometimes related to specific fears, obsessions 
or separation anxieties.  Other children worry about many different aspects of their lives.  
They may have specific fears, obsessions or separation anxieties, but they also have a wide 




Is [Name] a worrier in general? No, s/he just has a  
few specific worries 
Yes, s/he worries in 
general 




       ↓  ↓ 
  Only continue if SDQ 





G3 Over the last 6 months, has [Name] worried  














If G3 = “Perhaps” or G3 = “Definitely” or SDQ emotion score is ≥ 4, then continue.  If neither, then skip 
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G4 Over the last 6 months, and by comparison  
with other children of the same age, has  














a) Past behaviour: Did I do that wrong? Have I  







































Bad things happening to others: family,  










The future:  e.g.  changing school, moving house, 





























































If 2 or more of these worries were answered ‘a lot more than others’ then continue, else skip to section H 
 
G6 Over the last 6 months has s/he worried 










           









If G6 = “Yes” or G7 = “Yes” then tick Generalized Anxiety on the check list in M1 (p.55) and continue.  If 
neither are “Yes” then skip to section H. 
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G8 If any of the following questions are answered “Yes”, ask “Has this been true for more days 
 than not in the last 6 months?” and record answer in second column. 
     
      
In general 
 More days than 
not in last 6 
months 
  No Yes  No Yes 
a) Does worrying lead to him/her feeling restless, 












b) Does worrying lead to him/her feeling tired 












c) Does worrying lead to difficulties in 











































Does worrying interfere with his/her sleep, 
e.g. difficulty in falling or staying  













G9 How upset or distressed is [Name] as a result of all 






























a) how well s/he gets on with you and the rest         















































G11 Have these worries put a burden on you or the     
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Section H    Depression  
 
This section of the interview is about his/her mood. 
 
 
H1 In the last 4 weeks, have there been times when 









       ↓  ↓ 
  H7 H2 
           
 
         
H2 Over the last 4 weeks, has there been a period when 












       
H3 During the time when s/he has been miserable, has 













   
H4 When s/he has been miserable, could s/he be 




only  briefly 
Not at  
all 











H5 Over the last 4 weeks, the period of being really 
miserable has lasted: 
Less than 
2 weeks 
2 weeks or 
more 






   
 
If H1 = “Yes” and H2 = “Yes” and H3 = “Yes”, then tick Depression on check list in M1 (p.55).   
 
   31
 
H7 In the last 4 weeks, have there been times when 









       ↓  ↓ 
  H13 H8 
         
 
 
H8 Over the last 4 weeks, has there been a period when 











        
H9 During the period when s/he has been grumpy or 










   
 
H10 Has the irritability been improved by particular 
activities, by friends coming round, or by 






only  briefly 
 
Not at  
all 









H11 Over the last 4 weeks, the period of being really 
irritable has lasted: 
Less than 
2 weeks 
2 weeks or 
more 






If H7 = “Yes” and H8 = “Yes” and H9 = “Yes”, then tick Irritability on check list in M1 (p.55). 
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H13 In the last 4 weeks, have there been times when   









       ↓  ↓ 
  Skip rule 
at start of 
H18 
H14 
           
               
  
H14 Over the last 4 weeks, has there been a period when 












        
H15 During these days when s/he has lost interest in things, 













H16 Over the last 4 weeks, this loss of interest has lasted: Less than 
2 weeks 
2 weeks or 
more 







H17 If Depression or Irritability box has been checked, ask: 
 
  
Has this loss of interest been present during the same  












If H13 = “Yes” and H14 = “Yes”, then tick Loss of Interest on check list in M1 (p.55). 
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H18 If Depression or Irritability or Loss of Interest box has been ticked on the check list M1 (p.55), 
then continue. Otherwise skip to H22. 
 
 During the period when [Name] was sad, irritable or lacking in 


































































































H18L Over the whole of his/her lifetime, has s/he ever tried  














H19 How much has his/her sadness, irritability or loss of 
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a) how well s/he gets on with you and the rest         


















































Has his/her sadness, irritability or loss of interest put a 
























Deliberate Self-Harm  
 
  No Yes 
H22 Over the last 4 weeks, has s/he talked about 






H23 Over the last 4 weeks, has s/he tried to harm or hurt himself/herself? 
 
0 1 
H24 Over the whole of his/her lifetime, has s/he 







         
 
If H22=“Yes” or H23=“Yes” or H24=“Yes”, then tick Deliberate Self-Harm on check list in M1 (p.55).
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Section J   Attention and Activity  
 
This section of the interview is about his/her level of activity and concentration over the last 6 months. 
Nearly all children are overactive or lose concentration at times, but what I would like to know is how 
[Name] compares with other children of his/her own age. I am interested in how s/he is usually - not on the 
occasional 'off day'.  
       
J1 Allowing for his/her age, do you think that [Name] definitely 











        
 If J1 = “Yes” or if SDQ hyperactivity score is ≥ 6, then continue. If neither, then skip to section K. 
 
J2 I would now like to go through some more detailed questions about how [Name] has usually 
been over the last 6 months. I will start with questions about how active s/he has been. 
 
 Over the last 6 months, and compared  
with other children of his/her age...   






































d) Does s/he find it hard to play or take part in other 








e) If s/he is rushing about, does s/he find it hard to  









J3 The next few questions are about impulsiveness. 
 
   
 Over the last 6 months, and compared with  
other children of his/her own age…  
 









a) Does s/he often blurt out an answer before 










b) Is it hard for him/her to wait his/her turn? 
 
0 1 2 
c) Does s/he often butt in on other people's  








d) Does s/he often go on talking even if s/he 
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J4 The next set of questions are about attention.  
 
   
 Over the last 6 months, and compared with    
other children his/her age… 
 









a) Does s/he often make careless mistakes or fail to pay 










b) Does s/he often seem to lose interest in  








c) Does s/he often not listen to what people 








d) Does s/he often not finish a job properly?  
 
0 1 2 
e) Is it often hard for him/her to get himself/ 








f) Does s/he often try to get out of things s/he 








g) Does s/he often lose things s/he needs for  








h) Is s/he easily distracted? 
 
0 1 2 
i) Is s/he often forgetful? 
 
0 1 2 
 
      
J5 Have his/her teachers complained           

























c) acting without thinking about what s/he is doing, 











If two or more of the items in J2, J3, or J4 have been answered “A lot more than others,” then tick the box 
for Hyperactivity on the check list in M1 (p.55) and continue to J6. If not, skip to section K. 
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J6 Have his/her difficulties with activity or concentration 













J7 How old was s/he when his/her difficulties with activity or 
concentration began? 
(if since birth, enter 0) 





J8 How much have his/her difficulties with activity or 


































a) how well s/he gets on with you and the rest         














































      
       
 
J10 Have these difficulties with activity or concentration 
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Section K    Awkward and Troublesome Behaviour 
 
This next section of the interview is about behaviour. Nearly all children are awkward and difficult at times 
– not doing what they are told, being irritable or annoying, having temper outbursts, and so on.  What I 
would like to know is how [Name] compares with other children of the same age. I am interested in how 
s/he is usually, and not just on occasional ‘off days’. 
 
 
K1 Thinking about the last 6 months, 
how does his/her behaviour compare 
with other children of his/her age? 






More awkward or 
troublesome 
 than average 








If K1 = “More awkward or troublesome than average,” or if SDQ conduct problems score is ≥ 3, then 
continue. If neither, then skip to section P. 
 
Some children are awkward or annoying with just one person - perhaps with yourself or just one brother or 
sister.  Other children are troublesome with a range of adults or children. The following questions are about 
how [Name] is in general, and not just with one person. 
 
K2 Over the last 6 months, and as compared  
with other children of the same age, has s/he often… 







































































































If any of the items in K2 have been answered “A lot more than others”, then tick Awkward Behaviour on 
the check list M1 (p.55)  and continue with K3. If not, skip to K8. 
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K3 Have his/her teachers complained over the last 6 months 




























K5 How old was s/he when this sort of awkward behaviour began? 
 
(if since birth, enter 0) 

















how well s/he gets on with you and the rest         
















































K7 Has his/her awkward behaviour put a burden on you or 



















  Continue with K8. 
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Behaviour that sometimes gets children into trouble. 
           
K8 I’m now going to ask about behaviour that sometimes gets children into trouble, including dangerous, 
aggressive or antisocial behaviour. Please answer according to how s/he has been over the last year - 
I’m switching to the last 12 months for this next set of questions. 
 
If any of the following questions are answered “Definitely” ask “Has this been going on for the last 6 
months?” and record answer in second column. 
 
  Over the last 12 months  Last 6 months 












a) has s/he often told lies in order to get things 
or favours from others, or to get out of 














b) has s/he often started fights? 


























d) has s/he often stayed out after dark  














e) has s/he stolen from the house, or from other 
people’s houses, or from shops or school? 
(This doesn’t include very minor thefts, e.g. 
stealing his/her brother’s pencil or food 














f) has s/he run away from home more than 





























    
If any of the items in K8 have been answered “Definitely”, then tick Troublesome Behaviour on the check 
list in M1 (p.55). 
  
K9   If 13 or older and definitely playing truant in the past year, ask this question. Otherwise go to the skip 
rule at the beginning of K10) 
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K10 Only continue if check list M1 (p.55) has been ticked for Awkward Behaviour or Troublesome 
Behaviour. Otherwise skip to section P. 
 
May I now ask you about a list of less common but potentially more serious behaviours. I have to 
ask all people all questions even when they are not likely to apply.  
 
If any of the following questions are answered “Yes” then ask “Has this happened in the last 6 
months?” and record answer in second column. 
 
 As far as you know, have any of the following 
happened even once in the last 12 months? 
Over the last 12 
months 
  
Last 6 months 
  No   Yes  No Yes 
a) Has s/he used a weapon or anything that 
could 
seriously hurt someone? (e.g. a bat, brick, 












b) Has s/he really hurt someone or been 
physically 













c) Has s/he been really cruel on purpose to 












d) Has s/he deliberately started a fire? 
(This is only if s/he intended to cause severe 
damage. This  question is not about lighting 
campfires, or burning individual matches or 












e) Has s/he deliberately destroyed someone 
else’s 
property? (This question is not about fire 
setting or very minor acts, e.g. destroying 
sister's drawing. It does include behaviour 













f) Has s/he been involved in stealing on the 












g) Has s/he tried to force someone to have 
sexual 












h) Has s/he broken into a house, any other 













If any of the items in K10 have been answered “Yes”, then tick Troublesome Behaviour on the check list in 
M1 (p.55). 
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K11 Have his/her teachers complained of troublesome behaviour over 






































If K11A= “Yes” then tick Trouble With The Police on the check list in M1 (p.55). 
  
 















how well s/he gets on with you and the rest         

















































K13 Has his/her troublesome behaviour put a burden on 
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Section P    Dieting, weight and body shape 
 




Has [Name] ever thought s/he was fat even when other people said s/he 
























Do worries about eating (what? where? how much?) really interfere 














If two or more of the P1 questions is answered ‘Yes’ continue.  Otherwise skip to next section 
 
 
P2a How tall is [Name]? (approximately)  cms 
     
    feet + inches 
     
     
P2b How much does [Name] weigh at present? (approximately)  kg  
     
   pounds 
     
    stones + pounds 
     
     
P2c What was his/her lowest weight in the last 12 months?  kg  
     
   pounds 
     
    stones + pounds 
     
     
P2d What was his/her highest weight ever?  kg  
 (excluding pregnancy)    
   pounds 
     
    stones + pounds 
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P3 At present, would you describe him/her as 





















       ↓
 
↓ 144424443 
     P4 Skip to P5 
 
 
P4 Comparing how s/he is this year with how 
s/he has been in previous years, would you 
say s/he was even thinner in previous years, 
always this thin, a little thinner this year than 


















year than in 
previous 
years 













P5 At present, would s/he describe him/herself 






















If P3 = ‘Very thin’ or P5 = ‘Very thin’, then tick ‘Very Thin’ on the check list in M1 (p.55).  
 
P6 Have you or other people – family, a friend, a doctor – been 











P7 What does [Name] think? Does s/he think that his/her weight has 











P8 Is [Name] afraid of gaining weight or getting fat? No A little A lot 






  144424443 ↓ 
  P10 P9 
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P10 If a doctor told him/her that s/he needed to put on  Easy Difficult Impossible 
  five pounds (two kilograms) for the sake of her 
health, would s/he find this easy, difficult or 







 (If a child has physical problems that make it hard 
for him/her to put on weight, the question is whether 
s/he is willing to try, not whether s/he can succeed.) 
   
 
 
P11 Does [Name] avoid the sorts of food that s/he 













  144424443 ↓ 
  P13 P12 
 
P12 How often does [Name] succeed in this? 



















P13 Does [Name] spend a lot of his/her time thinking about food? No Yes 





P14 Sometimes people say that they have such a strong desire for food, and that this desire is so 
hard to resist, that it is like the way an addict feels about drugs or alcohol. 
 
 Does this apply to him/her? No A little A lot 







If P9 = ‘Yes or P10 = ‘Impossible’ or P14 = ‘A lot’, then tick ‘Focus on Weight and Food’ on the check 




Sometimes people lose control over what they eat, and then they eat a very large amount of 
food in a short time. For example, they may open the fridge and eat as much as they can find 
– eating and eating until they feel physically ill. This usually happens when people are by 
themselves. 
 
 Does this happen to him/her? No Yes 




       ↓  ↓ 
  P18 Tick ‘Loss of Control’ on the 
check list in M1 (p.55) and 
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P16 Over the last three months, how often 























P17 When this happens, does [Name] have a sense of having lost control 





















   P18 Over the last three months, has [Name] done any of 
the following to avoid putting on weight:     
  





































Going without food for long periods,  

















































Taking pills or medicines in order to lose weight 
 












Doing other things (e.g. not taking insulin if 











If the answer to any of the parts of P18 is ‘a lot’, tick ‘Avoidance of Weight Gain’ on the check list in M1 
(p.55).  If the ‘Loss of Control’ checkbox is also ticked, then continue with P19.  Otherwise skip to P20 for 
females or P26 for males. 
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P19 You told me earlier about the times when [Name] loses control and 





 eating/ exercise/ vomit/ take pills or medicine) to stop him/herself 






Skip to P26 for males. 
 
P20 Has she had any periods in the last three months? No Yes 




       ↓  ↓ 
  P21 P22 
 
 
P21 Has she ever had any periods? No Yes 




       ↓  ↓ 
  P26 P23 
 
 
P22 Is she taking any hormone pills or injections?  









       ↓  ↓ 
  Continue with P23 in 
all cases 
 






If P20 was ‘No’ and P21 was ‘Yes’, ask: 






If P22 was ‘Yes’, ask: 
P25) Please describe what effects the hormone pills or injections have on her periods. 
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P26 Skip rule before starting P26:  If ‘Very Thin’ or ‘Focus on Weight and Food’ or ‘Loss of 
Control’ or ‘Avoidance of Weight Gain’ has been ticked on the check list M1 (p.55), then 
continue. Otherwise skip to the next section. 
 
 You have told me about his/her eating pattern and 





















P27 How much have his/her eating pattern or concern 














a) how well s/he gets on with you and the rest         




















































Has her eating pattern or concern about weight or body 
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Section Q   Tics 
 
Q1 Over the last 12 months, has [Name] had any tic movements that 











Q2 Over the last 12 months, has [Name] had any tic sounds that s/he 










If Q1 = “Yes” or Q2 = ‘Yes’ then continue. If both are ‘No’, then skip the rest of this section 
 
 
Q3 What doctors mean by ‘motor tics’ are repeated movements that are sudden and rapid, that 
follow more or less the same pattern every time, and that occur without the person really 
wanting them to. 
 
 Thinking about the whole of his/her life, has s/he ever had motor 




































































































































If any of the parts of Q3 are answered ‘Yes’ then tick Motor Tics  on the check list in M1 (p.55) and 
continue with the following, otherwise skip to Q6 
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Q4 Sometimes, movements that look like tics turn out to have some other explanation.  For 
example, some children squint because they need to wear glasses or change to stronger 
glasses.  Similarly some children have nose and eye problems during the hay fever season. 
 
 Do you think that some or all of his/her movements could have 









       ↓  ↓ 
  Q6 Q5 
 








Q6 We are now going to move on from motor tics to vocal tics.  These are sounds that come from 
the mouth, nose or throat.  They are sudden and rapid, they follow more or less the same 
pattern every time, and they occur without the person really wanting them to. 
 
 Thinking about the whole of his/her life, has s/he ever had vocal 































































































If any of the parts of Q6 are answered ‘Yes’ then tick Vocal Tics  on the check list in M1 (p.55) and 
continue with the following, otherwise skip to Q9 
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Q7 Sometimes, sounds that seem like tics turn out to have some other explanation.  For 
example, some children clear their throat when they are nervous or cough a lot because 
they have a tickly throat with a cold or hay fever. 
 
 Do you think that some or all of his/her sounds could have been 









       ↓  ↓ 
  Q9 Q8 
 









Skip rule before Q9: Only continue if either Motor or Vocal Tics has been ticked in M1.  Otherwise, skip 
the rest of this section. 
 
Q9 Do the tics go away when s/he is asleep? No Yes 






Q10 Do the tics sometimes worsen when s/he relaxes, e.g. while 











Q11 If [Name] tries really hard, can s/he stop the tics from happening? No Yes 




       ↓  ↓ 




Q12 If s/he uses her will power to keep the tics under control for a 
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Q13 How old was s/he when the tics first began? 
 
(if since birth, enter 0) 




Q14 I am going to be asking next about bad weeks for tics.  What I mean by a bad week for tics 
is one when the tics are happening many times a day, either every day that week or most 
days that week. 
 




 (Optional:) Just to remind you, that means at least one week when 






       ↓  ↓ 





Q15 When did [Name] first start having bad weeks for 
tics?  
 














  ↓ 144424443 
  Q21 Q16 
               
 
 
Q16 Over the last year, roughly how 
many weeks have been bad weeks  
Well under 




half of them 
All or nearly 
all of them 










Q17 Over the last year, has [Name] had a period of at least 4 weeks in a 









       ↓  ↓ 
  Q19 Q18 
 
 
Q18 Have the last 4 weeks been bad weeks for tics? No Yes 
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Q19 Some children/young people have tics week in, week out – though the pattern and number of 
tics isn’t necessarily the same every week. 
 
Other children/young people have weeks or months when the tics go away completely 
 
 Over the last year, has [Name] had any tic-free periods lasting 









       ↓  ↓ 




Q20 What has been the longest tic-free period this 
year?  
Up to 2 
months 
 
3 months  
More than 
3 months 






































a) how well s/he gets on with you and the rest         
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Section L   Other concerns 
 
Do NOT ask if you are including the Development section (p.4 onwards) in this interview 
Ll In his/her first 3 years of life, was there anything that seriously 
























any odd rituals or unusual habits that  were very hard to interrupt? 
 
0 




Do NOT ask unless L1a, L1b or L1c = Yes) 








   
0 
 
1           
 
Do NOT ask if you are including the Tics section (p.49 onwards) in this interview 











Do NOT ask if you are including the Eating Disorders section (p.43 onwards) in this interview 
L4 Have you been concerned about him/her being too 










ASK in all cases   
L5 Apart from the things you have already told me about,










ASK in all cases 
L6 Apart from the things you have already told me about, 










If L2 = "Some continuing problems", or L3 = "Yes" or L4 = "Yes" or L5 = “Yes” or L6 = “Yes” then tick 
Other Concerns on the check list in M1 (p.55). 
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Section M    Areas of Difficulty 
 
M1  Check list of difficulties 
 
Dev [ ]   Development = difficulties with language, routines, play, or social ability    
 
A    [ ]   Separation anxiety =  fear of being separated from  (list from A1) 
 
B    [ ]  Specific phobia = fear of (from B1) 
 
C    [ ]  Social phobia =  fear of (from C2) 
 
D    [ ]  Panic =  panic attacks  
       [ ]  Agoraphobia = avoidance of crowds, being out alone etc. (from D2). 
 
E    [ ]  Post traumatic stress =  distress triggered by his/her experience of (from E2) 
 
F    [ ]  Obsessions and compulsions = rituals or obsessions involving  (from F2, F 3 and F4) 
 
G    [ ]  Generalized anxiety =  excessive worrying about  (from G4) 
 
H    [ ]  Depression  
       [ ]   Irritability 
       [ ]   Loss of interest 
       [ ]   Deliberate self-harm 
 
J     [ ]  Hyperactivity =  difficulties with activities and attention such as (from J2,  J3  and  J4) 
 
K    [ ]  Awkward behaviour =  awkward behaviours such as ( from  K2)   
       [ ]  Troublesome behaviour =  troublesome behaviour such as (from K8 and K10)   
       [ ]  Trouble with the Police 
 
P     [ ]  Very thin 
       [ ]   Focus on weight and food 
       [ ]   Loss of control 
       [ ]   Avoidance of weight gain 
 
Q    [ ]  Motor tics  
       [ ]   Vocal tics 
 
L    [ ]  Other concerns =  Concerns about  (from L2, L3 L4  L5 and L6 ) 
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M2   Getting a description of the child’s difficulties in the parent’s own words 
 
If none of the boxes in M1 are ticked, skip to section N. 
 
Whenever you have checked a box for one of the sections in M1, you should make sure that you get 
answers to the corresponding open-ended questions about that section.  These open-ended questions are 
listed below as suggestions, but you can use your initiative to add extra questions or explain the existing 
questions more clearly. 
 
You have a choice – you can ask the open-ended questions as you go along, or you can ask them after you 
have finished sections A to L.  For example, if you tick the box for section A, then you could ask the extra 
questions before going on to section B, or you could wait until you have finished all the sections from A to 
L.  If you are asking all the open-ended questions at the end, then it is often a good idea to let the parents 
choose which order to take the different topics in, starting with the area that concerns them most. 
 
Whichever you decide to do, it is usually a good idea to note down the parents’ spontaneous comments 
when they make them.  That way, you will have less need to ask them to repeat themselves in this section. 
But do check before the end of the interview to make sure all questions have been covered for each area of 
difficulty. 
 
When parents provide a vague or generalized answer, then ask them for specific examples.  For example, if 
they say, “he worries about everything,” then ask “What sorts of worries?”  Or if they say, “he never does 
what he is told,” then ask “Can you tell me about a recent occasion when he caused problems by not doing 
what he was told?” 
 
Don’t feel that you need to keep your answers short just because there’s only a small space on this form – 
write small and use extra paper if necessary! 
 
Introducing the open-ended questions: 






If M1Dev is ticked for development, ask: 
 
M2R1  Please describe any aspects of his/her language, routines, play, or social ability that have concerned 









M2R2 Are any of these difficulties interfering with his/her everyday life at present?  If so, please describe 
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M2R3 Have these difficulties ever been given a diagnosis or label?  If so, who suggested the diagnosis or 











M2A: Separation anxiety 
 
If M1A is ticked for separation anxiety, ask 
 













M2A3) How severe are the difficulties at their worst? 
 













M2A7) Have you tried to do anything about these worries? If so, please describe what you've tried to do, 





M2B: Specific phobia 
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If M1B is ticked for specific phobia, ask 
 
M2B1) Please describe any fears that are a real nuisance, that seriously upset him or her, or that lead to him 





















M2B5) Have you tried to do anything about these fears? If so, please describe what you've tried to do, any 





M2C: Social phobia 
 
If M2C is ticked for social phobia, ask 
 
M2C1) Please describe any social fears that are a real nuisance, that seriously upset him or her, or that lead 

















M2C4) Are his or her social fears interfering with his or her quality of life? If so, how? 




M2C5) Have you tried to do anything about these social fears? If so, please describe what you've tried to 







If M1D is ticked for panic or agoraphobia, ask one or both of the following (according to whether the 
child has panic attacks or avoidance, or both) 
 
M2D1) Please describe as fully as possible what these panic attacks are like, how often they occur, when 






M2D2) We’d like to hear more about his/her fear or avoidance of crowds, public places, travelling alone, 
or being far from home. Please describe this as fully as possible. Please also tell us how often this occurs, 









M2E: Post traumatic stress 
 
If M1E is ticked for post traumatic stress, ask 
 
M2E1) What was the extremely stressful event? We're very sorry if asking about this is upsetting for you 
































M2E6) Have you tried to do anything about these symptoms? If so, please describe what you've tried to do, 






M2F: Obsessions and compulsions 
 
If M1F is ticked for obsessions and compulsions, ask 
 
























M2F6) Have you tried to do anything about these rituals or obsessions? If so, please describe what you've 
tried to do, any help that you have had, and whether this has made a difference. 
 





M2G: Generalized anxiety 
 
If M1G  is ticked for generalized anxiety, ask 
 




















M2G5) Are his or her worries interfering with his or her quality of life? If so, how? 
 
 
M2G6) Have you tried to do anything about these worries? If so, please describe what you've tried to do, 






If M1H is ticked for depression, irritability or loss of interest, ask 
 






M2H2) What else has changed at the same time as his or her mood and level of interest? If relevant, tell us 
about energy, appetite, sleep, self-confidence, blaming him or herself, hopelessness about the future, 
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M2H10) Have you tried to do anything about his or her mood or loss of interest? If so, please describe 




M2H2: Deliberate self-harm 
 
If M1H is ticked for deliberate self-harm, ask 
 
M2H11) It would help us to hear more about his/her harming or hurting himself/herself , or at least talking 







If M1J is ticked for hyperactivity, ask 
 
M2J1) Please describe difficulties that [Name] has with overactivity, lack of attention or impulsiveness. 
 
 


















M2J5) Is his or her level of activity or his or her lack of attention interfering with his or her quality of life? 




M2J6) Have you tried to do anything about his or her overactivity, lack of attention or impulsiveness? If 






M2K: Awkward and troublesome behaviour 
 
If M1K is ticked for awkward or troublesome behaviour, ask 
 

















M2K3) How severe are the difficulties at their worst? 
 
 















M2K6) Have you tried to do anything about his or her behaviour? If so, please describe what you've tried 






M2P: Dieting, weight and body shape  
 
If M1P is ticked for very thin, focus on weight and food, loss of control, or avoidance of weight gain, 
ask: 
 


















M2P4) Thinking about a typical day, please tell us what [Name] eats, what s/he avoids eating, and any 




M2P5) Has his/her eating pattern or concern about his/her weight affected other aspects of his/her life? For 
example, reducing his/her interest in things that other people of his/her age enjoy, or affecting how well 
s/he gets on with family or friends. 
 





M2P6) Has s/he, or have you or anyone else in the family, asked a doctor or a psychologist to help him/her 




M2P7) Has [Name] had any medical problems related to his/her eating patterns, to his/her weight, or to the 
ways s/he controls his/her weight? (Include bleeding after vomiting, fainting, excessive weakness, 






If M1H is ticked for motor tics or vocal tics, ask: 
 





















M2Q5) Have you tried to do anything about the tics? If so, please describe what you've tried to do, any 
help that you have had, and whether this has made a difference. 
 
 
M2L: Other concerns 
 
If M1L is ticked for less common difficulties, ask whichever of the following apply: 
 
 
M2L1) We would like to hear more about the sorts of difficulties that [Name] has with language, getting on 
with people, odd habits or unusual rituals. 
 
 



























M2X: The interview in general: 
 
M2X1) Finally, this is your opportunity as an interviewer to comment on the interview in general, e.g. to 
describe the level of motivation or understanding of the respondent, or to record your observations about 
the child’s activity level while you were interviewing the child’s parent. 
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Section N    Strengths 
 
I have been asking you a lot of questions about his/her difficulties and problems. I now want to ask you 
about his/her good points or strengths. 
 
 
N1  Do the following descriptions apply to him/her?  No A little A lot 
a ) Generous  0 1 2 
b)  Lively  0 1 2 
c)  Keen to learn  0 1 2 
d)  Affectionate  0 1 2 
e)  Reliable and responsible  0 1 2 
f)  Easy going  0 1 2 
g)  Good fun, good sense of humour  0 1 2 
h)  Interested in many things  0 1 2 
i)  Caring, kind-hearted  0 1 2 
j)  Bounces back quickly after setbacks  0 1 2 
k)  Grateful, appreciative of what s/he gets  0 1 2 
l) Independent 0 1 2 
 
 
N2  What are the things s/he does that really please you?  No A little A lot 
a ) Helps around the home  0 1 2 
b)  Gets on well with the rest of the family  0 1 2 
c)  Does homework without needing to be reminded  0 1 2 
d)  Creative activities: art, acting, music, making things  0 1 2 
e)  Likes to be involved in family activities  0 1 2 
f)  Takes care of his appearance  0 1 2 
g)  Good at school work  0 1 2 
h)  Polite  0 1 2 
i)  Good at sport  0 1 2 
j)  Keeps his/her bedroom tidy  0 1 2 
k)  Good with friends  0 1 2 
l) Well behaved 0 1 2 
 





Development and Well-being Assessment (Teacher Version)
Student's Name ...................................................................................... Male / Female
Date of Birth ....................................................................................... Form or Class .........................
Teacher (form, year, subject etc.) ......................................................
Signature ............................................................................................ Today's Date ...........................
For each item, please mark the box.  It would help us if you answered all items as best you can even if you are not
absolutely certain or the item doesn’t seem very relevant to this student.  Please give your answers on the basis of
the student's behaviour over the last six months or this school year.
Emotions
   Not     Partly              Certainly
   True         True       True ───────────────────────────────────────────────────────────────────────   
A1  Excessive worries               
A2  Marked tension or inability to relax               ───────────────────────────────────────────────────────────────────────
A3  Excessive concern about his/her own abilities,
      (e.g. academic, sporting or social)               
A4  Particularly anxious about speaking to class or reading aloud               ───────────────────────────────────────────────────────────────────────
A5  Reluctant to separate from family to come to school               
A6  Unhappy, sad or depressed               ───────────────────────────────────────────────────────────────────────
A7  Has lost interest in carrying out usual activities               
A8  Feels worthless or inferior               ───────────────────────────────────────────────────────────────────────
A9  Concentration affected by worries or misery               
A10 Other emotional difficulties
      (e.g. marked fears, panic attacks, obsessions or compulsions)                *───────────────────────────────────────────────────────────────────────
* A11  Please describe briefly:
If you have ticked "Certainly True" to any of the questions A1 to A10, please complete the rest of this page. 
If not, go to the next page.
Do these difficulties .....   Not at        A    A medium   A great
                                                  all         little                 amount        deal───────────────────────────────────────────────────────────────────────
A12 upset or distress him/her?                      
A13 interfere with his/her peer relationships?                      ───────────────────────────────────────────────────────────────────────
A14 interfere with his/her classroom learning?                           
A15 put a burden on you or the class as a whole?                      ───────────────────────────────────────────────────────────────────────
2
Attention, Activity and Impulsiveness
B1   When s/he is doing something in class that s/he enjoys and is good at, whether reading or
       drawing or making a model or whatever, how long does s/he typically stay on that task?
Less than 2-4 5-9 10-19 20 minutes
2 minutes minutes minutes minutes or more
Not     Partly              Certainly
            True         True       True ───────────────────────────────────────────────────────────────────────
B2  Makes careless mistakes            
B3  Fails to pay attention                          ───────────────────────────────────────────────────────────────────────
B4  Loses interest in what s/he is doing                          
B5  Doesn't seem to listen                          ───────────────────────────────────────────────────────────────────────
B6  Fails to finish things s/he starts            
B7  Disorganised            ───────────────────────────────────────────────────────────────────────
B8  Tries to avoid tasks that require thought            
B9  Loses things                                       ───────────────────────────────────────────────────────────────────────
B10 Easily distracted            
B11 Forgetful            ───────────────────────────────────────────────────────────────────────
B12 Fidgets            
B13 Can't stay seated when required to do so            ───────────────────────────────────────────────────────────────────────
B14 Runs or climbs about when s/he shouldn't            
B15 Has difficulty playing quietly            ───────────────────────────────────────────────────────────────────────
B16 Finds it hard to calm down when asked to do so            
B17 Blurts out answers before questions are finished            ───────────────────────────────────────────────────────────────────────
B18 Hard for him/her to wait their turn            
B19 Interrupts, butts in on conversations or activities            
B20 Goes on talking if asked to stop            ───────────────────────────────────────────────────────────────────────
If you have ticked "Certainly True" to any of the questions B2 to B20, please complete the rest of this page. 
If not, go to the next page.
Do these difficulties .....   Not at        A    A medium   A great
                                                  all         little                 amount        deal───────────────────────────────────────────────────────────────────────
B21 upset or distress him/her?                       
B22 interfere with his/her peer relationships?                       ───────────────────────────────────────────────────────────────────────
B23 interfere with his/her classroom learning?                    
B24 put a burden on you or the class as a whole?                    ───────────────────────────────────────────────────────────────────────
3
Awkward and Troublesome Behaviour
Not     Partly              Certainly
             True         True       True ───────────────────────────────────────────────────────────────────────
C1  Temper tantrums or hot tempers             
C2  Argues a lot with adults             ───────────────────────────────────────────────────────────────────────
C3  Disobedient at school             
C4  Deliberately does things to annoy others             ───────────────────────────────────────────────────────────────────────
C5  Blames others for his/her own mistakes             
C6  Easily annoyed by others             ───────────────────────────────────────────────────────────────────────
C7  Angry and resentful             
C8  Spiteful              ───────────────────────────────────────────────────────────────────────
C9  Tries to get his/her own back                                                  
C10 Seriously lies or cheats              ───────────────────────────────────────────────────────────────────────
C11 Starts fights               
C12 Bullies others                ───────────────────────────────────────────────────────────────────────
C13 Plays truant                
C14 Uses weapons when fighting               ───────────────────────────────────────────────────────────────────────
C15 Has been physically cruel, has really hurt someone             
C16 Deliberately cruel to animals             ───────────────────────────────────────────────────────────────────────
C17 Sets fires deliberately             
C18 Steals things              *───────────────────────────────────────────────────────────────────────
C19 Vandalises property, or destroys things belonging to others              *
C20 Shows unwanted sexualized behaviour towards others              *
C21 Has been in trouble with the law              *───────────────────────────────────────────────────────────────────────
* C22  Please describe briefly:
If you have ticked "Certainly True" to any of the questions C1 to C21, please complete the rest of this page. 
If not, go to the next page.
Do these behaviours .....   Not at        A    A medium   A great
                                                  all         little                 amount        deal───────────────────────────────────────────────────────────────────────
C23 upset or distress him/her?                    
C24 interfere with his/her peer relationships?                    ───────────────────────────────────────────────────────────────────────
C25 interfere with his/her classroom learning?                    
C26 put a burden on you or the class as a whole?                    ───────────────────────────────────────────────────────────────────────
4
Other concerns
 Not     Partly              Certainly
 True         True       True ───────────────────────────────────────────────────────────────────────
D1 Tics, twitches, involuntary grunts or noises              *
D2 Diets to excess              *───────────────────────────────────────────────────────────────────────
     No        Yes ───────────────────────────────────────────────────────────────────────
D3 Do you have any other concerns about
       the child’s psychological development?            *───────────────────────────────────────────────────────────────────────
* D4  Please describe:
D5   The rest of this page is for any additional comments about this child






The Adult Autism Spectrum Quotient (AQ)  
Ages 16+ 
 
SPECIMEN, FOR RESEARCH USE ONLY. 
 
 
Name:...........................................     Sex:........................................... 
 
Date of birth:...................................     Today’s Date................................. 
 
 
How to fill out the questionnaire 
Below are a list of statements. Please read each statement very carefully and rate how strongly 
you agree or disagree with it by circling your answer. 
 
 DO NOT MISS ANY STATEMENT OUT. 
Examples 



























































3. If I try to imagine something, I find it very easy 










4. I frequently get so strongly absorbed in one 




















6. I usually notice car number plates or similar 










7. Other people frequently tell me that what I’ve 










8. When I’m reading a story, I can easily imagine 





















10. In a social group, I can easily keep track of 

































































16. I tend to have very strong interests which I get 





















18. When I talk, it isn’t always easy for others to get 






















20. When I’m reading a story, I find it difficult to 











































































27. I find it easy to “read between the lines” when 










28. I usually concentrate more on the whole picture, 





















30. I don’t usually notice small changes in a 































33. When I talk on the phone, I’m not sure when it’s 
































36. I find it easy to work out what someone is 










37. If there is an interruption, I can switch back to 





















39. People often tell me that I keep going on and on 










40. When I was young, I used to enjoy playing 










41. I like to collect information about categories of 
things (e.g. types of car, types of bird, types of 










42. I find it difficult to imagine what it would be 











































































49. I am not very good at remembering people’s 










50. I find it very easy to play games with children 












The Autism Research Centre 








The Adult Autism Spectrum Quotient (AQ) 
Ages 16+: Scoring Key 
For full details, please see: 
 
S. Baron-Cohen, S. Wheelwright, R. Skinner, J. Martin and E. Clubley, (2001) 
The Autism Spectrum Quotient (AQ) : Evidence from Asperger Syndrome/High 
Functioning Autism, Males and Females, Scientists and Mathematicians 
Journal of Autism and Developmental Disorders 31:5-17 
 
 
Responses that score 1 point are marked. Other responses score 0. For total score, sum all items.  
 








1. I prefer to do things with others rather than on 
my own. 
 
  1 1 
2. I prefer to do things the same way over and over 
again. 
 
1 1   
3. If I try to imagine something, I find it very easy 
to create a picture in my mind. 
 
  1 1 
4. I frequently get so strongly absorbed in one 
thing that I lose sight of other things. 
 
1 1   
5. I often notice small sounds when others do not. 
 
1 1   
6. I usually notice car number plates or similar 
strings of information. 
 
1 1   
7. Other people frequently tell me that what I’ve 
said is impolite, even though I think it is polite. 
 
1 1   
8. When I’m reading a story, I can easily imagine 
what the characters might look like. 
 
  1 1 
9. I am fascinated by dates. 
 
1 1   
10. In a social group, I can easily keep track of 
several different people’s conversations. 
 
  1 1 
11. I find social situations easy. 
 
  1 1 
12. I tend to notice details that others do not. 
 













13. I would rather go to a library than a party. 
 
1 1   
14. I find making up stories easy. 
 
  1 1 
15. I find myself drawn more strongly to people than 
to things. 
 
  1 1 
16. I tend to have very strong interests which I get 
upset about if I can’t pursue. 
 
1 1   
17. I enjoy social chit-chat. 
 
  1 1 
18. When I talk, it isn’t always easy for others to get 
a word in edgeways. 
 
1 1   
19. I am fascinated by numbers. 
 
1 1   
20. When I’m reading a story, I find it difficult to 
work out the characters’ intentions. 
 
1 1   
21. I don’t particularly enjoy reading fiction. 
 
1 1   
22. I find it hard to make new friends. 
 
1 1   
23. I notice patterns in things all the time. 
 
1 1   
24. I would rather go to the theatre than a museum. 
 
  1 1 
25. It does not upset me if my daily routine is 
disturbed. 
 
  1 1 
26. I frequently find that I don’t know how to keep a 
conversation going. 
 
1 1   
27. I find it easy to “read between the lines” when 
someone is talking to me. 
 
  1 1 
28. I usually concentrate more on the whole picture, 
rather than the small details. 
 
  1 1 
29. I am not very good at remembering phone 
numbers. 
 
  1 1 
30. I don’t usually notice small changes in a 
situation, or a person’s appearance. 
 
  1 1 
31. I know how to tell if someone listening to me is 
getting bored. 
 
  1 1 
32. I find it easy to do more than one thing at once.   1 1 
 








33. When I talk on the phone, I’m not sure when it’s 
my turn to speak. 
 
1 1   
34. I enjoy doing things spontaneously. 
 
  1 1 
35. I am often the last to understand the point of a 
joke. 
 
1 1   
36. I find it easy to work out what someone is 
thinking or feeling just by looking at their face. 
 
  1 1 
37. If there is an interruption, I can switch back to 
what I was doing very quickly.  
 
  1 1 
38. I am good at social chit-chat. 
 
  1 1 
39. People often tell me that I keep going on and on 
about the same thing. 
 
1 1   
40. When I was young, I used to enjoy playing 
games involving pretending with other children. 
 
  1 1 
41. I like to collect information about categories of 
things (e.g. types of car, types of bird, types of 
train, types of plant, etc.). 
 
1 1   
42. I find it difficult to imagine what it would be 
like to be someone else. 
 
1 1   
43. I like to plan any activities I participate in 
carefully. 
 
1 1   
44. I enjoy social occasions. 
 
  1 1 
45. I find it difficult to work out people’s intentions. 
 
1 1   
46. New situations make me anxious. 
 
1 1   
47. I enjoy meeting new people. 
 
  1 1 
48. I am a good diplomat. 
 
  1 1 
49. I am not very good at remembering people’s 
date of birth. 
 
  1 1 
50. I find it very easy to play games with children 
that involve pretending. 
 
  1 1 
 
 MRC-SBC/SJW Apr 2007 
Hospital Anxiety and Depression Scale (HADS) 
Instructions: Doctors are aware that emotions play an important part in most illnesses. If your doctor knows about these 
feelings he or she will be able to help you more. This questionnaire is designed to help your doctor know how you feel. Read 
each item and circle the reply which comes closest to how you have been feeling in the past week. Don’t take too long over 
your replies: your immediate reaction to each item will probably be more accurate than a long thought out response.  
 
I feel tense or ‘wound up’:  A   I feel as if I am slowed down:  D  
Most of the time  3   Nearly all of the time  3  
A lot of the time  2   Very often  2  
Time to time, occasionally  1   Sometimes  1  
Not at all  0   Not at all  0  
     
I still enjoy the things I used to enjoy:  D    I get a sort of frightened feeling like 
‘butterflies in the stomach’:  
A  
Definitely as much  0    Not at all  0  
Not quite so much  1    Occasionally  1  
Only a little  2    Quite often  2  
Not at all  3    Very often  3  
     
I get a sort of frightened feeling like 
something awful is about to happen:  
A   I have lost interest in my appearance:  D  
Very definitely and quite badly  3   Definitely  3  
Yes, but not too badly  2   I don’t take as much care as I should  2  
A little, but it doesn’t worry me  1   I may not take quite as much care  1  
Not at all  0   I take just as much care as ever  0  
     
I can laugh and see the funny side of things:  D    I feel restless as if I have to be on the 
move:  
A  
As much as I always could  0    Very much indeed  3  
Not quite so much now  1    Quite a lot  2  
Definitely not so much now  2    Not very much  1  
Not at all  3    Not at all  0  
     
Worrying thoughts go through my mind:  A   I look forward with enjoyment to things:  D  
A great deal of the time  3   A much as I ever did  0  
A lot of the time  2   Rather less than I used to  1  
From time to time but not too often  1   Definitely less than I used to  3  
Only occasionally  0   Hardly at all  2  
     
I feel cheerful:  D    I get sudden feelings of panic:  A  
Not at all  3    Very often indeed  3  
Not often  2    Quite often  2  
Sometimes  1    Not very often  1  
Most of the time  0    Not at all  0  
     
I can sit at ease and feel relaxed:  A   I can enjoy a good book or radio or TV 
programme:  
D  
Definitely  0   Often  0  
Usually  1   Sometimes  1  
Not often  2   Not often  2  
Not at all  3   Very seldom  3  
Questions relating to anxiety are indicated by an 'A' while those relating to depression are shown by a 'D'. Scores of 0-7 in respective subscales are considered 
normal, with 8-10 borderline and 11 or over indicating clinical 'caseness' 
10/03/2008 © John R Hodges 
 
Cambridge Behavioural Inventory Revised (CBI-R) 
 For the Carer  
 
Your Name:_____________________________________________ Today’s date:___/___/___ 
Patient’s name: _____________________________Relationship to the patient_____________ 
 
 
We would like to ask you a number of questions about various changes in the patient’s 
behaviour that you may have noticed. It is important that we obtain your view as it will help us 
in our assessment.  
Please read the description of each problem carefully. Then circle the number under the 
heading “Frequency” that best describes the occurrence of the behavioural change.  
Some of the everyday skill questions may not apply, if for instance the person you care for has 
never done the shopping. Please enter N/A (not applicable).   
 






 a few times per 
month 
2  







Memory and Orientation 
 
FREQUENCY 
Has poor day-to-day memory (e.g. about conversations, trips etc.)   0    1    2    3    4 
Asks the same questions over and over again  0    1    2    3    4 
Loses or misplaces things                0    1    2    3    4 
Forgets the names of familiar people                    0    1    2    3    4 
Forgets the names of objects and things                     0    1    2    3    4 
Shows poor concentration when reading or watching television           0    1    2    3    4 
Forgets what day it is 0    1    2    3    4 





Has difficulties using electrical appliances (e.g. TV, radio, cooker, 
washing machine) 
0    1    2    3    4 
Has difficulties writing (letters, Christmas cards, lists etc.) 0    1    2    3    4 
Has difficulties using the telephone                 0    1    2    3    4 
Has difficulties making a hot drink (e.g. tea/coffee)   0    1    2    3    4 





Has difficulties grooming self (e.g. shaving or putting on make-up)    0    1    2    3    4 
Has difficulties dressing self  0    1    2    3    4 
Has problems feeding self without assistance       0    1    2    3    4 





Finds humour or laughs at things others do not find funny  0    1    2    3    4 
Has temper outbursts            0    1    2    3    4 
Is uncooperative when asked to do something  0    1    2    3    4 
Shows socially embarrassing behaviour   0    1    2    3    4 
Makes tactless or suggestive remarks    0    1    2    3    4 
Acts impulsively without thinking      0    1    2    3    4 
  
10/03/2008 © John R Hodges 
 






 a few times per 
month 
2  










Cries                 0    1    2    3    4 
Appears sad or depressed    0    1    2    3    4 
Is very restless or agitated      0    1    2    3    4 





Sees things that are not really there (visual hallucinations)  0    1    2    3    4 
Hears voices that are not really there (auditory hallucinations)  0    1    2    3    4 




Prefers sweet foods more than before   0    1    2    3    4 
Wants to eat the same foods repeatedly 0    1    2    3    4 
Her/his appetite is greater, s/he eats more than before                          0    1    2    3    4 





Sleep is disturbed at night           0    1    2    3    4 
Sleeps more by day than before (cat naps etc.) 0    1    2    3    4 
 
Stereotypic and Motor Behaviours 
 
 
Is rigid and fixed in her/his ideas and opinions 0    1    2    3    4 
Develops routines from which s/he can not easily be discouraged e.g. 
wanting to eat or go for walks at fixed times 
0    1    2    3    4 
Clock watches or appears pre-occupied with time  0    1    2    3    4 





Shows less enthusiasm for his or her usual interests 0    1    2    3    4 
Shows little interest in doing new things 0    1    2    3    4 
Fails to maintain motivation to keep in contact with friends or family 0    1    2    3    4 
Appears indifferent to the worries and concerns of family members 0    1    2    3    4 
Shows reduced affection 0    1    2    3    4 
 









Thank you for your time. 
ADDENBROOKE'S COGNITIVE EXAMINATION - ACE-R 
F
Name





Age at leaving full-time education:
Occupation:
Handedness:
O R I E N T A T I O N
Ask: What is the 













R E G I S T R A T I O N 
Register number of trials
[Score 0-3] 
A T T E N T I O N   &   C O N C E N T R A T I O N 
Stop after five subtractions (93, 86, 79, 72, 65). 
Ask: 'could you please spell WORLD for me? Then ask him/her to spell it backwards:
[Score 0-5] 
(for the best 
performed task)
M E M O R Y  - Recall
Ask: 'Which 3 words did I ask you to repeat and remember?'
[Score 0-3] 
M E M O R Y - Anterograde Memory
Tell: ' I'm going to give you a name and address and I'd like you to repeat after me. We'll be 
doing that 3 times, so you have a chance to learn it. I'll be asking you later' 
Score only the third trial
1st Trial 2nd Trial 3rd Trial 
Harry Barnes




[Score 0 -4] 
M E M O R Y - Retrograde Memory
Name of current Prime Minister                        
Name of the Premier of New South Wales              
Name of the USA president                                    
Name of the USA president who was assassinated in the 1960s
Tell: 'I'm going to give you three words and I'd like you to repeat after me: lemon, key and ball'. 
After subject repeats, say 'Try to remember them because I'm going to ask you later'. Score only 
the first trial (repeat 3 times if necessary).
Ask the subject: ' could you take 7 away from a 100? After the subject responds, ask him or her 
to take away another 7 to a total of 5 subtractions.  If subject make a mistake, carry on and 































inal Revised Version A (May 2004) - Australian Version
V E R B A L   F L U E N C Y  - Letter 'P' and animals
Letters





















L A N G U A G E  -  Comprehension
Show written instruction: [Score 0-1] 
Close  your  eyes 
3 stage command: 
'Take the paper in your right hand. Fold the paper in half. Put the paper on the floor' 
[Score 0-3] 
L A N G U A G E  - Writing
Ask the subject to make up a sentence and write it in the space below: 

















Say: ‘I’m going to give you a letter of the alphabet and I’d like you to generate as many words 
as you can beginning with that letter, but not names of people or places. Are you ready? You’ve 
got a minute and the letter is P’ 
Say: ‘Now can you name as many animals as possible, beginning with any letter?















P E R C E P T U A L   A B I L I T I E S
Ask the subject to count the dots without pointing them  [Score 0-4] 
ADDENBROOKE'S COGNITIVE EXAMINATION - ACE-R Final Revised Version A (May 2004)
R E C A L L 
R E C O G N I T I O N





Jerry Barne Harry Barnes Harry Bradford recalled
37 73 76 recalled
Mar ket Road Martin Street Market recalled
Margate R ockhampton C airns recalled
Queensland New South Wales Victoria recalled
General Scores 
MMSE          /30
ACE-R /100
Subscores






























P E R C E P T U A L   A B I L I T I E S 
Ask the subject to identify the letters [Score 0-4]
ADDENBROOKE'S COGNITIVE EXAMINATION - ACE-R Final Revised Version A (May 2004)
This test should be done if subject failed to recall one or more items.  If all items were recalled, skip the 
test and score 5.  If only part is recalled start by ticking items recalled in the shadowed column on the 
right hand side.  Then test not recalled items by telling “ok, I’ll give you some hints: was the name X, Y or 
Z?” and so on.  Each recognised item scores one point which is added to the point gained by recalling.
Rockhampton
Queensland
Street
